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Abstract 
Opioids remain unsurpassed as our most effective treatment for severe pain despite their 
propensity to induce serious on-target adverse effects. Both the therapeutic and adverse 
effects of opioids are mediated through their activation of the  opioid receptor (MOPr), 
a G protein-coupled receptor (GPCR). The disclosure of biased signalling at GPCRs has 
heralded the development of a new generation of refined GPCR-targeting drugs. G 
protein-biased agonists at MOPr have been developed in the anticipation that they will 
be effective analgesics, devoid of the adverse-effects of traditional, balanced opioids. 
Additionally, G protein-biased MOPr agonists also have the potential to induce less 
receptor desensitization than balanced opioids due to their low coupling to traditional 
pathways of receptor regulation (arrestin and GRK). This implies that tolerance to their 
effects may develop slower and to a lesser extent than in the case of traditional opioids, 
making them clinically beneficial. As such, we sought to characterise the receptor 
desensitization and regulation induced by G protein-biased MOPr agonists. Firstly, we 
characterised the biased signalling profiles of a series of putatively G protein-biased 
agonists at MOPr in recombinant systems using BRET assays of G protein coupling and 
arrestin recruitment. These assays demonstrated that the cyclic endomorphin analogue 
Tyr-c[D-Lys-Phe-Tyr-Gly] (Compound 1) is a G protein-biased agonist at MOPr with a 
similar intrinsic activity for G protein signalling as morphine. In contrast, we demonstrate 
that the reportedly G protein-biased agonist PZM21 is in fact a non-biased lower efficacy 
agonist. We then investigated the receptor desensitization induced by previously 
characterised MOPr agonists in rat locus coeruleus (LC) neurones using patch clamp 
electrophysiology. It was hypothesised that G protein-biased agonists would induce less 
rapid MOPr desensitization due to their weak coupling to arrestin and GRK pathways. 
Intriguingly, the G protein-biased agonist Compound 1 conversely induced substantial 
receptor desensitization in LC neurones, to a greater degree than the balanced opioid 
morphine. Using pharmacological tools, it was determined that Compound 1-induced 
desensitization in LC neurones was in fact GRK-dependent, but PKC-independent. 
MOPr phosphorylation and internalization was studied in recombinant systems to outline 
the potential mechanisms underlying the implied GRK-dependent, arrestin-independent 
mechanism of Compound 1-induced desensitization. In these assays, Compound 1 
induced minimal MOPr phosphorylation and internalization, in line with its G protein-
biased profile. Together, the work within this thesis characterised Compound 1 as a novel 
G protein-biased agonist at MOPr, which intriguingly induces substantial receptor 
desensitization through GRK. Our findings refute the assumption that G protein-biased 
agonists will evade receptor desensitization and the subsequent development of 
tolerance.   
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Chapter 1: Introduction 
1.1 G protein-coupled receptors 
1.1.1 Classification, biology and structural characteristics  
G protein-coupled receptors (GPCRs) constitute a large family of evolutionary-related 
membrane signalling proteins. GPCRs function as cell surface receptors, to transmit 
signals from the extracellular space, through the plasma membrane, to the intracellular 
space; enabling cells to respond to external stimuli. Canonically, GPCRs transduce 
signals through conformational rearrangement and subsequent functional coupling to 
intracellular heterotrimeric guanine nucleotide binding proteins known as G proteins 
(Chapter 1.1.3). There is a diverse array of stimuli to which different GPCRs can respond, 
including protons, photons, mechanical force, lipids, neurotransmitters and hormones. In 
a reflection of such diverse stimuli, GPCRs are expressed in all tissue types, with their 
function implicated in the regulation of many physiological and pathophysiological 
processes. 
GPCRs represent the largest superfamily of membrane receptors, comprising over 800 
different receptors, around 400 of which are olfactory (Hauser et al., 2017). The 
superfamily of GPCRs is sub-divided into 6 classes based on evolutionary sequence 
homology. 4 of these classes are found in humans: Class A (rhodopsin-like), Class B1 
(secretin receptor-like), Class B2 (adhesion receptors), Class C (metabotropic glutamate 
receptor-like) and Class F (frizzled-like) (Schiöth et al., 2005). Class A rhodopsin-like 
receptors are by far the largest sub-family of GPCRs, containing approximately 670 
human receptors, accounting for around 80% of the total population (Gloriam et al., 
2007). The Class A family of GPCRs can be further subdivided by the type of 
endogenous stimuli they are activated by. These subfamilies include aminergic receptors 
(e.g. muscarinic acetylcholine receptors, adrenoceptors and dopamine receptors), 
peptide receptors (e.g.  opioid receptors and orexin receptors), protein receptors (e.g. 
chemokine receptors), lipid receptors (e.g. cannabinoid receptors and prostanoid 
receptors) and nucleotide receptors (e.g. adenosine receptors and P2Y receptors) 
(Hauser et al., 2017). Despite belonging to a given class due to their structural homology, 
approximately 30% of the ~400 non-olfactory human GPCRs have not been definitively 
paired with their endogenous ligands, designating them as “orphan” receptors (Laschet 
et al., 2018; Hauser et al., 2020). Orphan GPCRs, of which a great proportion are class 
A receptors, represent a huge untapped source of therapeutically unexplored biology.  
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The GPCR family share a conserved architecture, consisting of an extracellular amino-
terminus (N-terminus), 7 hydrophobic -helical transmembrane domains (TM1-7) 
connected by three extracellular and intracellular loops (ECLs and ICLs respectively), 
and an intracellular carboxyl-terminal (C-terminal) tail (Figure 1.1). This shared structure 
has led to alternative nomenclature referring to the family as 7 transmembrane domain 
(7TM) receptors. The ICLs serve as interaction sites for intracellular signalling proteins, 
including G proteins (Chapter 1.1.3.), with the individual conformation and structure of 
these regions defining the selectivity of G protein interactions for a specific receptor. The 
intracellular C-terminal tail, and in some cases the ICLs, of the receptor is involved in the 
regulation of receptor function as an interaction site for intracellular kinases (Chapter 
1.1.4.). For non-sensory GPCRs, the hydrophobic core formed by the 7 TM domains 
constitutes the orthosteric binding pocket for both endogenous and exogenous ligands. 
The TM domain residues which form the ligand binding pocket define the binding and 
functional interactions of the receptor with ligands, giving the receptor stimulus 
specificity. While the composition of the binding pocket is quite distinct between families 
of GPCRs, the orthosteric binding pocket is highly conserved for GPCRs within the same 
sub-family (Manglik et al., 2012; Thal et al., 2016). Receptor function can also be 
regulated at sites outside of the orthosteric binding pocket, termed allosteric sites (Conn 
et al., 2009). Allosteric modulation of GPCR function can be induced by some specific 
exogenous ligands (Keov et al., 2011), but also modulation in the physiological 
functioning of the receptor such as by sodium ions at the sodium ion binding site, a well-
described regulatory mechanism conserved across Class A GPCRs (Liu et al., 2012).  
Over the past 20 years, recent technological breakthroughs in X-ray crystallography 
have facilitated a structural revolution in the field of GPCRs (Congreve et al., 2020). The 
developed techniques have overcome traditional problems concerning GPCR 
crystallography through the stabilization of receptors in a detergent solution during 
purification. This has been achieved through the use of thermostabilising receptor 
mutagenesis (Magnani et al., 2016), antibody fragments (Steyaert et al., 2011), fusion 
proteins (Chun et al., 2012) and high-affinity ligands (Zhang et al., 2015). To date, the 
structures of 70 unique GPCRs have been determined through such methods, a figure 
which is rising year-on-year (Congreve et al., 2020). Recently, an increasing number of 
GPCR structures have been solved through an alternate method: electron cryo-
microscopy (cryo-EM) (Garcia-Nafria et al., 2020). For example, pioneering work 
illustrated the structure of agonist-bound  opioid receptor in complex with Gi G protein 




Figure 1.1 – A representative structure of a Class A GPCR 
A schematic representation of the inactive structure of the  opioid receptor (blue) bound 
to the antagonist -FNA (green and red spheres) showing views of the receptor from the 
membrane plane (A), the extracellular side (B) and the intracellular side (C). Figure is 
adapted from Manglik et al. (2012). TM = transmembrane helix, ECL = extracellular loop, 
ICL = intracellular loop.  
 
Detailed crystal structures of GPCRs have provided the field with remarkable insight into 
the relationship between receptor structure and function. For instance, comparisons of 
active and inactive receptor crystal structures can provide an understanding of the 
conformational basis of GPCR activation (Weis et al., 2018). Additionally, a crystal 
structure reveals the molecular shape of the orthosteric binding pocket of a receptor and 
the residues which constitute it, enabling refined structure-based drug design (SBDD) 
(Congreve et al., 2020). SBDD at GPCRs have been of particular interest to drug 
discovery, particularly in the refinement of ligand-specificity between largely homologous 
receptor subtypes. In particular, examples of crystallography-driven SBDD include the 
development of the adenosine 2A receptor antagonist AZD4635, which is selective for 
the adenosine 2A receptor over the adenosine A1 receptor  (Congreve et al., 2012). This 
drug is now in Phase II clinical trials after showing preclinical efficacy in cancer studies 
as an immune modulator (Borodovsky et al., 2018). Similarly, SBDD has been utilised to 
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develop agonists of the M1 muscarinic receptor, a pro-cognitive therapeutic target for 
neurodegenerative diseases (Shirey et al., 2009). These agonists have selectivity for M1 
over the other highly homologous muscarinic receptor subtypes (M2, M3 and M5 in 
particular) (Thal et al., 2016). While there are no current examples of licensed drugs 
developed with the aid of crystallography-aided SBDD, this approach will likely bear fruit 
in the near future with many agents in clinical trials.  
1.1.2 GPCRs as therapeutic targets 
GPCRs are widely considered to be exemplary drug targets from many perspectives. As 
a family of membrane receptors, they are implicated in a large array of 
pathophysiological processes. Additionally, the structure of the orthosteric site of non-
sensory GPCRs, which is evolutionarily designed for the binding of signalling molecules, 
is exceptionally well-suited to the design of compatible small synthetic molecules 
(Shoichet et al., 2012), giving them good druggability. The shared fundamentals of 
GPCR signalling and behaviour across the receptor family also give GPCRs the 
tendency to be relatively tractable drug targets. 
As a reflection of this, recent analysis from Hauser et al. (2017) indicates that over a third 
of all drugs currently approved by the US Food and Drug Administration (FDA) exert their 
therapeutic effects through GPCRs. This equates to 475 drugs acting at 108 unique 
GPCR targets, highlighting the importance of GPCR-targeting agents in our current 
therapeutic arsenal, with the aminergic and opioid GPCR families accounting for the 
majority (77%) of the 108 established GPCR drug targets.  
Recent trends in GPCR drug discovery have demonstrated the expansion of our pool of 
druggable GPCRs. There are a number of recently approved agents targeting novel 
GPCRs previously untargeted by established therapeutics, with many more novel 
GPCRs targeted by agents in clinical trials (Hauser et al., 2017). This includes the orexin 
receptors (Sakurai et al., 1998) and the calcitonin gene-related peptide (CGRP) receptor 
(Edvinsson et al., 2018), which are now targeted by clinically approved drugs for 
insomnia and migraine respectively (Yang, 2014; Edvinsson et al., 2018). With 66 further 
novel GPCR targets highlighted in clinical trials, it is hoped that the pool of druggable 
GPCRs will be expanded in coming years (Hauser et al., 2017). Moreover, there is an 
enormous untapped therapeutic potential held in the 30% of non-olfactory GPCRs that 
are orphan receptors (Chapter 1.1.1). Given growing evidence implicating orphan 
receptors in disease (Dershem et al., 2019), one would hypothesise that a number of 
current orphan GPCRs will come to be valuable therapeutic targets in the near future.  
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A number of contemporary developments in GPCR biology and pharmacology have 
rallied momentum in GPCR drug discovery in recent years. Firstly, while crystallography-
based SBDD (Chapter 1.1.1.) has yet to be fully utilised to develop an approved 
therapeutic agent, it has undoubtedly transformed GPCR drug discovery (Congreve et 
al., 2020). The wealth of structural information now provided for GPCRs allows for the 
development of more selective, refined GPCR-targeting agents.  
Another mechanism employed within drug discovery to refine agonist selectivity is the 
development of allosteric, rather than orthosteric, GPCR-targeting agents (Conn et al., 
2009). By developing drugs at characterised allosteric sites, selectivity issues arising 
from high homology in the orthosteric sites in related receptors are effectively 
circumvented. A small number of allosteric modulators at GPCRs are clinically approved 
thus far, including cinacalcet, a positive allosteric modulator at the calcium sensing 
receptor (CaSR) approved for the treatment of hyperparathyroidism (de Francisco, 
2005). Allosteric modulators act to increase or decrease the affinity or efficacy of 
endogenous signalling molecules, therefore maintaining temporal control of endogenous 
signalling, but in an amplified or reduced manner. This is particularly appealing for the 
treatment of neurological conditions such as schizophrenia, where maintaining the 
temporal manner of endogenous signalling may alleviate potentially serious adverse 
effects following pharmacological intervention (Foster et al., 2017).  
Finally, the phenomenon of biased signalling, alternatively termed functional selectivity, 
has more recently energised GPCR drug discovery (Kenakin, 2011; Michel et al., 2018). 
Drug discovery groups targeting an array of GPCRs have attempted to harness biased 
signalling to develop more selective GPCR drugs, which may evade the traditional 
adverse effects of activating a GPCR by preferentially activating selected pathways 
downstream of receptor activation. This thesis focuses on the phenomenon of biased 
signalling (Chapter 1.1.6) in the context of the  opioid receptor (MOPr) (Chapter 1.3). 
1.1.3 G protein coupling and signal transduction 
Upon activation by an agonist, GPCRs undergo a conformational change which favours 
the physical interaction (coupling) of the receptor with intracellular heterotrimeric G 
proteins. Relatively small agonist-induced changes in conformation at the binding pocket 
are transduced to produce larger conformational changes in the TM helices toward the 
intracellular portion of the GPCR. Structural insights suggest a conserved, archetypal 
mechanism of activation for Class A, with activation inducing “outswing” movement of 
TM6 (Figure 1.1) which results in an “open” receptor confirmation which allows for the 
coupling of G proteins through revealing previously occluded relevant residues (Huang 
et al., 2015; Wang et al., 2020; Wingler et al., 2020). 
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The heterotrimeric G protein complex is composed of G, G and G subunits, with G 
and G forming a stable heterodimer termed G. The function of G protein complexes 
is dependent on guanosine nucleotide exchange at the G subunit, as well as the 
function of GTPases. In an inactive state, guanosine diphosphate (GDP) is bound to the 
G subunit of the heterotrimeric G protein complex. Upon coupling of the G protein with 
the activated receptor, the GPCR acts as an exchange factor to enhance the release of 
GDP from the G protein, leading to the subsequent binding of guanosine triphosphate 
(GTP). GTP binding to G promotes a destabilising conformational change in the G 
protein complex resulting in dissociation of the G and G subunits, which are 
subsequently able to interact with downstream enzymes or channels through which they 
modulate cellular responses. G protein signalling is terminated upon hydrolysis of GTP 
to GDP, a process which can be catalysed by GTPase activating proteins, also termed 
regulators of G protein signalling (RGS) (Oldham et al., 2008).  
The G protein family consists of numerous individual subunit isoforms, with 20 different 
G isoforms, 5 different G isoforms and 12 different G isoforms. The coupling profile 
of G protein signalling downstream of a GPCR is primarily dictated by the isoform of the 
G subunit to which the receptor couples (Hepler et al., 1992). The isoforms of the G 
subunits are grouped into the following 4 subfamilies: Gs, Gi/o, Gq/11 and G12/13 
(Wettschureck et al., 2005). Activated Gs G proteins directly bind and stimulate adenyl 
cyclase (AC), increasing the latter’s catalytic production of the second messenger cyclic 
adenosine monophosphate (cAMP) from adenosine triphosphate (ATP). An increase in 
cAMP activates cAMP-dependent pathways including protein kinase A (PKA). Activated 
GI family G proteins conversely inhibit the activity of AC through direct binding, thereby 
inhibiting AC-dependent cAMP production from ATP. All Gi/o family members are 
sensitive to pertussis toxin, which inhibits G protein function through ADP-ribose 
modification of a unique cysteine residue within the C-terminus of Gi/o G proteins. 
Activated Gq/11 G proteins directly activate phospholipase C (PLC), which in turn 
hydrolyses the membrane lipid phosphatidylinositol 4,5-biphosphate (PIP2) to produce 
the second messengers inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 
initiates an increase in cytosolic calcium levels through interaction with IP3 sensitive 
calcium (Ca2+) channels on the endoplasmic reticulum. DAG and increased intracellular 
Ca2+ both directly activate protein kinase C (PKC). G12/13 G proteins pathways are the 
major pathway through which GPCRs are able to activate the Rho family of GTPases 
(Hart et al., 1998). 
While G subunits were traditionally thought to be the sole transducers of G protein 
signalling, it is now well established that G subunits also function as signal transducers 
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(Campbell et al., 2018). Notably, G subunits signal through interactions with a variety 
of selection of ion channels, with the specificity of such interactions dependent on the 
associated G protein (Khan et al., 2013). More specifically, Gi/o-associated G 
subunits signal through interactions with N-type and P/Q-type calcium (Ca2+) channels 
and inwardly rectifying potassium (K+) channels (Khan et al., 2013). 
1.1.4 Regulation of GPCR function 
The signalling of GPCRs is negatively regulated through a conserved two-step 
mechanism: receptor phosphorylation and the subsequent binding of arrestin proteins 
(Gurevich et al., 2019) (Figure 1.2).  
The primary mechanism of GPCR desensitization occurs upon receptor activation, 
whereby serine and threonine residues of the intracellular C-terminal tail and intracellular 
loops of the receptor are rapidly phosphorylated by GPCR kinases (GRKs). There are 
seven human GRK isoforms, which can be subdivided by their structure, expression and 
function: GRK1-like (GRK1 and GRK7), GRK2-like (GRK2 and GRK3) and GRK4-like 
(GRK4, GRK5 and GRK6). The expression of the GRK1-like family proteins is restricted 
to the visual system, whereas GRK2-like and GRK4-like proteins are ubiquitously 
expressed (Pitcher et al., 1998). As soluble proteins, GRKs require specific mechanisms 
to control their recruitment to membrane-localised GPCRs and subsequent 
phosphorylation. Regarding the non-visual GRKs, GRK2/3 bind G subunits through 
their pleckstrin homology (PH) domains (Koch et al., 1993; Lodowski et al., 2003). The 
recruitment of GRK2/3 to the membrane subsequent to G dissociation thus presents 
a negative feedback loop of regulation for G protein signalling. GRK4/5/6 lack a PH 
domain and instead associate with the plasma membrane via palmitoylation (Stoffel et 
al., 1994). Intriguingly, GRK4/5/6 are also associated with constitutive phosphorylation 
of non-activated GPCRs (Li et al., 2015), whereas GRK2/3 are associated with agonist-
induced phosphorylation of GPCRs (Gurevich et al., 2019). The patterns of GRK-
dependent GPCR phosphorylation and its functional implications are further explored in 
the case of MOPr (Chapter 1.2.5).  
Desensitization and receptor phosphorylation can also occur through heterologous, non-
GRK dependent mechanisms. For example, both activated or non-activated GPCRs can 
be desensitized through second messenger-dependent kinases (such as PKA or PKC) 
which could themselves be activated through the activation of other receptors (Kelly et 
al., 2008). The mechanisms and implications of heterologous desensitization in GPCR 





Figure 1.2 – A schematic of the mechanisms and timescales of GPCR regulation 
Upon agonist binding to a GPCR by an agonist (denoted A) the heterotrimeric G protein 
is activated and separates. Rapid receptor phosphorylation by G protein receptor kinase 
(GRK) family proteins occurs on the intracellular portions of the GPCR, causing 
desensitization of GPCR responses. The phosphorylated GPCR now has high affinity for 
arrestin proteins (in this case -arrestin 2, or arrestin-3), which bind the receptor and act 
as adaptors for endocytotic machinery to promote GPCR internalization. The 
internalization of receptors can lead to the development of tolerance to the effects of an 
agonist. GPCR function is restored upon either dephosphorylation or, following 
endocytosis, reinsertion to the plasma membrane through recycling endosomes. Figure 
is reproduced from Williams et al. (2013).  
 
 9 
Phosphorylation of GPCRs by GRKs is generally insufficient to provide full 
desensitization of G protein signalling. Instead, the recruitment of arrestin proteins to 
GPCRs is essential for the extensive uncoupling of G proteins from the receptor (Figure 
1.2). There are 4 isoforms of arrestin (arrestin 1-4). The expression of arrestin-1 and 
arrestin 4 is exclusive to the visual system, where arrestin-2 (-arrestin-1) and arrestin-
3 (-arrestin-2) are expressed ubiquitously. The phosphorylation of GPCRs by GRKs 
increases the affinity of the intracellular portions of the receptor for arrestin proteins. The 
arrestin-bound receptor is sterically inhibited from G protein coupling, effectively 
desensitizing the G protein signalling of a receptor. Aside from steric hinderance, arrestin 
proteins function as adaptor proteins to facilitate GPCR internalization (Figure 1.2). As 
such, non-visual arrestins specifically bind clathrin (Goodman et al., 1996) and the 
clathrin adaptor AP2 (Laporte et al., 1999) to promote the formation of clathrin coated 
pits through which GPCRs under endocytosis (Magalhaes et al., 2012).  
Following endocytosis, the vesicles containing the receptor shed their clathrin coating to 
become early endosomes (Hanyaloglu et al., 2008). The acidified environment of the 
early endosome promotes dissociation of ligand and arrestin from the receptor, as well 
as receptor dephosphorylation by phosphatase enzymes. The fate of the endocytosed 
GPCR is then dictated by endocytic sorting. GPCRs may undergo rapid recycling and 
membrane insertion if sorted through recycling endosomes, leading to resensitization of 
the receptor and restored function at the cell surface (Figure 1.2). Alternatively, GPCRs 
may undergo degradation through lysosomal pathways, leading to a downregulation of 
receptor function which is only restored following transcription and translation of new 
receptor protein. Emerging findings around GPCR signalling within endosomal 
pathways, termed compartmentalised signalling, are serving to redefine our current 
understanding of GPCR signalling (Irannejad et al., 2014; Pavlos et al., 2017). The 
pharmacological significance of compartmentalised signalling to the functionality of 
numerous GPCRs remains to be fully realised.  
1.1.5 G protein-independent signalling 
Beyond their traditional function in GPCR receptor desensitization and internalization, 
studies over the past two decades have demonstrated that GRKs and arrestin proteins 
additionally serve as effective signal transducers in their own right (Gurevich et al., 2006; 
Gurevich et al., 2019). This implicates both GRKs and arrestins as key mediators of G 
protein-independent signalling downstream of GPCRs. 
GRKs have been demonstrated to phosphorylate and thus regulate numerous non-
GPCR proteins, including toll-like receptors, receptor tyrosine kinases as well as other 
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receptor serine/threonine kinases among others (Gurevich et al., 2019). While in many 
cases, the functional relevance of GRK-mediated regulation of these pathways is poorly 
defined, the numerous interactions of GRK outside of GPCR signalling suggest they hold 
physiologically important non-canonical roles. Phosphorylation-independent roles have 
also been demonstrated for GRK subtypes, illustrating another non-canonical pathway 
of GPCR regulation and signalling by GRK. For example, negative regulation of Gq/11 
proteins by GRK2/3 has been demonstrated via a sequestration mechanism dependent 
on binding through its regulator of G protein signalling (RGS) homology (RH) domain 
(Dhami et al., 2002; Ribeiro et al., 2009). Similarly, as previously mentioned (Chapter 
1.1.4.), GRK2/3 bind G subunits through their pleckstrin homology (PH) domain (Koch 
et al., 1993; Lodowski et al., 2003). In addition to mediating GRK recruitment to the 
membrane upon GPCR activation, this process also negatively regulates G function 
through sequestration. This has been outlined as a heterologous mechanism of 
desensitization for the G-dependent function of G protein-coupled inwardly rectifying 
potassium channels (GIRKs) downstream of adenosine A1 and MOPr in recombinant 
systems (Raveh et al., 2010) and at  opioid receptor (Abraham et al., 2018). However, 
the functional relevance of this process to rapid MOPr desensitization in mature adult 
mammalian neurones is disputed (Llorente et al., 2012). 
The first accounts of arrestin-dependent signalling illustrated that GPCR-bound arrestins 
promote activation of the mitogen-activated protein kinases (MAPKs) extracellular 
signal-regulated kinase 1 (ERK1) and ERK2 (ERK1/2), through both Src-dependent and 
cRaf1-dependent activation pathways (Luttrell et al., 1999; Luttrell et al., 2001). 
Subsequently, the number of binding partners demonstrated for arrestin has increased 
greatly (Xiao et al., 2007), firmly demonstrating them as genuine mediators of G protein-
independent signalling. Other signalling pathways activated through visual arrestins 
include c-Jun N-terminal kinase 3 (JNK-3) (McDonald et al., 2000), glycogen synthase 
kinase-3 (GSK3) (Beaulieu et al., 2007) and phosphatidylinositol 3-kinase (PI3K) (Wang 
et al., 2006). 
However, recent findings suggest that arrestin-dependent activation of ERK1/2 signalling 
does not occur in cells genetically devoid of G protein signalling (Alvarez-Curto et al., 
2016; Grundmann et al., 2018). Additionally, GPCR-dependent ERK1/2 signalling is 
relatively unaltered in cells lacking visual arrestins, with arrestin-dependent ERK1/2 itself 
dependent on prior activation of G protein (O'Hayre et al., 2017; Grundmann et al., 2018). 
Together, these findings do not refute the existence of arrestin-dependent ERK1/2 
signalling, but they do imply that this process is instead mainly dependent on G protein 
signalling (Gurevich et al., 2019).   
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1.1.6 Biased agonism at GPCRs 
Historically, GPCRs had been conceptualised as simple switches, residing in either an 
active or inactive state. In this regard, GPCRs were envisaged to couple to one G protein 
and its respective signalling pathway. This simple perception of GPCR signalling has 
been eroded by observations that (i) GPCRs are able to couple to more than one 
individual family of G protein isoforms (Crawford et al., 1992; Schmidt et al., 1995) and 
moreover that (ii) GPCRs can signal through G protein-independent pathways, such as 
via arrestins (Chapter 1.1.5.) (Gurevich et al., 2006; Gurevich et al., 2019). As such, 
GPCRs are now considered allosteric microprocessors, which can signal through 
multiple transducers (Smith et al., 2018). This concept is based on the notion that GPCRs 
can occupy a range of conformational states, which have different affinities for the 
coupling of intracellular signalling partners (Smith et al., 2018).  
The term biased agonism (Jarpe et al., 1998) refers to the ability of an agonist to stabilise 
different receptor conformations which preferentially couple to individual intracellular 
signalling partners at the expense of others (Kenakin, 2011; Kenakin, 2018) (Figure 1.3). 
For example, a GPCR agonist preferentially signalling through specific G protein 
subtypes over others, (e.g. Gq over GI), or an agonist favouring the activation of G 
protein over arrestin signalling pathways, or vice versa (Figure 1.3). 
Biased signalling has been harnessed by drug discovery groups to innovate the 
development of GPCR-targeting drugs, with the potential that biased agonists may 
represent new improved therapeutics. The rationale for harnessing biased agonism to 
yield improved therapeutics broadly follows one of two scenarios (Kenakin, 2017). Firstly, 
biased agonism could be used to emphasize favourable GPCR-dependent signalling. 
For example, at glucagon-like peptide-1 (GLP-1) receptor (GLP-1R), GLP-1 dependent 
insulin release is arrestin-2 dependent (Sonoda et al., 2008), suggesting arrestin-biased 
GLP-1R ligands may be superior to non-biased (or “balanced”) agonists. Secondly, 
biased agonism could be utilised to de-emphasize the signalling of pathways which 
mediate clinically adverse effects of GPCR activation. This rationale is best explored at 
MOPr, where G protein-biased agonists have been developed with the intention of 
evading opioid-induced respiratory depression, constipation and tolerance which has 
been suggested to be arrestin-dependent (Raehal et al., 2005), but, in case of respiratory 







Figure 1.3 – A schematic description of biased agonism at GPCRs  
A balanced, or non-biased, agonist (pink) stabilises an active receptor conformation 
which couples equally to G protein and arrestin signalling pathways. A G protein-biased 
agonist (light blue) stabilises a distinct receptor conformation which favours coupling to 
G protein, with minimal coupling to arrestin pathways. The arrestin-biased agonist (red) 
stabilises another distinct receptor conformation, which preferentially couples to arrestin, 
with minimal G protein coupling. Expected concentration-response curves for G protein 
signalling and arrestin signalling in cell-based assays are presented for each agonist 
(pink = balanced agonist, light blue = G protein-biased agonist, red = arrestin-biased 
agonist). When compared to the balanced reference agonist, responses of the G protein-
biased agonist for G protein signalling are leftward shifted, but responses are reduced 
and rightward shifted for arrestin signalling. G protein responses induced by the arrestin-
biased are rightward shift compared to the balanced agonist, but arrestin responses 




Another example where biased agonism could allow for the effective evasion of particular 
clinical effects of GPCR activation is the development of G protein-biased agonists at 
the  opioid receptor (Conibear et al., 2020), for which the development of agonists as 
analgesics has previously been hampered by proconvulsive effects of balanced  opioid 
receptor agonists (Broom et al., 2002).  
Some approved GPCR-targeting ligands have retroactively been characterised as 
biased, including carvedilol, an arrestin-biased agonist at  adrenoceptors (Wisler et al., 
2007) and nalfurafine, a G protein-biased  opioid receptor agonist (Schattauer et al., 
2017). However, as the rational development of biased ligands at GPCRs is still in its 
infancy, we are yet to observe the widespread clinical approval of ligands specifically 
designed to be bias. The exception to this is the recent clinical approval of TRV130 
(oliceridine, Trevena Inc.) (Lambert et al., 2020), a reportedly G protein-biased agonist 
at MOPr (DeWire et al., 2013); but see (Yudin et al., 2019; Gillis et al., 2020a; Singleton 
et al., 2021), approved for the treatment of severe pain. MOPr (Chapter 1.2.) is arguably 
the most advanced target for the development of biased ligands at GPCRs (Chapter 
1.3.).  
Aside from MOPr, one of the first drugs to harness biased agonism and so enter clinical 
trials was the angiotensin II type I receptor (AT1R) agonist TRV120027 (TRV027), 
developed by Trevena Inc. TRV027 was specifically developed as an arrestin-biased 
agonist, effectively acting as an antagonist for G protein-mediated AT1R signalling 
induced by endogenous angiotensin (Violin et al., 2010). TRV027 demonstrated efficacy 
in preclinical models of congestive heart failure with reduced blood pressure and, unlike 
conventional clinically used AT1R antagonists, increased cardiac performance 
(Boerrigter et al., 2011). However, TRV027 failed to meet its primary endpoint in a Phase 
II clinical trial (Pang et al., 2017). Interestingly, arrestin-biased AT1R agonists have 
recently been suggested as treatments for coagulopathy associated with coronavirus 
disease 2019 (COVID-19) (Manglik et al., 2020), with TRV027 currently under 
repurposing clinical trials for this indication.  
Ligand bias is typically assessed through the definition of pharmacological parameters 
(efficacy, potency) in separate cell signalling assays performed in recombinant systems, 
yielding graphs of the type presented in Figure 1.3. The quantification of biased agonism 
has developed over the past decade, with common analyses often founded on utilisation 
of the operational model (Black et al., 1983; Kenakin, 2017). The optimisation of biased 
signalling within drug discovery is limited by the often-unappreciated technical 
complexity of such experiments and analysis. For one, kinetic context at both ligand-
receptor level, and in the comparison of ligand effects between assays run under 
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different time-frames, complicates interpretation of biased agonism (Lane et al., 2017). 
In addition, in recombinant systems, the differential levels of signal amplification between 
G protein and arrestin signalling assays often result in confounding results whereby 
partial agonists appear as biased agonists, due to the contributing effect of receptor 
reserve (Kelly, 2013; Gillis et al., 2020c). 
Additionally, translating of defined signalling bias from in vitro observations to in vivo 
therapeutic effects is a particular challenge (Kenakin, 2018; Michel et al., 2018). Cellular 
context, in particular the stoichiometry ratios and levels of receptor and signalling 
proteins expressed in a specific cell, can impact the relative function of biased agonists 
(Kenakin, 2020). As such, cellular context at therapeutically interesting cell populations 
could lead to unanticipated effects of biased agonists in vivo. More broadly, one could 
argue that only with the advent of recent technological advances are we really coming 
to understand the specific signalling pathways responsible for the specific GPCR-
dependent physiological responses. Accordingly, it may be too soon to select a desirable 





1.2 The  opioid receptor (MOPr) system 
1.2.1 Opioids and the opioid system 
Substances derived from the opium poppy plant Papaver somniferum, termed opiates, 
have been used for millennia, both therapeutically for their analgesic properties and 
recreationally for their ability to induce euphoria for millennia (Brownstein, 1993). In the 
modern day, opioids as a drug class remain unsurpassed as our most effective 
analgesics for the treatment of significant pain. However, their clinical utility has been 
limited by an assortment of common, on-target adverse effects. These include the risk 
of developing addiction (due to their euphoric, rewarding nature), constipation, 
respiratory depression, and the loss of therapeutic effect over repeat administration 
(termed tolerance).  
In the early 19th century, morphine was isolated as an active opiate from the opium 
poppy, allowing for its use in surgery and for post-operative pain (Brownstein, 1993). 
However, the characteristic adverse effects of morphine fostered a century-spanning 
drive to develop safer opioids, without the typical addictive properties. Heroin was 
synthesised in the late 19th century as one of the first opioids developed as a potent 
morphine alternative, purportedly devoid of abuse liability. While in hindsight this appears 
rather ironic, in reality this presents merely the first of several similar claims for novel 
opioids, spanning up to the modern day. Regardless, the unrelinquishing efforts of 
medicinal chemistry to develop the ‘holy grail’, an opioid devoid of adverse effects 
(Corbett et al., 2006), have yielded thousands of opioids, providing the area with a rich 
pharmacology. 
In the 1970s, endogenous opioid peptides were first identified with the discovery of the 
enkephalins by John Hughes and Hans Kosterlitz (Hughes et al., 1975). Subsequent 
studies have characterised a number of other endogenous opioid peptides including the 
endorphins and the dynorphins (Corbett et al., 2006). These peptides are generated by 
the proteolytic cleavage of the precursor proteins pro-enkephalin (the enkephalins), pro-
opiomelanocortin (the endorphins) and prodynorphin (the dynorphins). The synthetic tool 
peptide DAMGO ([D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin) is a highly MOPr-selective 
agonist derived from the enkephalins (Figure 1.8). Despite their isolation from bovine 
brain tissue (Zadina et al., 1997), the selective MOPr-targeting endomorphin peptides 
(endomorphin-1 and endomorphin-2) are not currently definitively classified as 
endogenous opioids as their respective precursor protein or encoding gene have not 
been identified (Terskiy et al., 2007). 
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1.2.2 The opioid receptor family  
All opioid analgesics, including morphine, exert their therapeutic and adverse effects 
through agonist activity at the  opioid receptor (MOPr) (Matthes et al., 1996). The MOPr 
is one subtype among the opioid receptor family, which includes the  opioid receptor 
(DOPr) and  opioid receptor (KOPr). These classical opioid receptors share a high level 
of sequence homology (around 70%) and to a degree share an overlapping 
pharmacology (Mollereau et al., 1994). Later, a previously orphan receptor, the 
nociceptin/orphanin FQ receptor (NOPr), was identified and which has relatively high 
sequence homology with the classical opioid receptors (Henderson et al., 1997). 
However, the pharmacology of NOPr is markedly different to that of the classical opioid 
receptors, owing to low homology in its orthosteric binding site (Thompson et al., 2012). 
All opioid receptors are G protein-coupled receptors (GPCRs) of the Class A family. In 
recent years, high-resolution crystal structures (Chapter 1.1.1.) of MOPr (Manglik et al., 
2012; Huang et al., 2015; Koehl et al., 2018), DOPr (Granier et al., 2012; Fenalti et al., 
2015), KOPr (Che et al., 2018), and NOPr (Thompson et al., 2012) have all been solved. 
There are currently 41 clinically approved therapeutics targeting opioid receptors 
(Hauser et al., 2017), all of which primarily target MOPr. While DOPr and KOPr present 
promising therapeutic targets for the development of analgesics, as well as in other 
indications, particularly emotional disorders, drug discovery programmes targeting these 
receptors have been hindered by the proconvulsive effects of DOPr activation (Pradhan 
et al., 2011) and the dysphoric and hallucinogenic effects of KOPr activation (Crowley et 
al., 2015). 
The opioid system, consisting of the opioid receptors and the endogenous opioid 
peptides (Chapter 1.2.1.) broadly functions as a central regulator of pain control and is a 
key mediator of hedonic homeostasis. The opioid receptors are widely expressed in the 
central and peripheral nervous system (Mansour et al., 1994; Calo et al., 2000), as well 
as in non-neuronal cells (Hutchinson et al., 2011). Specifically, regions particularly high 
in MOPr expression include the periaqueductal grey (PAG), the locus coeruleus (LC), 
the thalamus, dorsal root ganglion (DRG) and the dorsal horn of the spinal cord 





1.2.3 G protein-dependent signalling of MOPr 
In neurones, activation of MOPr broadly acts as an inhibitor of neuronal signalling. Upon 
activation, MOPr couples to inhibitory G proteins of the Gi/o family, a shared 
characteristic of all opioid family GPCRs. Upon MOPr-dependent activation and 
separation of heterotrimeric G proteins, the dissociated Gi/o proteins inhibit adenyl 
cyclase preventing generation of cAMP (Minneman et al., 1976) (Figure 1.4). This 
reduction in cAMP levels reduces the downstream activity of the cAMP-dependent 
kinase PKA.  
However, the modulation of ion channels through the dissociated G subunit presents 
the principle mechanism through which MOPr modulates neuronal function. 
Presynaptically, MOPr activation induces G-dependent inhibition of voltage-gated 
calcium channels (Schroeder et al., 1991; Seward et al., 1991). This process inhibits the 
calcium-dependent fusion of synaptic vesicles with the presynaptic membrane, reducing 
subsequent neurotransmitter release. Postsynaptically, G activates G protein-coupled 
inwardly-rectifying potassium (GIRK) channels (Williams et al., 1982; North et al., 1985). 
The MOPr-dependent activation of GIRK channels causes an increase in potassium 
conductance within affected neurones, efflux of K+ ions, and hyperpolarisation of the cell 





Figure 1.4 – MOPr-dependent G protein signalling in the context of synaptic 
transmission 
The presynaptic and postsynaptic effects of agonist-evoked MOPr-dependent G protein 
signalling on transmission of nociceptive signals. Under basal conditions (left) a noxious 
stimulus triggers the firing of an action potential. Upon reaching the synaptic terminal, 
the depolarising action potential triggers the opening of presynaptic voltage-gated 
calcium channels (VGCCs), propagating the fusion of synaptic vesicles with the 
membrane and subsequent neurotransmitter release. These neurotransmitters (e.g. 
glutamate) then activate postsynaptic AMPA and NMDA receptors, to transduce 
nociceptive signals along pain circuits. Agonist-induced activation of MOPr (right) 
promotes activation and dissociation of heterotrimeric G i G proteins, with activated Gi 
subunits downstream of both pre- and postsynaptic MOPr inhibiting adenyl cyclase (AC) 
to reduce cAMP production. Presynaptically, activated G subunits inhibit VGCC 
opening, resulting in reduced neurotransmitter release. Postsynaptically, activated G 
subunits activation G protein gated inwardly rectifying potassium channels (GIRKs), 
causing membrane hyperpolarisation. Through these mechanisms, the MOPr-mediated 
effects of opioids reduce transduction of nociceptive stimuli. Figure adapted from Corder 




1.2.4 Opioid-induced analgesia 
Opioids have been used for millennia to provide analgesia, and their clinical value in the 
treatment of severe pain remains unsurpassed today. The action of opioids on pain is 
selective, with opioids modulating the perception of pain without interfering with the basic 
sensations such as light touch, where local anaesthetics such as lidocaine completely 
block sensory transmission (Pasternak et al., 2013). Opioid-induced, MOPr-dependent 
analgesia occurs at numerous sites within both peripheral and central neuronal circuits 
which shape the pain experience, as summarised below. 
Pain is vital to survival as a natural physiological response to noxious stimuli. As such, 
pain prevents injury through evoking reflexive reactions away from harmful stimuli and 
promoting a tendency to protect an injured, pained body part allowing it to heal. Noxious 
stimuli are first perceived by sensory neurones of dorsal root ganglia (DRG) and 
trigeminal ganglia which innervate peripheral tissue, relaying this information to the 
spinal cord and medulla. The somatosensory neurones of the DRG transduce pain 
signals through the dorsal horn to second-order neurones in the spinal cord through 
release of pronociceptive neurotransmitters, including glutamate, substance P and 
calcitonin gene-related peptide (CGRP). Opioid receptors, including MOPr, are widely 
expressed at a number of sites which converge in the dorsal horn, including 
presynaptically on peripheral somatosensory neurones of the DRG, postsynaptically on 
second-order projection neurones and on excitatory interneurons (Arvidsson et al., 1995; 
Aicher et al., 2000; Corder et al., 2018). Activation of opioid receptors in this region, and 
ensuing regions mentioned, produces antinociception, through limiting the release of 
pro-nociceptive neurotransmitters (presynaptic) and restricting the excitability of 
postsynaptic neurones through the ion channel-dependent mechanisms outlined above 
(Chapter 1.2.3, Figure 1.4). The peripheral MOPrs of the DRG can be selectively 
targeted by drugs with low blood-brain-barrier permeability, with some results suggesting 
they can produce analgesia without CNS-related adverse effects (Vadivelu et al., 2011). 
However, recent work has highlighted that DRG MOPrs are not required for the 
antinociception induced by system morphine administration (Corder et al., 2017). This 
highlights the reliance of opioid analgesia on the function of MOPr in central pain 
pathways, outlined below. 
The second-order neurones of the dorsal horn propagate noxious stimuli to the thalamus, 
forming the ascending anterolateral tract. Here these neurones synapse with third-order 
neurones which project this signal to the somatosensory cortex resulting in the 
perception of pain (Corder et al., 2018). Aside from the somatosensory cortex, numerous 
thalamic projections, including those to the anterior cingulate cortex and amygdala, form 
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the affective component of pain, which coalesce to construct the perception of pain as a 
complex, subjective and emotional process (Corder et al., 2018). This is of particular 
interest in opioid analgesia, where patient reports typically suggest that under morphine, 
the sensation of pain is still present but that aversive qualities are reduced (Price et al., 
1985). In a similar vein, release of endogenous opioid release in the anterior cingulate 
cortex is a well-documented mechanism through which placebo-induced analgesia can 
occur (Bingel et al., 2006).  
Of particular interest to the action of opioids is the descending pain modulatory pathway, 
which modulates nociceptive signalling at the level of the dorsal horn. The 
periaqueductal grey (PAG), locus coeruleus (LC) and principally the rostral ventromedial 
medulla (RVM) form the key nodes involved in the descending pain modulatory system. 
Indeed, microinjection of the selective MOPr agonist DAMGO into the PAG or RVM is 
sufficient to produce opioid-induced analgesia (Rossi et al., 1994), with rich MOPr 
expression present in the PAG, LC and RVM (Mansour et al., 1994).  
1.2.5 Regulation of MOPr signalling 
As outlined in Chapter 1.1.4, the regulation of MOPr is broadly underpinned by a two-
step process. MOPr regulation is initiated by the largely GRK-dependent phosphorylation 
of the intracellular loops and C-terminal tail of MOPr, with subsequent arrestin 
recruitment leading to receptor desensitization and internalization. (Chapter 1.1.4, Figure 
1.2).  
The two primary sites of agonist-induced phosphorylation at MOPr are the 354TSST357 
and 370TREHPSTANT379 cassettes, located in the C-terminal tail (Lemel et al., 2020). As 
AGC family protein kinases, GRKs phosphorylate serine and threonine residues within 
these cassettes. The study of opioid-induced receptor phosphorylation has been 
progressed by the development of phosphorylation state-specific antibodies (Doll et al., 
2011) and more recently phosphorylation-site deficient MOPr mutants (Kliewer et al., 
2019). Agonist-induced MOPr phosphorylation within the 370TREHPSTANT379 cassette 
is hierarchical, where all opioids appear to phosphorylate Ser375, but sequential 
phosphorylation of flanking S/T residues within this cassette (Thr370, Ser376 and Ser379) is 
observed for high efficacy agonists such as DAMGO, but less so for partial agonists such 
as morphine (Just et al., 2013). The phosphorylation of these MOPr residues in HEK 293 
cells induced by DAMGO has been demonstrated to be dependent on GRK2 and GRK3, 
where morphine-induced Ser375 appeared to be dependent on GRK5 (Doll et al., 2012). 
GRK-dependent phosphorylation of the 370TREHPSTANT379 motif is necessary for 
sustained MOPr interaction with arrestin-3, and the consequent internalization and 
downregulation of MOPr signalling (Miess et al., 2018) (Chapter 1.1.4, Figure 1.2). 
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Studies in CRISPR/Cas9-edited HEK 293 cells have demonstrated that MOPr 
internalization and arrestin recruitment induced by high efficacy MOPr agonists is 
primarily dependent on GRK2 rather than GRK3 (Møller et al., 2020) 
The role of agonist-induced GRK-dependent phosphorylation in rapid MOPr 
desensitization has been extensively studied in the more physiological setting of the 
locus coeruleus (LC) through electrophysiological experiments in brain slices (Birdsong 
et al., 2020). Potassium currents evoked through the opening of GIRK channels 
downstream of MOPr activation provide a real-time measure of MOPr function, and its 
rapid desensitization. Pharmacological inhibition of GRK by Compound 101 (a reportedly 
GRK2/3 selective inhibitor (Thal et al., 2011)) inhibits the rapid MOPr desensitization 
induced by DAMGO, morphine, Met-enkephalin and endomorphin-2 in rat LC neurones 
(Lowe et al., 2015). The importance of these S/T sites in MOPr desensitization in LC 
neurones has also been highlighted genetically, with Met-enkephalin-induced rapid 
MOPr phosphorylation diminished in both mice and rats expressing the phosphorylation-
site deficient MOPr mutant constructs (Arttamangkul et al., 2019a; Kliewer et al., 2019).  
Other intracellular kinases have been described to regulate rapid desensitization of 
MOPr, the most prominent of which is Protein Kinase C (PKC) (Kelly et al., 2008). In 
recombinant systems, inhibition of PKC reduces MOPr desensitization induced by 
morphine, but not DAMGO (Johnson et al., 2006). Similarly, in rat LC neurones, 
activation of PKC through either phorbol 12-myristate 13-acetate (PMA) or activation of 
Gq-coupled M3 muscarinic receptors specifically increases rapid MOPr desensitization 
evoked by morphine and Met-enkephalin, but not DAMGO (Bailey et al., 2004). Evidence 
for the role of PKC in desensitization induced by morphine, but not DAMGO, is 
strengthened by findings in LC neurones from PKC knockout mice (Bailey et al., 
2009b). Intriguingly, the overexpression of a dominant negative GRK2 mutant in rat LC 
neurones inhibited DAMGO-induced MOPr desensitization but had no effect on 
morphine-induced MOPr desensitization (Bailey et al., 2009b). Together, the relative 
contribution of GRK and PKC to MOPr-desensitization is hypothesised to be agonist-
selective, dependent on the intrinsic efficacy of the agonist (Kelly et al., 2008). As such, 
low efficacy partial agonists such as morphine primarily induce MOPr desensitization 
through PKC, with little GRK involvement. Conversely, high efficacy full agonists such 
as DAMGO evoke MOPr desensitization solely through GRK, with no PKC involvement 
(Figure 1.5). The precise mechanisms underpinning the agonist-induced regulation of 
MOPr by PKC are poorly understood. There is however some evidence that Ser363 and 
Thr370 undergo PKC-dependent phosphorylation induced by PMA and morphine in 




Figure 1.5 – Agonist-selective mechanisms of MOPr desensitization dependent on 
agonist efficacy 
An illustration of the current hypothesis around agonist-selective mechanisms of MOPr 
desensitization with relation to the relative contribution of PKC and GRK. MOPr 
desensitization induced by the partial agonist morphine is primarily mediated by PKC, 
with a smaller contribution by GRK. MOPr desensitization induced by the full agonist 
DAMGO is regulated solely by GRK with no contribution from PKC. Met-Enkephalin, an 
agonist of slightly lower efficacy than DAMGO, induces MOPr desensitization primarily 
through GRK, however PKC also has been demonstrated to play a partial role. Together 
this suggests the relative contribution of PKC to agonist-induced MOPr desensitization 
scales dependent on agonist efficacy. The presentation of this diagram was adapted 
from Kelly et al. (2008). 
 
There are a wide range of additional protein kinases which have reported roles in MOPr 
regulation (Williams et al., 2013). One such kinase is c-Jun-N-terminal kinase 2 (JNK2). 
JNK2 has been implicated as a mediator of analgesic tolerance to morphine in mice 
(Melief et al., 2010). Additionally, JNK2 has been shown to regulate cellular tolerance to 
morphine in dorsal root ganglion neurons (Mittal et al., 2012). Other implicated kinases 
include extracellular signal regulated 1/2 (ERK1/2) (Macey et al., 2006; Dang et al., 2009) 
phospholipase D2 (Koch et al., 2004) and c-Src (Walwyn et al., 2007). 
Drug tolerance is defined as a loss of responsiveness to an agonist upon repeated 
exposure (Williams et al., 2013). The phenomenon of opioid tolerance is evident in 
clinical practice and also in whole-animal studies (McQuay, 1999; Morgan et al., 2011). 
In both cases, the precise cellular and molecular mechanisms underlying these 
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processes are difficult to resolve. However, there is a good body of evidence that agonist-
induced MOPr desensitization, through phosphorylation and internalization, is an 
important molecular mechanism as a progenitor of tolerance (Bailey et al., 2009a; 
Arttamangkul et al., 2019a). The role of GRK and arrestin proteins in the development 
of tolerance to opioids has been demonstrated through the use of genetically modified 
mice.  
Pivotal early studies in arrestin-3 knockout mice demonstrated that analgesia induced 
by morphine was enhanced and prolonged relative to wild type mice, with the degree of 
tolerance developed to the antinociceptive effects of morphine diminished (Bohn et al., 
1999; Bohn et al., 2000; Bohn et al., 2002). Genetic studies into the role of GRK, in 
particular GRK2, as the key modulator of MOPr phosphorylation and tolerance, have 
been limited given that homozygous deletion of GRK2 is embryonically lethal (Lemel et 
al., 2020). Conditional or inducible GRK2 knockout animals may present a future strategy 
to address this, alongside the recent development of systemically active pharmacological 
GRK inhibitors (Waldschmidt et al., 2017). However, more recent approaches have 
studied the role of GRK phosphorylation in opioid-induced tolerance using phosphosite-
deficient MOPr mutant mice. This was first examined in MOPr mutants in MOPr mutants 
in which the principal GRK phosphorylation site Ser375 was substituted for alanine 
(S375A), and consequently analgesic tolerance to DAMGO and fentanyl, but not 
morphine, were diminished (Grecksch et al., 2011). More recently, knock-in mice 
expressing a ‘total phosphosite-deficient’ MOPr have been generated, with alanine 
substitutions for all 11 serine/threonine residues within the C-terminal tail (11S/T-A) 
(Kliewer et al., 2019). In the 11S/T-A mice, antinociceptive tolerance to fentanyl and 
morphine is significantly reduced, highlighting that phosphorylation of these residues is 
necessary for the development of tolerance to both high and low efficacy agonists 
(Kliewer et al., 2019). Intriguingly, these studies replicated previous findings for S375A 
mice, with tolerance to fentanyl but not morphine diminished, suggesting that 
phosphorylation of C-terminal S/T residue(s) outside of Ser375 regulates morphine 
tolerance (Grecksch et al., 2011; Kliewer et al., 2019). 
In parallel with findings for morphine-induced MOPr desensitization, PKC has also been 
demonstrated to be a key mediator of antinociceptive tolerance to morphine through use 
of pharmacological PKC inhibitors (Bohn et al., 2002; Hull et al., 2010). Additionally, the 
agonist-selective mechanisms of MOPr desensitization previously highlighted (Figure 
1.5) are mirrored for opioid-induced tolerance, with the high efficacy agonist DAMGO 
inducing tolerance through GRK with no PKC involvement and morphine, a lower 
efficacy agonist, inducing tolerance through PKC with little GRK involvement (Hull et al., 
2010).   
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1.2.6 G protein-independent signalling of MOPr 
As previously described in broad terms, aside from their function in GPCR regulation, 
arrestins and GRKs activated downstream of GPCRs are able to function as platforms 
for G protein-independent GPCR signalling (Chapter 1.1.5). The principal signalling 
pathway through which arrestin-dependent signalling occurs appears to involve the 
activation of ERK1/2 MAPKs (Luttrell et al., 1999; Luttrell et al., 2001). 
Particular interest in the physiological relevance of this signalling originated from pivotal 
work in arrestin-3 knockout mice (Bohn et al., 1999; Bohn et al., 2000; Raehal et al., 
2005). As expected, initial findings in this model demonstrated the importance of arrestin 
proteins in the development of opioid tolerance (Bohn et al., 1999). Subsequent work 
within these models intriguingly showed that morphine-induced constipation and 
respiratory depression were reduced in the arrestin-3 knockout mice (Raehal et al., 
2005), implying that these common opioid-induced on-target adverse effects were 
mediated by G protein-independent, arrestin-3-dependent mechanisms. These findings 
fostered a dominant hypothesis within the opioid field, that the analgesic effects of MOPr 
activation are G protein-dependent, but the clinically limiting adverse effects of MOPr 
activation are arrestin-3-dependent (Figure 1.6). As a direct consequence of this, drug 
discovery groups have sought to harness biased agonism at MOPr in anticipation of 
developing safer opioid analgesics (Chapter 1.3) (Conibear et al., 2019).  
However, recent evidence has directly contradicted previous findings in arrestin-3 
knockout mice (Gillis et al., 2020b). Firstly, in mice expressing phosphosite-deficient 
MOPr the observed degree of opioid-induced respiratory depression and constipation 
was similar to that in wild type animals (Kliewer et al., 2019). Additionally, recent studies 
in arrestin-3 knockout mice failed to reproduce the original findings of Raehal et al. 
(2005), with morphine- and fentanyl-induced respiratory depression persisting in 
arrestin-3 knockout mice (Kliewer et al., 2020). In addition, recent mechanistic evidence 
in brain regions regulating respiratory function have similarly demonstrated that opioid-
induced respiratory depression occurs in the main through activation of GIRK channels 
and inhibition of VGCCs downstream of MOPr activation, not through arrestin-mediated 
signalling (Levitt et al., 2015; Montandon et al., 2016; Wei et al., 2019). Together, these 
data imply that GRK/arrestin-dependent MOPr signalling does not regulate specific 
adverse effects of opioids as previously hypothesised (Figure 1.6). However, within this 
new evidence, it is clear that in mice expressing phosphosite-deficient MOPr, morphine 
and fentanyl-induced receptor desensitization and antinociceptive tolerance is reduced 
(Kliewer et al., 2019). In line with findings in arrestin-3 knockout mice (Bohn et al., 2000), 





Figure 1.6 – Functional effects of MOPr-mediated G protein and arrestin signalling 
A schematic depiction showing the signalling pathways responsible for MOPr-
dependent, opioid-induced physiological effects under (left) previous hypothesis (Raehal 





1.3 Biased signalling at MOPr 
1.3.1 Rationale for the development of G protein-biased MOPr agonists 
In light of recent developments, it is evident that ligands at GPCRs have the potential to 
preferentially couple to specific signalling downstream of receptor activation, through the 
phenomenon of biased signalling (Chapter 1.1.6). Previous hypotheses regarding 
arrestin-mediated signalling at MOPr (Chapter 1.2.6, Figure 1.6) (Raehal et al., 2005) 
actively drove drug discovery to seek and develop G protein biased agonists at MOPr 
(Conibear et al., 2019). By preferentially coupling to G protein signalling and evading 
arrestin-3 signalling, it was postulated that G protein-biased MOPr agonists would retain 
the analgesic properties of typical opioids with fewer of the adverse effects which are 
archetypal of opioids (Figure 1.7). The therapeutic potential of G protein-biased agonists 
under this hypothesis is evidently of particular interest, as it may provide a means to the 
‘holy grail’ – an opioid analgesic without adverse effects. As such, following significant 
focus and intent from drug discovery groups, a number of reportedly G protein-biased 
agonists at MOPr have been developed (Chapter 1.3.2).  
However, in light of recent evidence regarding arrestin-mediated MOPr signalling 
(Chapter 1.2.6, Figure 1.6), the rationale underlying the anticipated therapeutic potential 
of G protein-biased agonists at MOPr has recently come under significant scrutiny (Gillis 
et al., 2020b). Nevertheless, the reaffirmed role of GRK/arrestin pathways in MOPr 
desensitization and the development of tolerance to opioids (Chapter 1.2.6) suggests 
that G protein-biased MOPr agonists would induce less MOPr desensitization and 
tolerance than typical, non-biased opioids (Figure 1.7). If G protein-biased MOPr 
agonists are indeed less susceptible to the develop of analgesic tolerance, they would 
present substantial clinical benefit in the treatment of chronic pain compared to typical 




Figure 1.7 – The potential pharmacological profile of G protein-biased agonists at 
MOPr 
A schematic depiction of the potential pharmacological profile of G protein-biased 
agonists at MOPr effects under (left) previous hypothesis of arrestin-dependent 
signalling at MOPr (Raehal et al., 2005) and (right) in light of current evidence (Kliewer 




1.3.2 The pharmacology of reportedly biased agonists at MOPr 
Opioid ligands which possess bias for either G protein or arrestin signalling have been 
reported over the past decade (Conibear et al., 2019). Indeed, many programmes 
specifically seeking to develop biased ligands at MOPr have yielded novel MOPr 
agonists. Additionally, a number of established opioids have retrospectively been 
redefined as biased ligands based on new data on their signalling profiles (Rivero et al., 
2012).  
The first noteworthy small molecule specifically developed as a G protein-biased agonist 
at MOPr was TRV130, also known as oliceridine. TRV130 was reported to be G protein-
biased relative to morphine in comparisons of its activity between cAMP accumulation 
assays and assays of arrestin-3 recruitment (DeWire et al., 2013). In preclinical studies, 
TRV130 was demonstrated to be an effective analgesic in comparison to morphine, but 
possessed a somewhat favourable adverse effect profile, inducing less respiratory 
depression and constipation than morphine at equi-effective doses for analgesia 
(DeWire et al., 2013). Despite displaying minimal benefit relative to morphine in clinical 
trials, with little to no evidence of a favourable adverse effect profile (Singla et al., 2019), 
TRV130 was recently clinically approved for the treatment of severe pain (Markham, 
2020). Additionally, the reported G protein-biased profile of TRV130 has been called in 
to question (Dekan et al., 2019; Gillis et al., 2020a), with suggestions that its 
pharmacological profile is instead due to its low intrinsic efficacy relative to morphine 
(Yudin et al., 2019; Gillis et al., 2020a). 
The novel ligand PZM21 was also specifically designed and developed as G protein-
biased agonist at MOPr. PZM21 demonstrated substantial activity in assays of cAMP 
accumulation with minimal levels of arrestin-3 recruitment, however no formal 
calculations of biased agonism were conducted (Manglik et al., 2016). In preclinical 
mouse studies by Manglik et al. (2016), PZM21 produced analgesia comparable to 
morphine in mouse hot plate assays, but was less liable to induce respiratory depression, 
constipation and reward. This is in line with the previously anticipated profile of G protein-
biased agonists at MOPr (Figure 1.7). Intriguingly, PZM21 did not produce analgesia in 
mouse tail flick assays, presenting a potential discrepancy between its effects on 
affective (hot plate) and reflective (tail flick) nociception (Manglik et al., 2016). However, 
PZM21 was found to induce respiratory depression to comparable levels as morphine 
by a separate subsequent study (Hill et al., 2018b). Additionally, in a similar manner to 
TRV130, the reportedly biased signalling profile of PZM21 has been subject to opposing 
reports (Hill et al., 2018b; Gillis et al., 2020a), with again its low efficacy being proposed 
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as the signalling parameter which is responsible for its pharmacological profile (Yudin et 
al., 2019; Gillis et al., 2020a).  
The synthesis of the SR-series of small molecules by Schmid et al. (2017) yielded a 
range of MOPr agonists with reported varied biased profiles. SR17018 displayed the 
highest degree of G protein-bias within this series, displaying relative bias for activity in 
GTPS assays over arrestin-3 recruitment compared to DAMGO. SR17018 produced 
effective analgesia in vivo yet was reported to induce minimal respiratory depression 
(Schmid et al., 2017). Attempts to repeat the in vivo experiments of MOPr pharmacology 
for SR17018 have been limited by its very poor solubility (Gillis et al., 2020a). 
Additionally, the reportedly biased signalling profile of SR17018 is disputed by other 
reports, again suggesting it is instead a low efficacy partial agonist (Gillis et al., 2020a).  
The development of the novel opioid peptide bilorphin came from a rather “left field” 
source of an Australian estuarine fungus (Dekan et al., 2019). Dekan et al. (2019) 
demonstrated that bilorphin exhibited a greater degree of G protein-bias than TRV130 in 
recombinant systems. Importantly, the G protein efficacy of bilorphin was similar to 
morphine both in a system of physiological receptor expression (LC electrophysiology) 
and in cells expressing recombinant MOPr pharmacologically depleted of receptor 
reserve. This suggests the perceived bias profile of bilorphin is not in fact due to weak 
partial agonism. Unfortunately, the study of bilorphin pharmacology in vivo was limited 
by a lack of systemic activity due to poor blood-brain barrier penetration.   
The endomorphin peptides, endomorphin-1 and endomorphin-2, were among the first 
ligands formally demonstrated to possess bias at MOPr. In contrast to the preceding 
discussion, the endomorphin peptides were demonstrated to be biased for arrestin-
signalling over G protein-signalling (McPherson et al., 2010; Rivero et al., 2012; 
Burgueño et al., 2017; Dekan et al., 2019). The functional significance of this observation 
is yet to be defined in physiological terms. Interestingly, a number of cyclic endomorphin 
analogues, originally developed to improve the metabolic stability of these peptides 
(Czapla et al., 2000; Wilson et al., 2000), possess attractive in vivo pharmacology akin 
to the hypothesised pharmacological of G protein-biased agonists (Zadina et al., 2016; 
Webster et al., 2020). In the absence of formal assessment for the signalling properties 
of this agonists, it could be speculated that these cyclic endomorphins are indeed G 
protein-biased agonists at MOPr. This could indicate that the endomorphin scaffold could 
be disposed to yielding biased agonists. The recent development of a series of cyclic 
endomorphin analogues with by high MOPr affinity by Li et al. (2016) has yielded Try-
c[D-Lys-Phe-Try-Gly] (termed Compound 1) (Figure 1.8), which is of significant interest 




Figure 1.8 – The chemical structures of both non-biased and reportedly biased 
agonists at MOPr 
The chemical structures of non-biased (or ‘balanced’) reference MOPr agonists (black), 
as well as reportedly G protein-biased (blue) and arrestin-biased (red) at MOPr. 
Morphine and DAMGO are non-biased reference agonists at MOPr. Reported G protein-
biased MOPr agonists include TRV130, PZM21, Try-c[D-Lys-Phe-Try-Gly] (Compound 
1), SR17018 and bilorphin. Endomorphin-2 is reported to be an arrestin-biased agonists 
at MOPr. The reported data for reportedly biased MOPr ligands is summarised in 
Chapter 1.3.2.   
 
 31 
1.3.3 MOPr regulation and tolerance induced by G protein-biased agonists 
Current evidence around arrestin-mediated MOPr signalling suggests that GRK/arrestin 
pathways are responsible for the rapid desensitization of MOPr and the subsequent 
development of tolerance in vivo (Chapter 1.2.6, Figure 1.6) (Bohn et al., 2000; 
Arttamangkul et al., 2019a; Kliewer et al., 2019). In turn, this suggests that G protein-
biased agonists at MOPr may induce less receptor desensitization and may 
subsequently be less liable to develop tolerance to their effects in vivo (Figure 1.7). 
However, agonist-selective non-GRK dependent mechanisms of receptor 
desensitization and tolerance are well described at MOPr, particularly concerning PKC 
(Kelly et al., 2008). It is possible that G protein-biased agonists may instead induce MOPr 
desensitization and tolerance through such non-GRK mechanisms. Studies of G protein-
biased agonist pharmacology have largely focussed on analgesia and respiratory 
depression, with limited evidence available on their ability to induce receptor 
desensitization and tolerance (Conibear et al., 2019).  
Although the arrestin/GRK coupling induced by G protein-biased MOPr agonists is 
relatively well studied in recombinant systems, MOPr desensitization induced by these 
ligands in a physiological setting has not been examined. One would hypothesise 
however that G protein-biased agonists would induce lower levels of MOPr 
desensitization than balanced agonists, due to their low coupling to related GRK/arrestin 
pathways (Figure 1.7). As anticipated, the arrestin-biased MOPr agonist endomorphin-2 
produces substantially more receptor desensitization in rat LC neurones than the 
balanced agonist morphine, with which it shares a similar G protein efficacy (Rivero et 
al., 2012).  
Current evidence around tolerance induced by reportedly G protein-biased MOPr 
agonists is variable. In mice, TRV130 has been demonstrated to induce less 
antinociceptive tolerance than morphine after 3-4 days repeated administration (Altarifi 
et al., 2017; Liang et al., 2019). A  separate study by Singleton et al. (2021) also 
demonstrated that TRV130 produces potent antinociception in mice, without evidence of 
tolerance. However, tolerance to the antinociceptive effects of TRV130 was observed 
upon reduction of MOPr availability through use of heterozygous MOPr knockout mice 
(Singleton et al., 2021). Similarly tolerance was not observed to the antinociceptive 
effects of SR17018 after 6 days of repeated oral dosing (Grim et al., 2020) However, 
PZM21 produced robust antinociceptive tolerance in mice over 4 days of repeated 
administration (Hill et al., 2018b). Together this limited, variable evidence potentially 
implies that G protein-biased agonists at MOPr may induce less tolerance, which would 
make them clinically beneficial compared to typical opioids. However, the validity of the 
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proposed biased profile of the aforementioned agonists is keenly debated (Chapter 
1.3.2), and the long-term functional consequences of biased signalling at MOPr therefore 




1.4 Scope and aims of this thesis 
Opioid agonists at MOPr remain unsurpassed as our most effective therapeutic option 
for the treatment of moderate to severe pain. This is despite their clinical utility being 
severely limited by the propensity of opioids to induce serious on-target adverse effects 
such as respiratory depression, and the rapid development of tolerance to their analgesic 
effects. Historically, drug discovery has relentlessly pursued the development of novel, 
safer opioid drugs through a series of means. The characterisation of biased signalling 
at GPCRs could potentially bring about a new generation GPCR-targeting therapeutics, 
selective and refined in their pharmacological profile. Biased signalling has been widely 
harnessed at MOPr with the development of a panel of reportedly G protein-biased MOPr 
agonists developed, in the anticipation that they will be effective analgesics devoid of 
typical opioids adverse effects.  
The long-term functional effects of G protein-biased MOPr agonists remain 
understudied. There is potential that G protein-biased agonists at MOPr may induce less 
receptor desensitization due to their low coupling to common receptor regulatory 
pathways (GRK and arrestin). It is therefore hypothesised that subsequent tolerance to 
the effects of G protein-biased opioids may develop more slowly and to a lesser extent 
than traditional opioids, making them clinically appealing. However, agonist-selective 
non GRK-dependent mechanisms of agonist-induced receptor desensitization and 
tolerance are well described at MOPr in the case of morphine. This implies that non-
GRK/arrestin pathways could also regulate MOPr function upon activation by G protein-
biased agonists and drive the development of tolerance to these novel opioids. 
The work within this thesis seeks to characterise the receptor desensitization and 
regulation induced by biased agonists at MOPr to further our understanding of their long-
term functional effects. Accordingly, the specific aims of this thesis are as follows: 
1. To characterise the signalling properties and biased signalling profiles of putatively 
G protein biased MOPr agonists using recombinant BRET assays and isolated tissue 
experiments (Chapter 3). 
2. To investigate receptor desensitization induced by previously characterised G 
protein-biased MOPr agonists in rat locus coeruleus neurones in brain slices using 
patch clamp electrophysiology (Chapter 4). 
3. To characterise using pharmacological tools the mechanisms involved in the 
potential MOPr desensitization induced by G protein-biased agonists in locus 
coeruleus neurones (Chapter 5). 
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Chapter 2: Materials & Methods 
2.1 In vitro cell signalling studies 
2.1.1 General cell culture methods and transfection 
Human embryonic kidney (HEK) 293 cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) containing L-Glutamine (ThermoFisher), supplemented with 10 % (v/v) 
foetal bovine serum (FBS) (Life Technologies), 100 U/ml penicillin and 100 g/ml 
streptomycin (Invitrogen). Cells were maintained at 37°C in a humidified atmosphere of 
95 % air and 5 % CO2. Cells were seeded onto 10 cm dishes and grown to approximately 
80 % confluency before transient transfection. 
HEK 293 cells were transiently transfected with required plasmids using lipofectamine 
2000 (Invitrogen) transfection. Transient transfections were conducted approximately 48 
hours prior to the desired assay time. DMEM growth media was removed and cultured 
cells were washed with phosphate-buffered saline before replacement of growth media 
with reduced serum OptiMEM media (ThermoFisher). The desired plasmid DNA for the 
individual experiment was diluted in OptiMEM media to a total volume of 500l to the 
experiment-specific desired concentrations outlined below. Separately, the lipofectamine 
reagent was diluted in OptiMEM at a ratio of 1 : 2.7 DNA (g) to lipofectamine (l). DNA 
and lipofectamine solutions were incubated at room temperature for 5 min before they 
were combined. After 20 min incubation at room temperature, the DNA-lipofectamine 
solution was then added gently, dropwise to the HEK 293 cells. Cells were incubated 
with DNA-lipofectamine in OptiMEM media overnight before the replacement of the 
media with DMEM growth media the following day. Cells were allowed to grow in DMEM 
growth media for a further 24-32 hours before assay.  
2.1.2 Bioluminescence Resonance Energy Transfer (BRET) assays 
A number of bioluminescence resonance energy transfer (BRET) assays were utilised 
in our studies to determine the ability of opioid agonists to induce activation of GI G 
proteins downstream of opioid receptors, and recruitment of both arrestin-3 and arrestin-
2 at MOPr. The optimisation of these BRET assay platforms was conducted previously 
by Dr Gerta Gasiuniate, demonstrating the optimal ratio of donor : acceptor DNA and the 
absence of BRET signal in cells transfected with pcDNA alone (Gasiunaite, 2017).  
Assays of BRET are dependent on energy transfer between a bioluminescent donor and 
a fluorescent acceptor, such as Renilla luciferase (Rluc) and green fluorescent protein 
(GFP) respectively. Rluc catalyses the oxidation of the introduced substrate 
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coelenterazine to coelenteramide, a process which emits light with a peak at a 410 nm 
wavelength (for coelenterazine 400a). Light of this wavelength is then able to excite GFP, 
which then emits light at a longer wavelength of 515 nm. However, due to the efficacy of 
this energy transfer being heavily dependent on distance, BRET will only occur when the 
distance between the BRET donor and acceptor is very low (less than approximately 100 
Å). The magnitude of this energy transfer can be quantified through calculation of the 
ratio between the acceptor and donor emissions peaks: the BRET ratio. An increase in 
the BRET ratio indicates that the distance between the donor and acceptor has 
decreased, while a decrease in the BRET ratio reflects the distance between the donor 
and acceptor increasing.  
The use of BRET donor and acceptor tags provides an effective method to study protein-
protein interactions in a whole cell environment. The configurations for our BRET assays 
for GI activation and arrestin translocation are schematically depicted in Figures 2.1 
and 2.2.  
In our assays of opioid-induced GI activation, HEK 293 cells were transiently 
transfected with 3 g of Gi-RlucII and 3 g GFP10-G2 as well as 3 g of rat HA-MOPr, 
human HA-DOPr or human HA-KOPr per 10 cm dish (Figure 2.1). Under no receptor 
activation, the labelled G protein subunits remain associated and in close proximity, 
producing a BRET signal (Figure 2.1A). Upon receptor activation by an agonist, the 
labelled G protein subunits dissociate, or rearrange, resulting in a reduction in the BRET 
ratio (Figure 2.1B).  
In assays of opioid-induced arrestin-3 translocation, HEK 293 cells were transiently 
transfected with 5 g of human MOPr-RlucII and 5 g of either arrestin-3-GFP10 or 
arrestin-2-GFP10 per 10 cm dish (Figure 2.2). In assay of arrestin-3 recruitment in which 
GRK2 was overexpressed, cells were in addition transfected with 5 g of wild type GRK2 
or pcDNA3.1. In this instance, under basal conditions the labelled MOPr and arrestin 
proteins are not in close proximity, meaning the BRET ratio is low (Figure 2.2A). Upon 
MOPr activation by an agonist, the labelled arrestin protein is recruited to the receptor 
bringing the BRET donor and acceptor in close proximity thereby increasing the BRET 




Figure 2.1 – The methodological principles of the G protein activation BRET assay 
in the case of MOPr 
In both scenarios, renillia luciferase II (RlucII), which is conjugated to the GI subunit, 
catalyses the oxidation of added Coelenterazine 400a to coelenteramide, a process 
which releases light (hv) of 395 nm wavelength. (A) Under basal conditions (no agonist), 
the BRET donor/acceptor tagged G protein subunits are in close proximity. Hereby, the 
395 nm light emitted from the RlucII excites the GFP10 which is tagged to the associated 
G subunit, in turn releasing light of a longer wavelength (510 nm). (B) Upon addition of 
an agonist and subsequent activation of MOPr, the G protein subunits dissociate or 
rearrange relative to one another. As such, the BRET donor (RlucII) and acceptor 





Figure 2.2 – The methodological principles of the arrestin recruitment BRET assay 
in the case of arrestin-3 
In both scenarios, renillia luciferase II (RlucII), which is conjugated to MOPr, catalyses 
the oxidation of added Coelenterazine 400a to coelenteramide, a process which releases 
light (hv) of 395 nm wavelength. (A) Under basal conditions (no agonist), the BRET 
donor/acceptor tagged receptor and arrestin-3 are not in close proximity. Therefore, no 
increase in BRET is observed. (B) However, upon activation of MOPr by an agonist, the 
GFP10-tagged arrestin-3 is recruited to MOPr-RlucII, bringing them in to close proximity. 
Now the 395 nm light emitted from the RlucII excites the GFP10 which is tagged onto  
arrestin-3, in turn releasing light of a longer wavelength (510 nm). As such, an increase 





In all BRET assay configurations, transfected HEK 293 cells were resuspended in clear, 
serum-free DMEM (ThermoFisher) and then transferred to flat-bottomed 96 well Corning 
plates at 90 l per well 1 hour prior to assaying. Drug solutions, dissolved in water or 
DMSO, were diluted to the required concentration in clear, serum free DMEM, with the 
final assay concentration of DMSO never exceeding 0.1% v/v. 10 l of the drug dilutions 
was added to the plated cell suspension prior to measurements of BRET activity. Drugs 
were incubated with cell suspensions at 37°C within the FLUOstar Omega microplate 
reader (BMG Labtech) for 2 min or 10 min for the G protein and arrestin assays 
respectively. These incubation times were based on previous optimisations conducted 
within the University of Bristol laboratory by Dr Katy Sutcliffe (Sutcliffe, 2019). 
Coelenterazine 400a (5 M final concentration, dissolved in methanol) was injected into 
the wells of the cell plate by the FLUOstar Omega microplate reader prior to the taking 
of BRET measurements. Measurements of BRET were recorded using the following 
filters: acceptor (GFP), 410  80 nm; and donor (RlucII), 515  30 nm. BRET signals 
were recorded at both 5- and 8-seconds post coelenterazine 400a injection and results 
were averaged to form the final result for each well.  
All conditions were performed in duplicate and the average response was taken. For the 
GI activation assays, the percentage decrease in the BRET ratio was calculated to 
express opioid-induced responses, with the BRET ratio from transfected cells treated 
with media + DMSO used as the baseline control. In the case of the arrestin recruitment 
assays, measurements of BRET are presented as BRET ratio minus the background 
BRET ratio obtained from transfected cells treated with media + DMSO.  
Concentration-response data from 5 independent experiments was combined and fitted 
using non-linear curve models in GraphPad Prism version 8, in order to obtain pEC50 
and EMax values. The equation for the 3-parameter logistic equation is given below 
(Equation 1). 




where Top and Bottom represent the maximal and minimal asymptotes of the 
concentration response curve, EC50 is the molar concentration of agonist required to 
induce a response halfway between the Top and Bottom values and [A] is the molar 
concentration of the agonist, and Y is response. Given that the BRET ratio output of the 
assays had baseline values subtracted, the minimal asymptote of concentration-
response curves was constrained to 0.  
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A 3-parameter logistic fit was utilized in our studies as opposed to a 4-parameter logistic 
fit in order to reduce uncertainty around parameter fitting within our models. As such, the 
Hill Slope value of our concentration response curves was effectively constrained to 1 
(effect on fitted parameters described in Chapter 3.2.1.1).  
Concentration-response data to our test agonists were compared to those determined 
for the well-characterised MOPr control ligands DAMGO and morphine, which were run 
in the same experiments. Fitted parameters for test agonists were statistically compared 
to control agonists through one-way ANOVA with post-hoc Tukey tests.  
2.1.3 Quantification of biased signalling 
A number of analytical methods were employed in Chapter 3 in attempts to quantify 
potential biased agonism at MOPr in our BRET assays of opioid induced G protein and 
arrestin signalling (Chapter 3.2.1.2).  
The prevailing method used for the analysis of biased agonism at GPCRs is through the 
generation of a pathway-specific metric of agonist activity, the transduction coefficient 
(/KA), calculated using a form of the Black-Leff operational model. The operational 
model describes the response of an experimental system to an agonist (Equation 2). 
(2) 𝑌 = 𝑏𝑎𝑠𝑎𝑙 +  
(𝐸𝑀 − 𝑏𝑎𝑠𝑎𝑙)
𝑛[𝐴]𝑛
𝑛[𝐴]𝑛 + ([𝐴] + 𝐾𝐴)𝑛
 
Where basal is the response in absence of agonist, EM is the theoretical maximal 
possible response of the system,  is the operational efficacy (a composite factor of an 
agonist’s intrinsic efficacy, effector coupling and receptor density), n is the slope of the 
transducer function, [A] is the concentration of agonist and KA is the functional equilibrium 
dissociation constant, and Y is response. The fitted  values from this analysis were 
utilised for analyses of signalling bias through the log() methodology (Chapter 
3.2.1.2, Figure 3.4) (Burgueño et al., 2017).  
In order to allow for curve fitting, the transduction coefficient (/KA) was expressed as a 
single parameter, R. To obtain this coefficient, concentration response data were fitted 
to a modified version of the operational model (Equation 3), which was derived from 
Equation 2 (Sutcliffe, 2019). 













In use of both equations 2 and 3 for fitting concentration response data, the basal value 
was constrained to 0 and the n value was constrained to be shared across all agonist 
concentration-response curves. 
The following calculation was made to remove influence of systems bias, through 
normalisation of the pathway specific metric of agonist activity (/KA) to that of the 
reference agonist morphine in each assay (Equations 4).  
(4)    log (

𝐾𝐴











The log(/KA) thereby provides an index of an agonist’s activity at a specific pathway, 
relative to a reference agonist. In order to calculate potential biased signalling between 
assays of G protein activity and arrestin-3 recruitment for a specific agonist, the following 
calculation was made (Equation 5), resulting in a final log(/KA) value. The antilog 
value of an agonist’s log(/KA) value was then reported as its “bias factor”. 
(5)    log (

𝐾𝐴











The standard error values for each agonist’s log(/KA) values was calculated through 
Equation 6. The error associated with an agonist’s log(/KA) value was then propagated 
through Equation 7. 












































An identical approach was used to calculate mean and error values within the 
methodologically similar log() analysis (Burgueño et al., 2017), with log(/KA) in 
Equations 4-7 substituted by the metric log(). 
For partial agonists, in systems of low receptor reserve, the fitted maximal asymptote of 
an agonist’s concentration-response curves (EMax) from basic logistic fitting (Equation 1) 
can be used as a robust affinity-independent estimate of that agonist’s intrinsic efficacy 
or  (Stephenson, 1956; Dekan et al., 2019). A comparison of an agonist’s normalised 
EMax values, or  normalised EMax between different pathways (for instance between G 
protein activation and arrestin-3 recruitment) can be used as an efficacy-dependent 
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measure of agonist bias (Dekan et al., 2019). To calculate the  normalised EMax values 
for our agonists, the EMax values of our test agonists were normalised to that of morphine 
and subtracted between the pathways (Equation 8). The standard error of  normalised 
EMax values was propagated through Equation 9. 
(8)    𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝐸𝑀𝑎𝑥 = 𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝐸𝑀𝑎𝑥 𝐺 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 − 𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝐸𝑀𝑎𝑥 𝐴𝑟𝑟𝑒𝑠𝑡𝑖𝑛−3 
(9)   𝑆. 𝐸. 𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝐸𝑀𝑎𝑥
= √(𝑆. 𝐸.𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝐸𝑀𝑎𝑥 𝐺 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 )
2
+ (𝑆. 𝐸.𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑠𝑒𝑑 𝐸𝑀𝑎𝑥 𝐴𝑟𝑟𝑒𝑠𝑡𝑖𝑛−3 )
2
 
The resulting agonist-specific bias factors, either log(/KA), log() or  Normalised 
EMax, were each compared through one-way ANOVA with Tukey’s post-hoc test to define 
statistical significance. 
2.1.4 Surface MOPr enzyme-linked immunosorbent assay (ELISA) 
In order to study opioid-induced internalization of MOPr, we assessed surface 
expression of rat HA-MOPr in HEK 293 cells using an enzyme-linked immunosorbent 
assay (ELISA), based on previously used methods (Rivero et al., 2012).  
HEK 293 cells at approximately 80% confluency were transiently transfected with HA-
MOPr pcDNA (5 g per 10 cm dish) using the lipofectamine 2000 transfection method 
(Chapter 2.1.1). Transfected cells were then plated in a 24 well plate coated with 0.1 
mg/ml  poly-L-lysine (Sigma-Aldrich) 24 hours prior to assay. Wild type, non-transfected 
HEK 293 cells were also plated in the same 24 well plate to be used as background 
controls. 
The following morning, cell media was replaced with serum-free clear DMEM. Drug 
dilutions, made in serum-free clear DMEM, were then incubated with the cells for 15 to 
60 min at 37°C before the media was aspirated and the reaction was fixed with 3.7 % 
(v/v) paraformaldehyde (PFA) (VWR) for exactly 5 minutes. The PFA solution was then 
aspirated and fixed cells were washed 3 times with tris-buffered saline (TBS) to remove 
remaining PFA. Fixed cells were then incubated with 1% (w/v) bovine serum albumin 
(BSA) (Sigma-Aldrich), in TBS, for 45 min to reduce non-specific antibody binding. 
Subsequently, the BSA solution was aspirated and cells were incubated with the primary 
mouse anti-HA monoclonal antibody (1:1000, in TBS containing 1% BSA) (#MMS-101R, 
BioLegend) for 1 hour. The primary antibody containing TBS was then aspirated and 
cells were again washed 3 times with TBS before they were blocked with 1% BSA, 
incubated for 15 min. The blocking media was then aspirated, and cells were incubated 
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with the secondary goat anti-mouse IgG alkaline phosphatase conjugate antibody 
(1:1000, in TBS containing 1% BSA) (#A5153, Sigma Aldrich). The secondary antibody 
solution was then aspirated, and cells were washed with TBS 3 times before they were 
incubated with alkaline phosphatase substrate (Bio-Rad Laboratories) for 1 h at 37°C to 
detect the signal from the secondary antibody conjugate. The alkaline phosphatase 
substrate was transferred from the 24 well cell plate to a 96 well reading plate and the 
alkaline phosphatase reaction was terminated by the addition of 0.4 M NaOH, at a 1:1 
ratio. Absorbance (405 nm) of the samples was then assayed on a Tecan Infinite plate 
reader (Tecan).  
Absorbance values were normalised to values in wells containing untreated HEK 293 
cells expressing MOPr (100%) and untreated, non-transfected WT HEK 293 cells (0%). 
All ELISA experiments were performed in triplicate and an average taken to constitute 
each repeat. Total agonist-induced loss of surface MOPr over time was assessed by 
determining the total area under the curve (AUC) for each agonist over the 60-minute 
time course using in built analysis in GraphPad Prism (version 8). A one sample t test 
was used to determine whether the generated AUC for induced surface loss of MOPr by 
an agonist was significantly different from 0. If the AUC of agonist-induced loss of surface 
MOPr over time was significantly higher than 0, it was inferred it induced significant loss 
of surface receptor.  
2.1.5 Phosphosite-specific immunoblotting of MOPr 
In order to study agonist-induced phosphorylation of C-terminal MOPr residues, we 
sought to utilise immunoblotting through phosphospecific antibodies. This work was 
kindly performed and analysed for us by Nina Kathleen Blum, supervised by Dr Andrea 
Kliewer and Prof Stefan Schulz at the University of Jena, Germany. 
Agonist-induced MOPr phosphorylation was assessed using Western blotting with 
phosphospecific antibodies as previously described (Gillis et al., 2020a). Briefly, HEK 
293 cells stably expressing mouse HA-MOPr were seeded on to 6 cm dishes, maintained 
in DMEM High Glucose (ThermoFisher) supplemented with 5% (v/v) FBS and 1% 
glutamine and streptomycin/penicillin. At approximately 90% confluency, cells were 
incubated with opioid agonists (10 M DAMGO, 30 M morphine and 30 M PZM21, 1 
nM – 30 M Compound 1) for 30 min before lysis in an immunoprecipitation buffer (50mM 
tris-HCl (pH 7.4), 150 mM NaCl, 5 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, 
0.1% sodium dodecyl sulfate (SDS)). The protease and phosphatase inhibitors complete 
Mini and PhosSTOP (Roche Diagnostics) were included in the immunoprecipitation 
buffer to conserve protein levels and induced phosphorylation. HA-tagged MOPr was 
 
 43 
enriched using Pierce HA epitope tag antibody agarose beads (ThermoFisher). SDS 
sample buffer was then incubated with the samples for 25 min at 43°C to elute proteins 
from the beads. Samples were then separated and resolved on 8% SDS-polyacrylamide 
gels and after electroblotting, PVDF membranes were incubated either anti-pT370, anti-
pS375, anti-T376, or anti-T379 antibodies (Just et al., 2013). Detection was performed 
using a chemiluminescence-detection system. Blots were subsequently stripped and 
incubated again with an anti-HA antibody (phosphorylation independent) to confirm 
equal well loading of receptor protein.  
Raw blot images were used to visually assess multi-site phosphorylation induced by our 
panel of opioids. Levels of agonist-induced pSer375 phosphorylation from 5 individual 
experiments were quantified using image processing software Fiji and signals were 
expressed relative to that of the HA loading control. Levels of agonist-induced pSer375 
phosphorylation were statistically compared to control values using one-way ANOVA 




2.2 Animal housing & welfare 
Wildtype male Wistar rats were used for all electrophysiology experiments (Chapter 2.4) 
and all vas deferens experiments (Chapter 2.3). These rats were bred and maintained 
at the University of Bath. Rats were weaned at approximately P21 and subsequently 
housed in single sex cage groups of 5-6 rats. Cages were housed within ventilated, 
temperature controlled (21  1°C) cabinets under a 12 h light/dark cycle (lights on at 
6am). Food and water were available to the animals ad libitum and cages were cleaned 
weekly. 
In warm water tail withdrawal tests of nociception conducted at the University of Bristol 
(Chapter 2.5), mice of CD-1 and C57BL/J strains were used. Male CD-1 mice weighing 
approximately 30 g were obtained from Charles River. Breeding pairs of MOPr knockout 
mice (Oprm1tm1Kff, RRID:IMSR_JAX:007559) were initially obtained from the Jackson 
Laboratory for a distinct study (Hill et al., 2020), and bred in house at the University of 
Bristol. Both male and female MOPr knockout offspring of these mice, weighing 
approximately 30 g, were used in this study. Male and female C57BL/J mice weighing 
approximately 30 g were obtained from Charles River, for use as background strain 
controls for studies with the MOPr knockout mice. During their holding at the University 
of Bristol, all mice were maintained at 22°C on a reversed dark-light cycle, with food and 
water available ad libitum. All experiments were conducted during the animals’ dark 
(active) phase. Mice were randomly ascribed to their treatment groups with the 
experimenter blind to the drug treatment. Additionally, cages of wildtype or MOPr 
knockout were also blinded to the experimenter. Blinding was maintained until 
completion of data analysis.  
All animal care and experimental procedures were performed in accordance with the UK 
Animals (Scientific Procedures) Act 1986, the European Communities Council Directive 
(2010/63/EU) and the ethical review documents of the University of Bath and the 
University of Bristol. Animal studies are designed and reported in compliance with the 




2.3 Rat vas deferens assay 
2.3.1 Tissue preparation 
Male Wistar rats (6-7 weeks old) were euthanized through exposure to rising CO2 
concentrations in a close-contained environment. The vasa deferentia were then 
dissected out by making incisions at the connecting points of the prostate gland and the 
testis. The connecting tissue, adhering fat, and blood vessels were carefully separated 
from the vasa deferentia and each vas deferens was then divided into two equal sized 
pieces for assaying. Dissected vasa deferentia were placed in warm Krebs solution of 
the following composition (in mM): NaCl 118, KCl 4.74, CaCl2 2.50, KH2PO4 1.19, MgSO4 
1.20, NaHCO3 25, glucose 11. 
2.3.2 Experimental procedures 
Sections of vas deferens tissue were maintained in organ baths (approximately 30 ml) 
containing Krebs solution at 37°C and aerated with 95% O2 and 5% CO2. One end of the 
vas deferens was mounted to an isometric force transducer (AD Instruments). The tissue 
section was then set up to sit between two stainless steel ring electrodes (submerged in 
the organ bath) with the opposing end of the tissue tied and mounted to a fixed hook on 
the electrode holder. Rat vas deferens was mounted under 1.0g initial basal tension. 
After approximately 30 min equilibration, the tissue was continuously stimulated through 
a Grass SD9 stimulator (Grass Medical Instruments) through the two ring electrodes with 
square pulses of supramaximal voltage, 1 ms duration and 0.1 Hz frequency. Electrically-
evoked contractions were measured isometrically and recorded through the data 
acquisition hardware Powerlab 4/26 (AD Instruments). The preparation was allowed to 
equilibrate under continuous stimulation for 1 hr prior to beginning the experiment. 
Drug solutions were serially diluted in Krebs solution. The ability of DAMGO (10-8–10-4.5 
M) to inhibit the electrically-evoked twitches of the rat vas deferens was assessed upon 
cumulative addition, from lowest to highest concentration. Each concentration of interest 
incubated with the tissue for at least 3 min before the addition of a higher concentration.  
Given the insensitivity of the rat vas deferens to MOPr agonists of lower efficacy (Lemaire 
et al., 1978), we sought to define the affinity of our panel of partial MOPr agonists through 
competitive antagonist experiments against DAMGO, using classical Schild experiments 
(Schild, 1947). In order to assess the ability of our panel of partial agonists to inhibit 
DAMGO function, select concentrations were preincubated with the rat vas deferens 
preparation for 20 min prior to, and during, the cumulative addition of DAMGO. For each 
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individual preparation, only a single partial agonist was studied, with the impact of 
different concentrations of the partial agonist examined sequentially working from the 
lowest to the highest test partial agonist concentration.  
2.3.3 Data processing and Schild analysis 
Data from the rat vas deferens preparation were processed and analysed within the 
LabChart software (AD Instruments) which was linked to the PowerLab recording 
hardware. The magnitude of electrically-evoked twitches in each condition (drug 
concentration) was measured by obtaining the maximum – minimum value of twitches at 
the end of the condition’s incubation period using the inbuilt processes within LabChart. 
This value was obtained and averaged across the last three twitches within each 
condition to reduce variability, and then the average baseline response (no twitch) in the 
tissue at this time was subtracted from this value to give a final metric of response. The 
‘% inhibition’ of electrically-evoked contractions of the rat vas deferens was then 
calculated through Equation 10.  
(10)   % 𝐼𝑛ℎ𝑖𝑏𝑡𝑖𝑜𝑛 = 100 × (
 1 − (𝑆𝑎𝑚𝑝𝑙𝑒 𝑇𝑤𝑖𝑡𝑐ℎ 𝐻𝑒𝑖𝑔ℎ𝑡)
𝐵𝑎𝑠𝑎𝑙 𝑇𝑤𝑖𝑡𝑐ℎ 𝐻𝑒𝑖𝑔ℎ𝑡
) 
Where ‘basal twitch height’ refers the magnitude of evoked twitches in the absence of 
drug, at the time point immediately prior to the addition of drug.  
The DAMGO concentration response curves from each preparation, in the presence of 
various concentrations of partial agonist, were all fitted to the 4-parameter logistic fit 
outlined below (Equation 11). 
 (11)   𝑌 = 𝐵𝑜𝑡𝑡𝑜𝑚 +  
(𝑇𝑜𝑝 − 𝐵𝑜𝑡𝑡𝑜𝑚)
1 + 10 (( 𝑙𝑜𝑔𝐸𝐶50−𝑙𝑜𝑔[𝐴])×𝐻𝑖𝑙𝑙 𝑆𝑙𝑜𝑝𝑒 )
 
Where Top and Bottom represent the maximal and minimal asymptotes of the 
concentration response curve, EC50 is the molar concentration of agonist required to 
induce a response half way between the Top and Bottom values and [A] is the molar 
concentration of the agonist. In this equation, the Hill Slope is a fitted parameter which 
describes the steepness of the fitted concentration response curve, where in the three-
parameter logistic equation described in Equation 1 it is a constant of value 1. The plotted 
Y values (% inhibition of evoked-twitch) were normalised to 0% (the basal magnitude of 
evoked-twitch) and 100% (maximum possible inhibition of twitch). Therefore, the Bottom 
value was given the constant value of 0. However, given that the maximum extent of 
inhibition of twitches achieved by opioids could be less than 100%, and naturally cannot 
be greater than 100% (negative twitch), the Top value was constrained to be a value 
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less than or equal to 100. The Hill Slope was constrained to be shared across DAMGO 
concentration response curves from the same tissue preparation. Differences in coupling 
efficacies or tissue viability could impact the Hill Slope of agonist responses, meaning  
constraining the Hill Slope to 1 would lead to poor curve fitting in the case of n ≠ 1. 
However, this should not vary within individual preparations, therefore the Hill Slope was 
shared to reduce error associated with parameter fitting. 
The EC50 values fitted from this regression analysis were used to calculate the dose 
ratios (DR) required for Schild analysis. The series of DRs were reported as log(DR - 1), 
where the log(DR - 1) metric was calculated as follows (Equation 12). 
(12)    log ((
𝐸𝐶50𝐁
𝐸𝐶50
) − 1) 
Where EC50 B represents the EC50 of DAMGO in the examined concentration of an 
antagonist, and EC50 is the potency of DAMGO in control conditions. 
In order to construct Schild plots for each partial agonist (which in this case act as 
antagonists , and are henceforth referred to as such), averaged log(DR - 1) values across 
multiple experiments were plotted against log [B], the antagonist concentration. The 
Schild plot data for each agonist was then subjected to a simple linear regression fit, with 
both the slope unconstrained and with the slope constrained to 1. Fitted slope values 
from unconstrained linear regressions were statistically compared to the hypothetical 
value of 1 through an extra sum-of-squares F test (Kenakin, 2009).  
The Schild equation (Equation 13) was used to determine the affinity of the antagonist 
for MOPr within the rat vas deferens preparation.  
(13)   𝑝𝐴2 = log(𝐷𝑅 − 1) − log [𝐵] 
Where the pA2 is the negative logarithm of the concentration of antagonist required to 
shift the agonist concentration response curve by a factor of 2. The pA2 is equal to the 
equilibrium constant (pKB) of antagonist binding to the receptor when the Schild slope is 
1 (Schild, 1947). [B] represents the concentration of antagonist. When log(DR-1) is 0 
(the x-axis intercept), this indicates a shift in the concentration response curve by a factor 
of 2. Therefore, according to the Schild equation (equation 13), the negative logarithm 
of the antagonist concentration at the x-axis intercept of the linear regression is equal to 
the pA2.  The best fit values of the x-axis intercept from linear regression performed on 
Schild plots containing pooled data, and the corresponding 95% confidence intervals, 
were then reported as the pA2 of the agonist. The pA2 values of select agonists were 
compared statistically using a one-way ANOVA with post-hoc Tukey test. 
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Data from competitive antagonist experiments was also alternatively fitted through an in-
built ‘Gaddum/Schild EC50 Shift’ equation in GraphPad Prism (version 8). The benefit of 
this approach was primarily convenience; however, the data were also fitted as a 
combined set from multiple experiments, rather than in individual repeats which the 
former model describes. A downside to this approach is that it does not output a 
traditional Schild Plot, only a pA2 value. The potential impact of using these two 
methodologies on the values of antagonist pA2 and associated variance on these 




2.4 Brain slice electrophysiology 
2.4.1 Brain slice preparation 
Male Wistar rats (4 weeks old) were anaesthetised via intraperitoneal injection of 160 
mg/kg ketamine and 20 mg/kg xylazine and then decapitated. The brains were rapidly 
removed and immediately submerged into ice-cold solution containing (in mM): 20 NaCl, 
2.5 KCl, 1.6 NaH2PO4, 7 MgCl2, 85 sucrose, 25 D-glucose, 60 NaHCO3, and 0.5 CaCl2, 
and saturated with 95% O2 / 5% CO2. While in this solution, coronal cuts were made with 
a razor blade to remove the anterior frontal cortex, the hippocampi and a portion of the 
cerebellum, leaving a smaller section of brain mainly composed of the midbrain and 
pons, containing the locus coeruleus (LC). Horizontal brain slices (230 m in thickness) 
containing the LC were then prepared using a vibratome (DTK-1000, DSK). During 
slicing, under the guide of the naked eye, the presence of an ‘open’ fourth ventricle (a 
diamond, or heart, shape) was used as an indication of the presence of LC within a 
horizontal slice. LC-containing slices were then cut using a razor blade to separate the 
two hemispheres of each slice. Slices were then transferred to a slice holder containing 
an artificial cerebrospinal fluid (aCSF) containing (in mM): 125 NaCl, 2.5 KCl, 1.2 
NaH2PO4, 1.2 MgCl2, 11.1 D-glucose, 21.4 NaHCO3, 2.4 CaCl2, and 0.1 ascorbic acid, 
saturated with 95% O2 / 5% CO2 which was maintained at 32°C. 
2.4.2 Whole cell voltage-clamped experiments  
Brain slices were submerged in a slice chamber and superfused with a continuous flow 
(2-3 ml/min) of aCSF saturated with 95% O2 / 5% CO2 at 32°C. Slices were visualised 
through oblique optics on an BX51WI upright microscope (Olympus). The surfaces of 
individual neuron somatas were cleared of debris through the application of a gentle flow 
of aCSF from a pipette prior to patching attempts. Whole-cell voltage-clamped 
recordings were made from LC neurones using recording electrodes (of 3-5 M 
resistance) filled with intracellular recording solution containing (in mM): 115 potassium 
gluconate, 10 HEPES, 11 EGTA, 2 MgCl2, 10 NaCl, 2 MgATP, and 0.25 Na2GTP, giving 
an osmolarity of 270 mOsm/L. The pH of this intracellular solution was adjusted to 7.3 
with KOH. Recordings of whole cell currents were amplified and filtered at 2 kHz using 
an Axopatch 200B amplifier (Axon Instruments) and digitised with a sampling rate of 10 
kHz using a Digidata 1440a (Axon Instruments).  
Activation of MOPrs on LC neurones evoked GIRK currents, providing a measurement 
of MOPr activation which could be monitored continuously and in real-time using whole-
cell patch-clamp recordings. LC neurones were voltage clamped at -60 mV, with a 
 
 50 
correction made for a previously calculated liquid junction potential of -12 mV for our 
intracellular solution. All drugs were applied to the brain slice through the superfusing 
solution at known concentrations. In LC neurones, it has been demonstrated that MOPrs 
and 2 adrenoceptors couple to the same population of GIRK channels (North et al., 
1985). Utilising this phenomenon, we controlled for inter-cell variations in opioid-evoked 
current amplitude by normalising to the amplitude of the maximal 2 adrenoceptor-
mediated GIRK current in the same cell, evoked by a supramaximal concentration of 
noradrenaline (NA, 100 M). All 2-adrenoceptor mediated currents were examined in 
the presence of 1 M prazosin and 3 M cocaine. Naloxone (NLX) was applied after 
each opioid application in order to fully reverse evoked GIRK currents to a baseline level. 
While a concentration of 1 M was initially used (Figure 4.1), the slow reversal of 
Compound 1-evoked GIRK currents with this naloxone concentration (Figure 4.1D) 
prompted us to increase this working concentration to 10 M in subsequent experiments. 
2.4.3 Data analysis  
All data from whole cell voltage clamped electrophysiological experiments were acquired 
using WinEDR recording software (University of Strathclyde) and analysed off-line. 
Where traces are presented, the best effort was taken to select individual traces from 
which data were representative of the entire dataset. Data points from traces were 
exported from WinEDR and graphically plotted using GraphPad Prism (Version 8). The 
decline in opioid-evoked GIRK currents was quantified through expression of the 
magnitude of evoked current over time as a percentage of the initial peak current. The 
overall of opioid-induced desensitization, ‘% desensitization’, was representative of the 
magnitude of the opioid-evoked current at a set time post-peak response, either 8 min 
(Figure 4.5) or 10 min (all relevant figures within Chapter 5). Statistical comparisons of 
opioid-induced desensitization or the magnitude of opioid-evoked currents were made 
using one-way ANOVA with post hoc Tukey or Dunnett tests, or through unpaired, two-
tailed t tests where appropriate. The utilised statistical analyses for each experiment are 




2.5 Warm water tail immersion test of nociception 
2.5.1 Experimental procedure  
The warm water tail immersion test of nociception was used in order to characterise the 
antinociceptive properties of morphine and Compound 1 (Janssen et al., 1963). Studies 
were conducted independently in both CD1 wildtype mice and in both C57BL/J wildtype 
and MOPr knockout animals (Chapter 2.2). Studies in CD1 were kindly conducted by Dr 
Rob Hill alongside the author, while studies in C57BL/J wildtype and MOPr knockout 
animals were conducted by the author alone. The methodology outlined below was used 
in both studies. 
A water bath was maintained at 52.5°C. In order to test nociception in this assay, mice 
were restrained in a scruff and the tip of their tail was immersed into the 52.5°C water 
bath. The portion of the tail exposed to the water was standardised to approximately half 
of the overall tail length. The latency of the response to the nociceptive stimulus (the 
removal of the tail from the water) was measured using a stopwatch. Once this response 
was observed, or the 15 second cut-off time was reached, the tail of the mouse was 
immediately removed from the water bath, the tail was dried, and the mouse was 
returned to its home cage.  
Control latency response times were obtained in all subjects at 30 min and 15 min prior 
to the time of injection, in order to provide a baseline value for tail flick latency in each 
mouse. For our studies of Compound 1-induced antinociception in CD1 mice, mice were 
injected with either morphine (10 mg/kg), Compound 1 (50 mg/kg and 100 mg/kg) or 
vehicle (saline) intraperitoneally. In our studies in C57BL/J mice, in both wild type and 
MOPr knockout animals, all mice were injected with Compound 1 (50 mg/kg, i.p.). The 
tail flick latency responses of treated animals were subsequently examined at 15, 30, 
45- and 60-min post-injection.  
2.5.2 Data analysis  
Raw values of tail flick latency (in seconds) were converted to % maximum possible 
effect values (% MPE) (Harris et al., 1964) through Equation 14. 
(14)    (
 T1 −  T0 
 T2 − T0 
) × 100 
Where T1 is the observed tail flick latency (in seconds), T0 is the baseline tail flick latency 
(in seconds) and T2 is the cut-off time (15 seconds). 
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The area under the curve (AUC) was also calculated for % MPE data from baseline – 60 
min post injection (Meymandi et al., 2006), using an in built equation in GraphPad 
(version 8). Non-parametric statistical analyses were used for the analysis of tail flick 
data, with the applied cut off time providing a non-normal distribution of data. A Kruskal-
Wallis test with post-hoc Dunn’s multiple comparisons test was used to compare AUC 
values between the various treatment groups in CD1 mice. A Mann-Whitney test was 





DAMGO [[D-Ala2, N-MePhe4, Gly-ol5]-enkephalin] was purchased from Bachem. 
Morphine sulphate was purchased from MacFarlan Smith. Naloxone hydrochloride and 
Takeda Compound 101 (CPD101) [3-[[[4-methyl-5-(4-pyridyl)-4H-1,2,4-triazole-3-yl] 
methyl] amine]-N-[2-(trifluoromethyl benzyl]benzamide hydrochloride] were purchased 
from HelloBio. Prazosin hydrochloride, GF102903X [2-[1-(3-dimethylaminopropyl)indol-
3-yl]-3-(indol-3-yl) maleimide], PMA [phorbol 12-myrtistrate 13-acetate], GSK650394 [2-
cyclopentyl-4-(5-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl-benzoic acid], Y-27632 [trans-4-
[(1R)-1-aminoethyl]-N-4-pyridinylcyclohexanecarboxamide dihydrochloride] and SNC80 
were purchased from Tocris. U-69,593 was purchased from Abcam. PZM21 [1‐[(2S)‐2‐
(dimethylamino)‐3‐(4‐hydroxyphenyl)propyl]‐3‐[(2S)‐1‐(thiophen‐3‐yl)propan‐2‐yl]urea] 
hydrochloride was kindly provided by Dr Alexander Disney (University of Bath). 
Compound 1 [Tyr-c[D-Lys-Phe-Tyr-Gly]] was kindly provided by Dr Yangmei Li 
(University of South Carolina) and also synthesised by Biomatik Corporation. Data from 
both sources of Compound 1 are presented together in this thesis. SR17018 [5,6-
dichloro-1-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]-1,3-dihdro-2H-benzimidazol-2-one] 
was purchased from MedChemExpress and kindly modified to the mesylate salt by Dr 
Alexander Disney (University of Bath). All other reagents and drugs were purchased from 




Chapter 3: Characterisation of putatively G protein-
biased MOPr agonists 
3.1 Introduction 
In recent years, a major drug discovery effort has been dedicated to the discovery and 
development of MOPr agonists which display signalling bias towards G protein 
signalling. This drive is founded on studies of morphine’s effects in arrestin-3 knockout 
mice, which suggested that a number of opioid-induced adverse effects may be 
regulated by arrestin-dependent signalling downstream of MOPr (Bohn et al., 1999; 
Bohn et al., 2000; Raehal et al., 2005) (Chapter 1.3.1). However, this dogma has been 
weakened with the reproducibility of these original findings recently being brought into 
question (Kliewer et al., 2020) and studies in phosphorylation-deficient MOPr knock-in 
mice reporting no change in opioid-induced respiratory depression or constipation 
(Kliewer et al., 2019) (Chapter 1.3.1). Despite this, the development of G protein biased 
agonists at MOPr could provide valuable tool compounds to dissect the physiological 
relevance of independent signalling pathways downstream of MOPr. Additionally, 
attenuation of morphine tolerance in both arrestin-3 knockout (Bohn et al., 2000) and 
phosphorylation-deficient MOPr knock-in mice (Kliewer et al., 2019) suggests that by 
evading arrestin-3 recruitment, G protein-biased MOPr agonists may be less liable to the 
development of tolerance compared with balanced agonists.  
The small molecule PZM21 was one of the first MOPr agonists defined to be G protein- 
biased (Manglik et al., 2016). PZM21 activated Gi G protein signalling but produced 
minimal arrestin-3 recruitment in recombinant cell systems, suggesting that it is 
putatively G protein-biased in the absence of formal calculations of bias. The authors 
originally described PZM21 as possessing analgesic properties but being devoid of the 
ability to produce respiratory depression, unlike the balanced agonist morphine. 
However, as with the arrestin-3 knockout data, the reproducibility of findings with PZM21 
regarding induced respiratory depression have also recently been brought into question 
(Hill et al., 2018b) (Chapter 1.3.2). 
The SR-series of small molecules developed by Schmid et al. (2017) also yielded a 
number of MOPr agonists which reportedly displayed bias toward G protein signalling in 
recombinant cell systems. These included SR17018, which promoted analgesia in mice 
with minimal induction of respiratory depression, similarly to the profile originally 
described for PZM21 (Manglik et al., 2016). 
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A number of cyclized analogues of the endomorphins, developed to improve the 
metabolic stability of these therapeutically promising opioid peptides (Czapla et al., 2000; 
Wilson et al., 2000), have also displayed attractive in vivo pharmacology akin to that 
produced by G protein biased agonists. One such peptide, Tyr-c[D-Lys-Trp-Phe-Glu]-
Gly-NH2 (ZH853) was shown to have similar analgesic properties to morphine in mice 
but reduced propensity to induced respiratory depression and tolerance (Zadina et al., 
2016). Similarly Tyr-c[D-Lys-Trp-Phe] (CYT-1010) demonstrated analgesia both 
preclinically and in phase I clinical trials, with a large therapeutic window for respiratory 
depression in rats preclinically (Webster et al., 2020). While the signalling properties of 
ZH853 and CYT-1010 have not been closely investigated, or published, it is evident that 
the attractive pharmacological profile of these peptides is akin to that previously 
associated with preclinical G protein-biased agonists at MOPr (Manglik et al., 2016; 
Schmid et al., 2017). Given that the endomorphins have been shown to display bias for 
arrestin signalling at MOPr (Rivero et al., 2012) (Chapter 1.3.2), it is possible that the 
nature of the endomorphin scaffold could be used to yield MOPr ligands with biased 
signalling properties. Considering this, we were interested to see whether Try-c[D-Lys-
Phe-Try-Gly] (Compound 1), a recently developed novel cyclic endomorphin analogue 
with high affinity for MOPr (Li et al., 2016) displayed signalling bias at MOPr. 
The work presented within this thesis chapter aimed to characterise the signalling 
profiles of the potentially G protein-biased agonists PZM21 and Compound 1 at the 
MOPr. This was performed in order to identify tool compounds which could be utilized to 
study the long-term functional consequences of biased agonism at the MOPr. In order 
to achieve this aim, we utilised a number of approaches: BRET-based assays in 
recombinant cell systems enabled refined measurements of the interactions of distinct 
signalling proteins, providing detailed quantification of agonist-induced MOPr signalling 
and bias measurements in a heterologous expression system. The electrically-evoked 
rat vas deferens (RVD) was also utilised as a classical bioassay of opioid activity, 
providing evidence of agonist- receptor interaction in a system of physiological MOPr 
expression.  
In this chapter, I demonstrate that Compound 1 is a potent partial agonist at the MOPr, 
which displays G protein bias relative to the partial agonist morphine. The putatively G 
protein-biased MOPr agonist PZM21 however did not display G protein bias as 
previously described, but in fact in my studies appears to be simply a lower efficacy 
partial agonist at MOPr than morphine. Using the rat vas deferens, it was determined 
that both PZM21 and Compound 1 are high affinity, lower efficacy agonists. The work in 
this chapter therefore details a new G protein-biased agonist, Compound 1, which could 
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be a useful tool compound for determining the long-term functional consequences of 




3.2.1 Compound 1 is a G protein-biased agonist at MOPr 
3.2.1.1 Characterising opioid-induced GI activation and arrestin-3 recruitment  
In order to characterise the signalling properties of ligands at MOPr, two separate BRET 
based assays were utilised in recombinant HEK293 cells. Firstly, opioid-induced Gi G 
protein activation was assessed in HEK293 cells transiently expressing HA-MOPr as 
well as Gi1-Renillia luciferase II (RlucII) and GFP10-G2. Agonist-induced dissociation of 
these two labelled G protein subunits, determined by loss of BRET signal, was 
representative of Gi G protein activation (Figure 3.1A; see Chapter 2.1.2). Opioid-
induced arrestin-3 recruitment to MOPr was determined in HEK293 cells transiently 
transfected with MOPr-RlucII and arrestin-3-GFP. Agonist-induced association of the 
labelled proteins, determined by an increase in BRET signal, was representative of 
arrestin-3 recruitment to MOPr (Figure 3.1B; see Chapter 2.1.2).  
Both DAMGO and morphine, well-documented agonists of MOPr, produced 
concentration-dependent increases in both Gi G protein activation (Figure 3.1C) and 
arrestin-3 recruitment (Figure 3.1D). The putatively G protein-biased MOPr agonist 
PZM21 (Manglik et al., 2016) also produced concentration-dependent increases in both 
Gi G protein activation (Figure 3.1C) and arrestin-3 recruitment (Figure 3.1D). The cyclic 
endomorphin analogue Compound 1 (Li et al., 2016) also produced concentration-
dependent activation of Gi G proteins (Figure 3.1C) and low but detectable 
concentration-dependent arrestin-3 recruitment (Figure 3.1D). 
Hill slopes for concentration-response curves for G protein and arrestin-3 recruitment 
were constrained to 1 in order to improve curve fitting and reduce error in the calculation 
of agonist potency and efficacy (Kenakin, 2009). When the Hill slopes were 
unconstrainted in curve fitting, the best-fit values ( S.E.M.) of agonist Hill slopes for Gi 
activation and arrestin-3 recruitment were as follows: Gi activation: DAMGO = 0.7  0.1, 
morphine = 1.0  0.2, PZM21 = 0.8  0.2, Compound 1 = 0.8  2. Arrestin-3 recruitment: 
DAMGO = 1.3  0.3, morphine = 1.1  0.4, PZM21 = 0.6  0.3. The Hill slope for 
Compound 1-induced arrestin-3 recruitment could not be determined when its value was 
unconstrained due to ambiguous curve fitting. When best-fit values of the Hill slopes for 
all agonists in both assays were compared statistically to a hypothetical value of 1 using 
an extra sum-of-squares F test, only the Hill slope for DAMGO-induced Gi activation was 
significantly different from 1 (P < 0.05). However, the R squared value for the curve fitting 
for DAMGO-induced Gi activation when the Hill slope was constrained to 1 was similar 
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to that when the Hill slope was unconstrained (0.94 and 0.93 respectively), indicating 
that either model could effectively describe this response.  
PZM21 and Compound 1 had significantly higher potencies for G i G protein activation 
than morphine (Table 3.1). No significant differences in agonist potencies were observed 
in the arrestin-3 assay, in part ascribed to sizable error with this parameter due to the 
large fitting error associated with derived parameters due to limitations in curve fit quality 
in the case of weak partial agonists PZM21 and Compound 1 (Table 3.1).  
In systems of low receptor reserve, the maximal response (EMax) of a partial agonist (their 
intrinsic activity) can be used as robust measure of their intrinsic efficacy (Stephenson, 
1956; Kelly, 2013). This is particularly important when utilisation of the operational model 
is limited by ambiguous curve fitting in the case of low efficacy partial agonists (see 
Compound 1 responses in Figure 3.1D). The EMax values for Gi G protein activation 
induced by morphine, PZM21 and Compound 1 were significantly lower than the full 
agonist DAMGO (Table 3.1), indicating they are partial agonists at MOPr for G protein 
activation in this system (Table 3.1). Similarly, the EMax values of morphine, PZM21 and 
Compound 1 for arrestin-3 recruitment were significantly lower than that of DAMGO 
(Table 3.1). 
The maximum responses of morphine and Compound 1 were statistically similar for Gi 
G protein activation, however the efficacy of Compound 1 for arrestin-3 recruitment was 
significantly lower than that of morphine (Table 3.1). The fact that Compound 1 had the 
same efficacy for Gi G protein activation as morphine but induced comparatively lower 
levels of arrestin-3 recruitment strongly suggest that it is a G protein-biased agonist 
relative to morphine at the MOPr. Considering that the rank order of agonist potency was 
conserved between assays of G protein activation and arrestin-3 recruitment, it could be 
postulated that the functional selectivity of Compound 1 is driven by differences in its 
efficacy rather than affinity.  
Similar comparisons of intrinsic efficacy examining PZM21 demonstrate that it is a low 
efficacy MOPr agonist, with a significantly lower efficacy for G protein activation than 
morphine (Table 3.1). Interestingly, the efficacy of PZM21 for arrestin-3 recruitment was 
statistically similar to that of morphine (Table 3.1). These data suggest that in our hands 
PZM21 is not a G protein-biased agonist at MOPr, contrary to the original findings for 
this agonist (Manglik et al., 2016). However, our finding that PZM21 has a lower efficacy 
for G protein activation than morphine is in agreement with other studies (Hill et al., 





Figure 3.1 – Opioid-induced Gi G protein activation and arrestin-3 recruitment in 
HEK293 cells transiently expressing recombinant MOPrs.  
(A) A schematic illustrating the principle of the Gi G protein activation assay. Opioid-
induced activation of MOPr results in a separation of labelled G protein subunits, 
resulting in a reduction in BRET signal. (B) A schematic illustrating the principle of the 
arrestin-3 assay. Opioid-induced MOPr activation results in translocation of arrestin-3 to 
the receptor. The association of the labelled MOPr and labelled arrestin-3 results in an 
increase in BRET signal. (C) DAMGO, morphine, PZM21 and Compound 1 produced 
concentration-dependent activation of Gi G protein as measured as a decrease in BRET 
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signal occurring between labelled G & G proteins. (D) DAMGO, morphine, PZM21 and 
Compound 1 produced concentration-dependent recruitment of labelled arrestin-3 
translocation as measured by an increase in BRET signal from association of labelled 
MOR and arrestin-3. Fitted values for agonist pEC50 and EMax were generated from 
combined concentration-response curves and are presented in Table 3.1. Data are 




Table 3.1 – The pEC50 and EMax values for opioids in the Gi protein activation and 
arrestin-3 recruitment assays. 
Values were determined from data presented in Figure 3.1. Data are expressed as mean 
 SEM, where n=5. * p < 0.05, significantly different from the respective morphine value, 
† p < 0.05, significantly different from all other respective values, one-way ANOVA with 
Tukey’s post-hoc test.   
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3.2.1.2 Quantifying the G protein-biased signalling of Compound 1 at MOPr  
The de facto method of quantifying biased signalling at GPCRs in vitro is the log(/KA) 
method. In this method, agonism for separate signalling pathways is quantified through 
a  transduction coefficient (/KA) computed using a form of the Black-Leff operational 
model (Black et al., 1983) (Chapter 2.1.3). However, the power of this approach is 
severely limited in the case of weak partial agonists, due to the large fitting error 
associated commonly with derived parameters due to variable curve fit quality when 
using the operational model (Kelly, 2013; Gillis et al., 2020c). Additionally, agonist 
efficacy and affinity (broadly  and KA respectively in this case) cannot be determined 
separately in this analysis, as agonism is considered as a composite of these factors in 
the single transduction coefficient (/KA). Under this analysis, in a case where functional 
selectivity is driven by differences in efficacy alone, readouts of bias would in effect be 
diminished by the incorporation of affinity in modelling.  
In situations where partial agonism is present, an alternate method of quantifying biased 
signalling has been developed which is driven by efficacy and not affinity (Burgueño et 
al., 2017). This analysis solely focuses on differences in agonist  values, which are 
calculated by fitting agonist concentration-response curves to the operational model 
(Black et al., 1983). A similar process is used in that the transduction coefficient model 
described above to generate a normalised log() values for each agonist (Chapter 
2.1.3). While this methodology recognises the limitations of the log(/KA) methods 
when it comes to the analysis of partial agonists, its utilisation of the operational model 
means its power is similarly limited where agonist response curves have variable fitting 
to the operational model, resulting in large values of error surrounding fitted parameters.  
In systems of low receptor reserve, the intrinsic activity (EMax) of partial agonists can be 
used as a robust, assumption free and affinity independent estimate of efficacy 
(Stephenson, 1956; Dekan et al., 2019). By normalising fitted EMax values of test ligands 
to a reference partial agonist and subtracting this normalised EMax value across 
comparison pathways, a singular  normalised EMax value can be generated for each test 
ligand, which can be used as an entirely efficacy-dependent measure of bias (Dekan et 
al., 2019) (Chapter 2.1.3). This model is less liable to be limited in cases of poor curve 
fitting for weak partial agonists as the asymptote of the fitted logistic function (EMax) can 
be fitted more confidently than the parameter  in the operational model, which is subject 
to more assumptions. While application of this model is not possible in scenarios where 
lower efficacy agonists appear as full agonists, such as in systems of high signal 
amplification or receptor reserve, this is not the case in our assays where there is 
relatively low receptor reserve (possibly owing to transient rather than stable MOPr 
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expression) and low signal amplification (through measuring separation of G protein 
subunits rather than second messenger systems such as cAMP).  
In light of these considerations, signalling bias within our test agonists was assessed 
using the  normalised EMax method, with the prototypical partial agonist morphine 
selected as a reference agonist, as importantly morphine was a partial agonist in both 
signalling assays. Similarly, to the unnormalized data in Table 3.1, the normalised EMax 
value of Compound 1 for Gi G protein activation was statistically similar to that of 
morphine, but the normalised EMax value of Compound 1 for arrestin-3 recruitment was 
significantly lower than that of morphine (Figure 3.2A). The normalised EMax values of 
PZM21 for both Gi G protein coupling and arrestin-3 recruitment were significantly lower 
than morphine (Figure 3.2A). The  normalised EMax value for Compound 1 was 
significantly different from morphine, demonstrating that it is a G protein biased agonist 
at MOPr (Figure 3.2B). PZM21 displayed no such significant difference in  normalised 
EMax analysis, indicating that it is not G protein biased, in our hands, but is in fact a lower 
efficacy partial agonist than morphine.   
When analysed through the log(/KA) method, Compound 1 does not appear G protein 
biased in comparison to morphine (Figure 3.3B). The transduction coefficient (log(/KA) 
for Compound 1-induced arrestin-3 recruitment has a large error value (Figure 3.3A), 
which reflects poor fitting of the operational model due to the very low efficacy coupling 
of Compound 1 for this pathway (Figure 3.1D). With affinity (KA) accounted for within the 
transduction coefficient, it is clear that the high potency of Compound 1 relative to 
morphine opposes the impact of its lower efficacy (Figure 3.2A) in this assessment of 
bias (Figure 3.3A). These factors mean that the implementation of this method is limited 
when assessing bias in our systems. 
Similarly, no significant bias is observed between our test ligands when utilising the 
log() method described above (Figure 3.4B) (Burgueño et al., 2017). However, 
Compound 1 did display statistically similar efficacy to morphine for G i G protein 
activation while showing significantly lower efficacy for arrestin-3 recruitment (Figure 
3.4A), supporting our findings from the  normalised EMax analysis (Figure 3.2). While 
there was no significant difference between the  values of Compound 1 and morphine 
for G protein activation, the fitted value for Compound 1 (0.4  0.1) is considerably lower 
than that of morphine (0.6  0.1) (Figure 3.4A). This is in spite of there being no significant 
differences in fitted EMax values of these two agonists (Table 3.1) or little discernible 
difference in the magnitude of the responses displayed in their concentration-response 
curves (Figure 3.1C). Evidently, this difference reduces the degree of bias recorded for 
Compound 1 in this method (Figure 3.4B). The margin of uncertainty around the fitted  
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parameters for our test agonists reflects previously discussed issues around generated 
uncertainty in a model such as the operational one where many interdependent 
unknowns must be fitted from limited data for weak partial agonists (Chapter 3.3.3). For 
this reason, the assumption-free  normalised EMax matrix has been utilised to assess 





Figure 3.2 – Calculation of biased agonism at MOPr through  normalised EMax. 
(A) EMax values generated from data presented in Figure 3.1 and Table 3.1 normalised 
to values for morphine for both Gi G protein activation and arrestin-3 recruitment. (B) 
Calculated differences in agonist normalised EMax values presented in A for G protein 
activation versus arrestin-3 recruitment. Data are presented as mean  SEM, where n=5. 





Figure 3.3 – Calculation of biased agonism at MOPr through log(/KA) 
(A) log(/KA) values for opioids in both the Gi G protein activation and arrestin-3 
recruitment assays, generated through fitting data presented in Figure 3.1C and Figure 
3.1D to the operational model. (B) Differences in agonist activity, represented in the 
parameter log(/KA) presented in A, across Gi G protein activation and arrestin-3 
recruitment when normalised to the activity of morphine. Data are presented as mean  



























































Figure 3.4 – Calculation of biased agonism at MOPr through log(). 
(A) The efficacy (log()) of opioids for both Gi G protein activation and arrestin-3 
recruitment determined through fitting data presented in Figure 3.1C and Figure 3.1D to 
the operational model. (B) Differences in agonist efficacy, log(), in Gi G protein activation  
and arrestin-3 recruitment assays when efficacy was normalised to morphine. Data are 
presented as mean  SEM, where n=5. * p < 0.05, ns p > 0.05, one-way ANOVA with 





3.2.1.3 Inhibition of DAMGO-induced arrestin-3 recruitment by partial MOPr agonists  
In attempts to handle the utilisation of the operational model, and classical log(/KA) 
analysis, in the assessment of bias for partial agonists, some groups have attempted to 
separately generate affinity (KA) values for weak partial agonists through competition 
assays in order to apply informed constraints to the operational model, leading to refined 
analysis (Stahl et al., 2015). This methodology was utilised in the determination of the G 
protein biased signalling profile of SR17018 at MOPr (Schmid et al., 2017). In order to 
determine functional KA values, the group tested the ability of SR17018 and related 
compounds to inhibit arrestin-3 recruitment induced by a submaximal (approximately 
EC50) concentration of DAMGO. Curiously, in this previous study SR17018 and related 
compounds did not inhibit DAMGO-induced arrestin-3 recruitment in examined 
concentrations (up to 30M). This is in spite of SR17018 and related ligands displaying 
high affinity for MOPr in radioligand binding assays and promoting MOPr-dependent G 
protein activation at the same concentrations. Accounting for these data, the group 
applied constraints to the operational model fitted to arrestin-3 recruitment induced by 
these ligands, inevitably affecting the final bias scores ascribed to these novel agonists.  
However, the finding that the partial MOPr agonist SR17018 does not inhibit DAMGO-
induced arrestin-3 recruitment at concentrations at which it promoted G protein coupling 
is in disagreement with the fundamental principles of receptor pharmacology. In this 
case, a partial agonist (such as SR17018) at high concentrations should competitively 
displace the full agonist (such as DAMGO) at the receptor and display its own minimal 
effect for the pathway, effectively behaving as an antagonist (Figure 3.5A) (Stahl et al., 
2015).  
We sought to investigate whether our test agonists (all of which are partial agonists in 
this system (Table 3.1)), as well as SR17018, would inhibit DAMGO-induced arrestin-3 
recruitment in our BRET assay. HEK293 cells expressing MOPr-RlucII and arrestin-3 
GFP were  incubated with our test partial agonists for 30 minutes at 37C before addition 
of 10-6M DAMGO and BRET readings taken (Figure 3.1B). 10-6M DAMGO was used as 
a submaximal concentration based on data in Table 3.1 suggesting this is approximately 
the EC50 value in our arrestin-3 recruitment assay.  
As anticipated, morphine (Figure 3.5B), PZM21 (Figure 3.5C) and Compound 1 (Figure 
3.5D) each produced concentration-dependent inhibition of arrestin-3 recruitment 
induced by a submaximal concentration of DAMGO. The fitted plateau values observed 
with these agonists generally reflected their intrinsic activity for arrestin-3 recruitment 
(Table 3.1), with Compound 1 displaying a lower plateau value than morphine and 
PZM21 (Table 3.2). Compound 1 and PZM21 inhibited DAMGO-induced arrestin-3 
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recruitment with a higher potency (pIC50) than morphine (Table 3.2), suggesting they 
have higher affinity for MOPr than morphine. 
Intriguingly, SR171018 did not inhibit DAMGO-induced arrestin-3 recruitment at the 
concentrations tested (Figure 3.5E). While these data are in agreement with the original 
finding from Schmid et al. (2017), in other studies from our lab group we have been 
unable to reproduce robust G protein activation in response to SR17018 (up to 3x10 -5M) 
in our assay systems (Ramos-Gonzalez, unpublished data). The structure of the 






Figure 3.5 – Partial antagonism of DAMGO-induced arrestin-3 recruitment by MOPr 
partial agonists. 
(A) A schematic depicting the theoretically expected interaction between a full agonist 
and a partial agonist at the same receptor. Where an agonist of full efficacy (black line) 
produces a concentration-response with an EMax of 100%, the hypothetical partial agonist 
Morphine
































































































































































here produces a concentration-response curve with an EMax of 15% (blue line). In this 
scenario, increasing concentrations of the partial agonist should be able to compete with 
a submaximal concentration (an EC50 in this case) of the full agonist for the receptor, 
antagonising the function of the full agonist but producing an incomplete inhibition due 
their own minimal efficacy for the receptor. Increasing concentrations of morphine (B), 
PZM21 (C), Compound 1 (D) and SR17018 (E) were preincubated for 30 minutes at 
37C with HEK293 cells transiently expressing MOPr-RlucII and arrestin-3-GFP before 
the addition of DAMGO (10-6M) and BRET measurements subsequently taken  (Figure 
3.1B). Responses were normalised to those induced by DAMGO (10 -6M) alone and 






Table 3.2 – pIC50 and maximum inhibition values for inhibition of DAMGO-induced 
arrestin-3 recruitment 
Values were determined from data presented in Figure 3.5. Data are presented as mean 





3.2.2 Compound 1 is a partial agonist at MOPr and DOPr, but lacks agonist 
activity at KOPr 
Given the high level of homology of the orthosteric ligand binding pocket of opioid 
receptors and the promiscuous nature of classical MOPr receptor agonists such as 
morphine, we sought to determine if Compound 1 possessed agonist activity at DOPr 
and KOPr. Compound 1 has previously been demonstrated to have a 40-fold higher 
affinity for MOPr over DOPr, with very low affinity at KOPr (Li et al., 2016), however its 
functional activity at DOPr and KOPr had not been assessed. 
A similar Gi G protein activation BRET methodology was used here to that depicted in 
Figure 3.1A for the MOPr (Chapter 2.1.2). The ability of Compound 1 and a reference 
agonist (SNC80 and U69,593 for DOPr and KOPr respectively) to produce 
concentration-dependent activation and separation of transiently transfected labelled G 
proteins was assessed in HEK293 cells either expressing HA-DOPr (Figure 3.6C) or HA-
KOPr (Figure 3.6E).  
Both SNC80 and Compound 1 produced concentration-dependent activation of Gi G 
proteins in HEK293 cells expressing HA-DOPr (Figure 3.6D). The intrinsic activity of 
Compound 1-induced Gi G protein signalling in HA-DOPr expressing cells was 
significantly lower than that of SNC80 (Table 3.3), indicating that it is a weak partial 
agonist at DOPr. The potency of Compound 1 for Gi G protein signalling at DOPr is 
slightly lower (~6 fold) than its potency at MOPr (Table 3.3), suggesting a lower degree 
of MOPr selectivity than found in radioligand binding assays (Li et al., 2016).  
While U69,593 produced concentration-dependent activation of Gi G protein signalling 
in HA-KOPr expressing HEK293 cells, no activation was observed with increasing 
concentrations of Compound 1 (Figure 3.6F). This finding is in line with the very low 
affinity of Compound 1 for KOPr in radioligand binding assays (Li et al., 2016). 
Additionally, the lack of Compound 1-induced Gi G protein signalling serves as a control 
that Compound 1-induced G protein activation in cells expressing HA-MOPr and HA-





Figure 3.6 – Assessing the selectivity agonist activity of Compound 1 across the 
opioid receptors. 
MOPr















































































Schematics describing the principle of the MOPr (A), DOPr (C) and KOPr (E) Gi G protein 
activation assays Agonist-induced activation of opioid receptors in these assays results 
in a separation of labelled G protein subunits, resulting in a reduction in BRET signal. (B) 
Data from Figure 3.1 showing DAMGO and Compound 1 promoted separation of Gi G 
protein subunits in HEK293 cells expressing MOPr. (D) SNC80 and Compound 1 
promoted separation of labelled Gi G proteins in HEK293 cells expressing DOPr. (F) 
U69,593, but not Compound 1, promoted separation of labelled G i G protein subunits in 





Table 3.3 – pEC50 and EMax values for Compound 1 and respective tool agonists for 
Gi G protein activation at MOPr, DOPr and KOPr 





3.2.3 Investigating the affinity of partial MOPr agonists in isolated rat vas 
deferens 
The electrically-stimulated isolated vas deferens preparation provides an effective 
bioassay of opioid receptor-activity. MOPr agonists are able to inhibit the electrically-
evoked release of noradrenaline through an action at presynaptic receptors (Henderson 
et al., 1976; Lemaire et al., 1978). While partial agonists such as morphine are able to 
inhibit such contractions in vas deferens preparations from mouse (Henderson et al., 
1976), the electrically evoked contractions of the rat vas deferens (RVD) are sensitive to 
high efficacy MOPr agonists such as -endorphin and DAMGO, but not lower efficacy 
agonists such as morphine (Lemaire et al., 1978). The lack of agonist activity for lower 
efficacy MOPr agonists in the RVD is due to the very low receptor reserve present in this 
system. Low efficacy agonists competitively bind MOPr, but in this system they do not 
possess intrinsic efficacy high enough to inhibit electrically-evoked contractions of the 
RVD, as done by high efficacy agonists. Therefore, when added in combination, low 
efficacy agonists effectively antagonise the inhibitory responses of a full agonist in the 
RVD (Ishii et al., 1981). Here we utilized this phenomenon for lower efficacy MOPr 
agonists in the RVD, to characterise the affinity of our test agonists in a system with 
physiological receptor expression, using traditional methods of quantifying competitive 
antagonism (Schild, 1947) (Chapter 2.3.3). 
Cumulative addition of the full MOPr agonist DAMGO (10-8M - 10-5M) caused 
concentration-dependent inhibition of electrically-evoked contractions of the isolated 
RVD (Figure 3.7). Generally, maximal concentrations of DAMGO reduced the 
electrically-evoked contractions of the RVD to non-detectable levels (Figure 3.7).  
DAMGO responses in RVD were assessed in the presence of several concentrations of 
test partial agonists in each individual RVD preparation (Figure 3.8). After 20 minutes of 
preincubation, increasing concentrations of morphine (Figure 3.8A), PZM21 (Figure 
3.8B) and Compound 1 (Figure 3.8C) resulted in a reduction of DAMGO potency in the 
RVD, resulting in a parallel rightward shift of its concentration-response curve. 
Concentration-response curves were fitted in order to generate dose-ratio (DR) values 
for each individual RVD preparation for each test partial agonist. DR values from each 
individual experiment were then pooled to give average DR ratio values for each test 





Figure 3.7 – DAMGO inhibits electrically-evoked contractions of the RVD. 
A representative trace from a single preparation demonstrating that cumulative addition 
of increasing concentrations of DAMGO inhibited the electrically evoked contractions of 
RVD smooth muscle.  
 
These averaged DR values were used to construct Schild plots for each test agonist 
(Figure 3.9). The slope of the constructed Schild plots was subjected to an extra sum-
of-squares F test to determine whether the slope was significantly different from the 
hypothetical value of 1. The alternative unconstrained Schild plot slope values (value, 
95% CI) for morphine (1.2, 0.6 – 1.7), PZM21 (1.3, 0.4 – 2.1) and Compound 1 (0.8, 0.1 
– 1.5) were not significantly different from 1 and therefore all data was fitted to Schild 





Figure 3.8 – Single representative experiments showing competitive inhibition of 
DAMGO activity in the RVD by partial MOPr agonists. 
Concentration-response curves for DAMGO-induced inhibition of electrically-evoked 
contractions in the RVD after 20 minutes of preincubation with increasing concentrations 
of morphine (A), PZM21 (B) and Compound 1 (C). Data presented are from individual 
preparations.   
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Figure 3.9 – Schild plots for inhibition of DAMGO responses in the RVD by partial 
MOPr agonists. 
Schild plots for morphine (A), PZM21 (B) and Compound 1 (C) inhibition of DAMGO-
induced responses in RVD. Dose ratio (DR) values were calculated from individual 
experiments of the type presented in Figure 3.8 and then pooled to form Schild plots. 
Data presented as mean  SEM, where n=3-6.  
Compound 1












































Figure 3.10 – Combined graphs showing inhibition of DAMGO activity in the RVD 
by partial MOPr agonists. 
Pooled data from multiple experiments of the type presented in Figure 3.8. 
Concentration-response curves for DAMGO-induced inhibition of electrically-evoked 
contractions in the RVD after 20 minutes preincubation of increasing concentrations of 
morphine (A), PZM21 (B) and Compound 1 (C). Data are presented as mean  SEM, 
where n=3-6. 
Morphine





























































Calculating DR values within each individual experiment as above reduced error 
resulting from variations in DAMGO potency between preparations. This is highlighted 
in Figure 3.10, where concentration-response curves were fitted to pooled data from all 
preparations. Despite the sizable error on these concentration response curves, when 
these combined data are fitted to a Gaddum-Schild EC50 shift model in GraphPad Prism 
(Chapter 2.3.3) the fitted parameters are similar to those computed through the 
evaluation of individual DR and traditional construction of Schild plots, albeit with more 
error (Table 3.4). For this reason, statistical analyses were solely performed on pA2 
values generated through the individual DR calculation method (Table 3.4).  
Compound 1 and PZM21 have a significantly higher pA2 than morphine, demonstrating 
they have a higher affinity for MOPr than morphine (Figure 3.9, Table 3.4). The higher 
potency of PZM21 and Compound 1 in the Gi G protein activation BRET (Table 3.1) and 
their pIC50 values for PZM21 and Compound 1 for inhibition of DAMGO-induced arrestin-
3 recruitment relative to morphine (Table 3.2) both support the above finding that they 
are higher affinity ligands (Table 3.4). Compound 1 also displayed a significantly higher 
affinity than PZM21 in the RVD (Table 3.4), which had not previously been demonstrated 
in other assays. (Table 3.1 and Table 3.2).  
 
 
Table 3.4 – Fitted pA2 and slope values for partial MOPr agonists from two methods 
of Schild analysis. 
Values were obtained from data presented and analysed in Figure 3.9 (‘Individual DR 
calculation’) and Figure 3.10 (‘Cumulative Schild Fit’). n=3-6. * p < 0.05, significantly 
different from the respective morphine value, † p < 0.05, significantly different from 
respective PZM21 value, one-way ANOVA with Tukey’s post-hoc test.   
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As discussed above, low efficacy MOPr agonists do not typically possess the intrinsic 
efficacy required to produce the functional responses associated with full MOPr agonists 
in the RVD, due to its very low receptor reserve. Test low efficacy agonists were 
preincubated with the RVD for 20 minutes before responses to DAMGO were assessed. 
Electrical stimulation was ongoing during this period, and so it was possible to determine 
whether the assessed concentrations of our test partial agonists did have any sizable 
effect on these electrical-evoked contractions. The magnitude of RVD electrically evoked 
contractions was unaffected by preincubation with morphine (Figure 3.11A) and PZM21 
(Figure 3.11B) at all concentrations examined. The highest concentration of Compound 
1 examined (3x10-7M) produced slight but significant attenuation (89  3% of baseline) 
of electrically-evoked contractions after 20 minutes of preincubation (Figure 3.11C). 
Given that this reduction in response is similar to that elicited at 10-7M and the examined 
concentration is 10-fold higher than the pA2 (Table 3.4), it is presumed that this small 
response is near the maximal possible effect for Compound 1.  
 
 
Figure 3.11 – Modulation of electrically-evoked contractions of the RVD by partial 
MOPr agonists. 
The ability of outlined concentrations of morphine (A), PZM21 (B) and Compound 1 (C) 
to exert their own inhibitory activity on the electrically-evoked contractions of the RVD 
was assessed over the 20-minute preincubation period. Data are presented as mean  
SEM, where n=3-6. * p < 0.05, significantly different from the hypothetical value of 100 




Figure 3.12 – SR17018 does not inhibit DAMGO-induced inhibition of electrically-
evoked contractions of the RVD. 
Preincubation of the RVD with indicated concentrations of SR17018 for 20 minutes had 
no effect on DAMGO concentration-response curves for inhibition of electrically-evoked 
contraction. Data are presented as mean  SEM, where n=3. 
 
The impact of high SR17018 concentrations on DAMGO responses in the RVD was also 
assessed (Figure 3.12). No significant differences in the potency (pEC50) of DAMGO 
were observed in the presence of 10-5M (6.1  0.1), 3x10-5M (6.0  0.2) or 10-4M 
SR17018 (5.9  0.2) and control (6.0  0.1). This finding is in line with the inability of 
SR17018 to inhibit DAMGO-induced arrestin-3 recruitment (Figure 3.5). Together these 


























3.3.1 Summary of findings 
The aim of this chapter was to characterise the signalling of the potentially G protein-
biased MOPr agonists PZM21 and Compound 1. In order to achieve this, I first 
investigated the ability of PZM21 and Compound 1 to induce MOPr-dependent Gi G 
protein activation and arrestin-3 recruitment in recombinant cell systems using BRET 
technology (Figure 3.1). The signalling bias of PZM21 and Compound 1 was then 
quantified relative to the prototypical MOPr partial agonist morphine through a number 
of published methods (Figures 3.2 – 3.4). Through these assays, we have demonstrated 
in this Chapter that Compound 1 is a G protein biased agonist at MOPr, while PZM21 
displayed no significant degree of biased signalling, in contrast to previous reports. 
The function of Compound 1 at other opioid receptors (DOPr and KOPr) was also 
assessed in similar recombinant systems, in order to determine the selectivity of 
Compound 1 for MOPr. These assays demonstrated that Compound 1 is a weak partial 
agonist for DOPr, with no activity at KOPr (Figure 3.6). This selectivity data was broadly 
in agreement with previously published affinity data for Compound 1 conducted in 
radioligand binding assays (Li et al., 2016). 
Additionally, we aimed to define the affinity of our agonists in a system of physiological 
receptor expression using the RVD as a functional bioassay. We hypothesised this would 
be a viable approach as lower efficacy agonists lack agonist activity in the RVD, due to 
very low receptor coupling levels in this tissue. This phenomenon allowed us to conduct 
competitive antagonist experiments, testing the ability of our test partial agonists (acting 
as antagonists in this circumstance) to inhibit DAMGO-induced inhibition of electrically-
evoked contractions of the RVD. Schild analysis demonstrated that both PZM21 and 




3.3.2 Compound 1 is a G protein-biased agonist 
In Compound 1, we have described a partial agonist at MOPr which is highly G protein-
biased (Figure 3.1 and Figure 3.2). We have demonstrated that Compound 1 displayed 
a significantly higher degree of bias than the reportedly G protein-biased agonist PZM21, 
which in fact did not display significant bias in our assays (Figure 3.1 and Figure 3.2). 
Our finding for PZM21 was contrary to previous reports (Manglik et al., 2016), but in 
agreement with more recent work from other groups (Hill et al., 2018b; Yudin et al., 2019; 
Gillis et al., 2020a). It is difficult to contextualise the degree of biased signalling exhibited 
by Compound 1 through comparisons to different studies due to system-based factors 
and the differing methodologies used to characterise bias across reports. However, it 
could be possible to roughly compare the bias profile of Compound 1 to that of bilorphin, 
given this study used the same method of bias calculation ( Normalised EMax) and the 
same reference ligand was used (morphine), and given that the amplification of the G 
protein assay appears similar (morphine is a partial agonist; Chapter 3.3.3) (Dekan et 
al., 2019). When compared to the  Normalised EMax values of bilorphin, Compound 1 
appears to display a higher degree, or at least similar degree, of G protein-bias, although 
direct numerical comparisons of this parameter value for Compound 1 and bilorphin 
cannot be conducted as the reference ligand used for normalisation in our two studies is 
different (Dekan et al., 2019). Given that TRV130 (oliceridine) was also used in the 
bilorphin study, displaying no significant G protein-bias, it could be inferred that 
Compound 1 likely displays a higher degree of G protein-bias than TRV130. As such, it 
is likely that Compound 1 displays a greater degree of G protein-bias than ligands 
previously reported as biased at MOPr (Figure 1.8). However, comparative studies 
examining the signalling of these agonists in the same system would be required to 
confirm this.  
In this Chapter, I have demonstrated that Compound 1 has a similar efficacy for G protein 
signalling as morphine (Figure 3.1, Table 3.1, Figure 3.2, Figure 3.4). This is of critical 
importance given the influence of efficacy on the perception of biased signalling in the 
case of partial agonists (Kelly, 2013; Gillis et al., 2020c). As such, agonists of lower 
efficacy than morphine are often declared G protein-biased, when their perceived effects 
are actually a function of differing amplification and receptor reserve between 
investigated systems (Chapter 3.3.3 and Chapter 4.3.1). An illustration of the distorting 
effect of efficacy on observed biased signalling comes from PZM21 (Manglik et al., 
2016). While original reports suggested PZM21 was G protein-biased, in this report we 
demonstrate no degree of bias for PZM21, but in fact it has a lower efficacy than 
morphine for G protein signalling (Figure 3.1, Table 3.1, Figure 3.2 and Figure 3.4, also 
see Chapter 4). This is in agreement with recent findings from other groups (Yudin et al., 
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2019; Gillis et al., 2020a). In fact, it has been demonstrated that low efficacy could 
account for the perceived biased signalling and differential therapeutic profile of most 
high-profile purported G protein-biased agonists at MOPr (Gillis et al., 2020a); including 
PZM21, TRV130 and SR-17018. In support of this, TRV130 has been demonstrated to 
be a low efficacy agonist relative to morphine by a number of other studies (Manglik et 
al., 2016; Dekan et al., 2019; Yudin et al., 2019; Vasudevan et al., 2020). This highlights 
the relative novelty of Compound 1, characterised here as a G protein-biased agonist 
with equivalent G protein efficacy to morphine, with the only other agonist clearly 
demonstrated to share this profile being bilorphin (Dekan et al., 2019). As such, it is 
important that we move to confirm the efficacy of Compound 1 in a system of 
physiological receptor expression. In order to do this, we characterised the function of 
Compound 1 in rat locus coeruleus (LC) neurones using electrophysiological methods 
(Chapter 4). 
Having characterised a novel G protein-biased agonist at MOPr, we sought to use this 
as a tool compound to study the long-term functional effects of biased signalling at MOPr 
in neurones (scope outlined in Chapter 3.3.7). Before addressing this, I have sought to 
address a number of issues and discussion points specifically around data presented in 
this chapter in this discussion, below. 
3.3.3 Limitations in methods of bias calculations in the case of partial agonists 
While the log(/KA) approach is the standard method of quantifying biased agonism, 
its utilisation of the operational model limits its power when assessing the responses of 
weak partial agonists. This is due to the large fitting error associated with derived 
parameters resulting from variable curve fit quality, meaning comparisons between such 
parameters for specific agonists are weakened (Kelly, 2013; Dekan et al., 2019) (Chapter 
3.2.2). As weak arrestin-recruitment responses for partial agonists are often responsible 
for such poor curve fitting quality, such parameters are often examined in amplified 
arrestin assays, with signal level increased through overexpression of GRK2 (Chapter 
5.2.7, Table 5.1).  
In light of these limitations, the log(/KA) approach therefore seems inappropriate for 
data presented in this chapter, with Compound 1 and PZM21 being partial agonists at 
MOPr relative to the full agonist DAMGO (Figure 3.1 and Table 3.1). Instead we have 
assessed biased agonism using the ‘Normalised EMax’ approach (Dekan et al., 2019), 




A crisis has arisen in the misappropriation of signalling bias for MOPr ligands. One could 
argue this is partially due to the commonplace use of the log(/KA) approach in 
inappropriate circumstances. The inappropriate designation of biased signalling has 
significantly hampered the development of the biased agonism field in the case of MOPr, 
and consequently at other GPCR targets.  
One particular limitation of the log(/KA) approach is an incorrect assumption that its 
normalisation accounts for all forms of systems bias (Gillis et al., 2020c). Biased 
signalling of MOPr ligands is often assessed through comparisons of activity between 
amplified assays of G protein activity (such as cAMP assays) and linear assays of 
arrestin recruitment. Commonly, a ceiling of effect is present in such highly amplified 
assays of G protein activity, particularly in cases of high levels of recombinant receptor 
expression (Gillis et al., 2020c). This often distorts the assessment of efficacy, with partial 
agonists such as morphine displaying equivalent maximum responses for G protein 
activation to full agonists such as DAMGO in some assays (Hothersall et al., 2017; 
Schmid et al., 2017; Gillis et al., 2020a; Pedersen et al., 2020). Given the linear nature 
of arrestin-recruitment assays, such partial agonists (which have appeared as full 
agonists in G protein assays) now appear as weak agonists for arrestin recruitment. As 
such, it is commonplace that low efficacy agonists are falsely ascribed as G-protein 
biased through the disregard of efficacy as a critical factor in assessment of bias (DeWire 
et al., 2013; Manglik et al., 2016; Schmid et al., 2017).  
Such high amplification is not present in the G protein activation assay presented in this 
chapter (Figure 3.1B), likely due to lower signal amplification than for instance assays of 
cAMP accumulation and a lower level of MOPr expression arising from the transient, 
rather than stable, nature of expression. As such, there is good separation present 
between the maximum responses of partial and full agonists for G protein activation in 
this assay. This allows for the use of EMax as a robust, assumption-free approximation of 
efficacy. This is as an alternative to calculations of  through the operational model, for 
which calculation again suffer from large error values arising from variable curve fit 
quality in the case of weak partial agonists (Figure 3.4). 
3.3.4 Reflection on the use of BRET methods to study receptor signalling 
The rapid development of resonance energy transfer (RET) technologies, both BRET 
and FRET, has revolutionised the study of GPCR signalling over the last decade. 
Principally, the study of GPCR ligand pharmacology began through determination of 
physiological responses in isolated tissue preparations. The elucidation of GPCR 
signalling in such systems allowed for the development of higher throughput assays in 
recombinant systems, many based on known second messenger systems, such as 
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adenyl cyclase (cAMP accumulation) and phospholipase C (Ca2+ accumulation) (Yasi et 
al., 2020). RET-based assays hold a number of advantages over their predecessors for 
the elucidation of GPCR pharmacology and the characterisation of novel GPCR ligands.   
RET techniques can provide unique resolution to the dynamics and kinetics of GPCR 
activation (Bacart et al., 2008). Additionally they hold an advantage over some 
alternative approaches such as [35S]GTPS assays of potency, radioligand binding 
assays of affinity and some assays of adenyl cyclase activity (for Gs and Gi) such as 
ELISA-based methods of cAMP accumulation, as they are run in live, intact cells 
(Salahpour et al., 2012).  
The primary advantage of RET-based approaches however is their adaptability. RET-
assays can be utilised to study practically the entire range of GPCR signalling processes, 
with assays of ligand binding (Stoddart et al., 2016), G protein activation (Janetopoulos 
et al., 2001), arrestin recruitment (Hamdan et al., 2005), receptor-GRK interaction (Hasbi 
et al., 2004), receptor internalization (Foster et al., 2018) and receptor dimerization 
(Angers et al., 2000; Milligan, 2010) among other processes (Lohse et al., 2012). The 
overall scope of these assays is impressive, and with new RET-based tools for the study 
of GPCRs constantly being developed the potential of this approach is yet to be fully 
utilised. This is highlighted by the recent development of platforms such as TRUPATH 
(Olsen et al., 2020), a BRET-based biosensor platform which can provide detailed, novel 
information on the transducerome of well-studied GPCRs, or potentially unlock the study 
of orphan GPCRs, expanding our understanding of the therapeutic scope of GPCRs.  
However, it is also clear that the application of RET techniques is limited by the need to 
transform cells to express genetically modified reporters and signalling counterparts. 
This brings a number of potential drawbacks. Firstly, the application of these methods is 
dependent on access to specific RET-based tools for the receptor or signalling pathway 
of interest. Additionally, the impact of large RET tags (such as GFP) on the dynamics of 
receptor interactions cannot simply be overlooked. One could argue that the ease of 
investigation in such assays has fostered an alarming move away from the study of 
GPCR function in systems which possess physiological expression of GPCRs and their 
signalling partners at endogenous expression levels, precipitating a translatability issue 
in the GPCR field. This highlights the necessity to validate and contextualise findings 
from convenient, high-throughput RET-based approaches in physiological systems 
expressing the receptor of interest (Chapter 3.2.3, Chapter 4). 
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3.3.5 Notes on inactivity of SR-17018 
The putative G protein-biased agonist SR-17018 was inactive in inhibiting DAMGO-
induced arrestin-3 recruitment in our recombinant assay (Figure 3.5E) and similarly did 
not show any competition for the binding of DAMGO to MOPr in the RVD (Figure 3.12). 
Our inability to obtain evidence of MOPr binding or agonist activity (Ramos-Gonzales, 
unpublished data) resulted in us ending our use of SR-17018 as a tool compound in our 
studies.  
While SR-17018 was described as G protein-biased in original reports, with a high 
efficacy for G protein activation (Schmid et al., 2017), studies from other groups have 
shown it be a very low efficacy agonist in other assays of G protein activity, lower than 
morphine, buprenorphine and TRV130 (Gillis et al., 2020a). This is likely due to the 
confounding effect of high amplification in assays presented in original reports (Schmid 
et al., 2017) (Chapter 3.3.3.). It could be that we do not see an effect of SR-17018 in 
recombinant systems due to its extremely low efficacy. This would support our findings 
in rat LC neurones (Chapter 4), in which we were unable to see a GIRK response elicited 
by SR-17018 (100M; data not shown). However, low efficacy is not able to explain the 
lack of competitive binding observed with SR-17018 against DAMGO in the arrestin-3 
BRET assay (Figure 3.5E; up to 30M), in the RVD (Figure 3.12; up to 100M) and in 
rat LC neurones (data not shown; up to 100M). 
A lack of competitive binding for SR-17018 could suggest that SR-17018 may act 
allosterically to exert its effects. However, it has been described to compete with the 
binding of radiolabelled DAMGO in receptor binding assays (Schmid et al., 2017). 
Severe solubility issues and high protein binding have been suggested for SR-17018 in 
both in vitro assays and in vivo (Gillis et al., 2020a; Grim et al., 2020). While not described 
in the original report (Schmid et al., 2017), the same group reported that they required 
the inclusion of the surfactant Tween-80 in the vehicle in order to get SR-17018 into 
solution for both in vitro and in vivo testing (Grim et al., 2020). Even with the inclusion of 
Tween 80, this group reported that SR-17018 was still only soluble up to 2.5 mg/ml 
(~5mM) in their hands (Grim et al., 2020). This implies the concentrations used in our 
study were outside of the range of solubility and the lack of effect or competition binding 
for SR-17018 are potentially due to it coming out of solution. However, it should be noted 
that no notable precipitate was observed in the preparation of SR-17018 for work 
conducted in this chapter.  
In light of accounts of solubility issues and, perhaps more importantly, subsequent 
reports of SR-17018 not being G protein biased as previously described (Gillis et al., 
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2020a), we could not warrant its inclusion in our investigations as a tool compound for 
the study of biased agonists at MOPr.  
3.3.6 Potential limitations of the RVD Schild experiment  
One potential problem with the experimental design in the RVD Schild experiments 
conducted in this chapter (Chapter 3.2.3) surrounds the logistics that increasing agonist 
concentrations were tested sequentially. This was undertaken to avoid potential 
contamination problems arising from agents residing after washing out the RVD 
preparation. As such, firstly the potency of DAMGO was assessed alone (control). Then 
in the presence of the lowest concentration of test partial agonist, before washing out 
and repeating in an increased test partial agonist concentration. The issue arising is that 
in the protocol for test agonist preincubation, the construction of these DAMGO 
concentration response curves and recovery of electrically-evokes responses takes 
around 1-2 hours. Should the potency of DAMGO fall due to a loss of responsiveness in 
the RVD over the collective 6-8 hour protocol, antagonists would be seen to be shifting 
the potency of DAMGO in a manner actually dependent on time. DAMGO 
responsiveness could not be assessed simply after test agonist effects on DAMGO 
potency were assessed as complete washout of inhibitory test agonists could not be 
assured. In the absence of a time-matched control experiment for DAMGO 
responsiveness over time, the results for SR17018 provide a control over a similar time-
course with ligand demonstrated not to interact with MOPr (Figure 3.12). There was no 
significant reduction of DAMGO potency with time (or increasing SR17018 
concentration, Figure 3.12) suggesting that observed effects with other ligands are not 
driven by time-dependent reductions in DAMGO potency. 
3.3.7 Studying the long-term effects of G protein-biased agonists at MOPr 
The long-term physiological consequences of biased signalling at MOPr is currently 
understudied. Given that receptor desensitization induced by opioids, and resulting 
tolerance to opioids, is dependent on receptor modulation by arrestin and GRK 
pathways, it is hypothesised that G protein-biased agonists would induce less receptor 
desensitization than balanced MOPr agonists. If this hypothesis is true, G protein-biased 
agonists may have more clinical utility than traditional opioids as the development of 
tolerance to these agonists could be reduced compared to balanced agonists. The 
identification in this Chapter of Compound 1 as a G protein-biased agonist at MOPr 
provides a tool compound to study this hypothesis.  
The following chapters will therefore be focussed on studying receptor desensitization 
potentially induced by Compound 1 and other opioids in rat locus coeruleus (LC) 
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neurons, using brain slice electrophysiology. Additionally, studying the agonist activity of 
Compound 1 and other opioids in a physiological system of receptor expression will 
support our findings in this Chapter around the importance of efficacy in considerations 
of biased agonism (Chapter 3.3.2). Furthermore, we will be investigating the analgesic 
effects of Compound 1 in vivo, in the hope of examining potential tolerance induce by G 




Chapter 4: Investigating receptor desensitization 
induced by G protein-biased MOPr agonists 
4.1 Introduction 
The MOPr undergoes rapid desensitization upon exposure to various opioid agonists. 
The short-term regulation of MOPr through rapid agonist-induced receptor 
desensitization represents a key cellular mechanism that contributes to the development 
of tolerance to opioids (Bailey et al., 2009a). Given that canonical MOPr desensitization 
is driven by agonist-induced GRK phosphorylation and arrestin recruitment (Williams et 
al., 2013), it could be hypothesised that G protein-biased agonists, which would 
inherently have low coupling to GRK/arrestin pathways, would induce less 
desensitization than a balanced agonist. Under this hypothesis, G protein-biased 
agonists would be clinically beneficial as they produce less tolerance. In order to 
investigate the ability of G protein-biased MOPr agonists to induce receptor 
desensitization, we studied the real time function of opioids in rat locus coeruleus 
neurons using patch-clamp electrophysiology. 
The locus coeruleus (LC) represents a dense cluster of largely homologous 
noradrenergic-neurons located near the wall of the fourth ventricle within the pons (Foote 
et al., 1983). Noradrenergic LC neurons express MOPr, but not DOPr or KOPr (Williams 
et al., 1984; North et al., 1987), giving them distinct utility as a model for the study of 
MOPr agonist function without the confounding effects of DOPr and KOPr agonism by 
these ligands. Activation of MOPrs in LC neurons produces hyperpolarising currents 
through inwardly rectifying potassium ion channels (Pepper et al., 1980; North et al., 
1985), the function of which are dependent on MOPr coupling to G proteins (Aghajanian 
et al., 1986; North et al., 1987). Opioid-induced currents in LC neurons provide a real-
time measure of receptor activation, making these currents ideal for the study of MOPr 
desensitization (Harris et al., 1991; Bailey et al., 2003).  
In LC neurons, GIRK currents evoked by the full agonists DAMGO and met-enkephalin, 
as well as the arrestin-biased MOPr agonist endomorphin-2, have been shown to 
undergo rapid desensitization, resulting in around a 50% reduction in current amplitude 
over a short (~10 minute) application at approximately receptor saturating concentrations 
(Osborne et al., 1995; Bailey et al., 2003; Rivero et al., 2012; Lowe et al., 2015). The 
decline of these opioid-evoked GIRK currents is a result of a reduction in functional 
MOPrs due to receptor desensitization (Bailey et al., 2009a). Morphine-induced currents 
have been shown to undergo lower amounts of rapid desensitization in LC neurons when 
compared to full agonists (Bailey et al., 2003; Bailey et al., 2004), however a number of 
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investigations have nonetheless demonstrated a sizable (around 20%) loss of function 
in morphine-evoked currents over the same time frame (Rivero et al., 2012; Lowe et al., 
2015).  
The difference in rapid MOPr desensitization induced by full agonists such as DAMGO, 
and the partial agonist morphine is thought to be dependent on agonist efficacy and the 
related intrinsic efficacy of an agonist to recruitment of GRK and arrestin to MOPr (Kelly 
et al., 2008). Given that the G protein-biased agonist Compound 1 (characterised in the 
previous chapter) is a partial agonist at MOPr, with the same G protein efficacy as 
morphine, we hypothesised that it would similarly produce minimal desensitization in LC 
neurons. Additionally, given that Compound 1 was demonstrated to have lower efficacy 
for GRK/arrestin pathways than morphine, it would be hypothesised that it would induce 
lower levels of MOPr desensitization than morphine in LC neurones. In the timeframe of 
rapid desensitization of MOPr-evoked GIRK currents in LC neurones, this process is not 
driven by arrestin recruitment (Arttamangkul et al., 2008), but by interconnected and 
precursory receptor phosphorylation by GRK (Bailey et al., 2009b; Lowe et al., 2015). 
Regardless, this hypothesis is supported by the finding that endomorphin-2, an arrestin 
biased MOPr agonist with a similar efficacy to morphine for G protein pathways, but 
higher efficacy for arrestin recruitment (McPherson et al., 2010), induces substantially 
more rapid receptor desensitization than morphine in LC neurons (Rivero et al., 2012). 
The work within this chapter aims to determine whether the G protein-biased agonist 
Compound 1 produces rapid MOPr desensitization in rat LC neurons. This was 
performed to inform us on the potential long-term functional consequences of G protein-
biased agonists at MOPr. In order to achieve this, the ability of Compound 1 to evoke 
MOPr dependent GIRK currents was assessed through whole-cell voltage-clamped 
electrophysiological recordings from LC neurons within rat brain slices. The amplitude 
and desensitization of Compound 1-evoked currents were compared to currents evoked 
by the test agonists characterised in the previous chapter, DAMGO, morphine and 
PZM21. Following this, the antinociceptive properties of Compound 1 were assessed 
using a warm water tail withdrawal test in mice, in the hope that a reliable response could 
obtained in order to later study in vivo tolerance to Compound 1. 
In this chapter, I demonstrate that the G protein biased MOPr agonist Compound 1 
induces MOPr desensitization in LC neurons to a greater degree than morphine. This 
intriguing finding was the opposite to what we had hypothesised, given that Compound 
1 displayed lower efficacy for arrestin-3 recruitment in the previous chapter. This finding 
implies that G protein-biased agonists at MOPr may not always induce less receptor 
desensitization than balanced agonists due to their low arrestin coupling, and highlights 
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concerns regarding their speculated ability to induce less tolerance than typical opioids. 
Additionally, considering the low arrestin recruitment efficacy of Compound 1, this finding 
potentially implies a non-arrestin/GRK mechanism of receptor desensitization may be 
involved in Compound 1-induced MOPr desensitization. Compound 1 induced MOPr-
dependent antinociception in mice, however the amount of antinociception was 
substantially lower than that evoked by morphine. The reason for the low efficacy of 
Compound 1 in vivo is unclear but was speculated to be due to poor pharmacokinetics 
and blood-brain barrier permeability. The following chapter will aim to characterise the 




4.2.1 Assessing the function and desensitization of opioid-induced GIRK 
currents in rat locus coeruleus neurons 
Opioid-evoked currents were assessed in single rat LC neurons from brain slices 
prepared from 4-week-old rats using whole-cell patch clamp electrophysiology (Chapter 
2.4). Approximately receptor saturating concentrations of DAMGO (Figure 4.1A, 10M), 
morphine (Figure 4.1B, 30M), PZM21 (Figure 4.1C, 30M) and Compound 1 (Figure 
4.1D, 30M) all evoked outward potassium currents through GIRK channels. Assessed 
agonists were superfused for 10 minutes, in an attempt to track the rapid decay of 
agonist-induced currents for approximately double the fitted t1/2 of an agonist’s current 
decline, guided by previous findings (Bailey et al., 2003). All agonist-evoked currents 
were effectively reversed with superfusion of naloxone (Figure 4.1, 1M or 10M), 
demonstrating that they are driven by agonist-induced MOPr activation in the absence 
of DOPr and KOPr expression and functionality in the LC (Williams et al., 1984; North et 
al., 1987; Mansour et al., 1994). While a concentration of 1M naloxone was initially 
used (Figure 4.1B-D), the slow reversal of Compound 1-evoked GIRK currents with this 
naloxone concentration (Figure 4.1D) prompted us to increase this working 
concentration to 10M in subsequent experiments, which included examinations of 
DAMGO-induced desensitization (Figure 4.1A). 
2 adrenoceptors and MOPrs couple to the same population of GIRK channels in LC 
neurons upon receptor activation (North et al., 1985). The maximal 2-adrenoceptor-
mediated current was assessed in each cell before and after the assessment of opioid-
induced currents by application of 100M noradrenaline (NA) in the presence of 1M 
prazosin and 3M cocaine (Figure 4.2). The inclusion of prazosin (an 1-adrenoceptor 
antagonist) and cocaine (monoamine reuptake inhibitor) was intended to maximise the 
2-adrenoceptor dependent NA-evoked GIRK current (Williams et al., 1987b; Llorente et 
al., 2012). In order to reduce variation in evoked-current amplitude between cells, the 
magnitude of opioid-evoked current was normalised to maximal 2-adrenoceptor-
mediated current evoked in the same cell prior to application of the opioid (Figure 4.2). 
The magnitudes of 2-adrenoceptor-mediated currents before and after opioid exposure 
were also assessed in order to investigate potential heterologous desensitization 
induced by opioids, as well as being indicative of current rundown over the duration of 






Figure 4.1 – Example traces of opioid-evoked GIRK currents in rat LC neurones. 
Representative traces showing outward potassium currents recorded from rat LC 
neurones in response to receptor saturating concentrations of DAMGO (10M, A), 
morphine (30M, B), PZM21 (30M, C) and Compound 1 (30M, D) over 10 mins of 
superfusion. Opioid-evoked currents were completely inhibited upon application of 
naloxone (NLX, 10M in A, 1M in B-D). Scale bars (shared across A-D) are 
representative of 50pA and 5 min.  
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Figure 4.2 – Example traces showing GIRK currents evoked through MOPr and 2 
adrenoceptor activation in rat LC neurones 
Representative traces demonstrating the full time-course for experiments investigating 
desensitization of opioid-evoked GIRK currents in rat LC neurons, of the type shown 
partially in Figure 4.1. At the beginning and end of each recording, the maximal 2-
adrenoceptor-mediated current in each individual cell was assessed by superfusion of 
noradrenaline (NA, 100M). In each case, prazosin (1M) and cocaine (3M) were 
perfused for 3 min prior to application of NA. The amplitude of NA-evoked currents before 
and after opioid application was compared to assess opioid-induced heterologous 
desensitization of GIRK currents as well as current rundown over time (see Figure 4.6). 
GIRK currents evoked by DAMGO (10M, A), morphine (30M, B), PZM21 (30M, C) 
and Compound 1 (30M, D) are also displayed, which were reversed by naloxone (NLX, 
10 M in A, 1 M in B-D). Scale bars are representative of 50pA and 5 min.  
 
High, receptor saturating concentrations were used for the assessment of opioid-evoked 
desensitization, in an attempt to standardise the degree of agonist-receptor occupancy 
to its maximum when studying agonists of differing affinity. For DAMGO and morphine, 
concentrations used in this experiment were previously demonstrated to be receptor 
saturating (Bailey et al., 2003; Bailey et al., 2009a). In the case of PZM21 and Compound 
1, 30M was assumed to be a receptor saturating concentration given previous 
observations of agonist potency and affinity relative to morphine (Chapter 3). At the 
approximately receptor saturating concentrations at which the opioids investigated were 
applied, the peak magnitudes of GIRK currents evoked by partial agonists can be used 
as an approximation of their intrinsic efficacy. The peak GIRK currents evoked by 
morphine, PZM21 and Compound 1 were all significantly lower than that evoked by 
DAMGO (Figure 4.3), demonstrating that they are partial agonists in rat LC neurons. The 
magnitude of Compound 1-evoked GIRK currents was statistically similar to those 
evoked by morphine, whereas the magnitude of PZM21-evoked GIRK currents was 
significantly lower than morphine (Figure 4.3). These findings in a system of 
physiological receptor expression are in agreement with data presented in the previous 
chapter from heterologous expression systems (Figure 3.1 and Table 3.1), supporting 
the finding that Compound 1 and morphine have the same efficacy for G protein 





Figure 4.3 – The amplitude of peak opioid-evoked GIRK currents in rat LC 
neurones 
The average peak GIRK currents elicited by opioids at receptor saturating concentrations 
(DAMGO, 10M; Morphine, PZM21 and Compound 1 , 30M) in rat LC neurones. Data 
collected from experiments of the type presented in Figure 4.2. Responses are 
normalised to the maximal 2-adrenoceptor-mediated current evoked by noradrenaline 
(100M) in the same cell. Data is presented as mean  SEM, where n = 5 – 10. # P < 
0.05, significantly different from all values for other agonists. * P < 0.05, significantly 
different from morphine value. ns P > 0.05, no significant difference from morphine value. 





























































The amplitude of DAMGO-, morphine-, PZM21- and Compound 1-evoked currents all 
decayed to different extents, in the continued presence of the drug (Figure 4.1). The time 
courses for the decay in currents evoked by all agonists could be fitted to a single-
exponential decay (Figure 4.4). The R squared values for the fitting of a single 
exponential decay to the decline in evoked currents for each agonists were as follows: 
DAMGO = 0.9, morphine = 0.6, PZM21 = 0.6, Compound 1 = 0.8. The fitted half-life (min) 
for the decay of agonist-evoked currents were as follows: DAMGO = 4.1, morphine = 
5.3, PZM21 = 8.6, Compound = 4.2. The 10 min drug incubation, which provided a 
window of around 8 min examination accounting for the time for the agonist effects to 
reach their peak, was therefore marginally insufficient to capture the decay of agonist-
evoked currents for the duration of double the half-life of decay. The fitted plateau for the 
decay of agonist-evoked currents (expressed as % peak GIRK current  SEM) were as 
follows: DAMGO = 36  8, Morphine = 67  11, PZM21 = 73  22, Compound 1 56  7. 
 
 
Figure 4.4 – Rapid desensitization of opioid-evoked GIRK currents in rat LC 
neurones 
Time-courses for the desensitization of GIRK currents evoked by receptor saturating 
concentrations (10M DAMGO, 30M morphine, PZM21 and Compound 1) in rat LC 
neurones post-peak responses. Data collected from experiments of the type presented 
in Figure 4.1. Responses are normalised to magnitude of the peak opioid-evoked GIRK 
current prior to desensitization. Data is presented as mean  SEM, where n = 5 – 10.   
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The observed rapid decline in the magnitude of agonist-evoked MOPr coupled-GIRK 
currents in LC neurons is indicative of rapid agonist-induced receptor desensitization 
(Bailey et al., 2009a). The rapid desensitization of agonist-evoked GIRK currents in rat 
LC neurons was quantified as the reduction in GIRK current magnitude at 8 min post-
peak agonist response compared to the peak response.  
The full agonist DAMGO (10M) produced marked desensitization of the evoked current 
over the 10 min of exposure (Figure 4.5). The partial agonist morphine (30M) produced 
significantly less MOPr desensitization than DAMGO (Figure 4.5). These findings are in 
line with previous studies of DAMGO-induced and morphine-induced desensitization in 
rat LC neurons (Alvarez et al., 2002; Bailey et al., 2003; Rivero et al., 2012; Lowe et al., 
2015). Similarly, PZM21 (30M) also produced relatively low levels of MOPr 
desensitization over the 10 min exposure (Figure 4.5), as would be expected for a partial 
agonist with a lower efficacy than morphine (Figure 4.3, Table 3.1). Unexpectedly, the G 
protein-biased agonist Compound 1 (30M) induced significantly more MOPr 
desensitization than morphine (Figure 4.5). This surprising finding was counter to our 
initial hypothesis that G protein-biased agonists, such as Compound 1, would induce 
less receptor desensitization than balanced agonists, such as morphine, due to their low 
intrinsic efficacy for arrestin coupling (Figure 3.1, Table 3.1). 
 
Figure 4.5 – Opioid-induced desensitization in rat LC neurones 
Average data for % desensitization in opioid-evoked GIRK currents after 8 min post-peak 
GIRK response. Data is presented as mean  SEM, where n = 5 – 10. # P < 0.05, 
significantly different from DAMGO value. * P < 0.05, significantly different from morphine 
value. One-way ANOVA with post-hoc Tukey test. 
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The magnitude of NA (100M) evoked currents was assessed before and after the 
application of opioids in order to assess both potential opioid-induced heterologous 
desensitization and current rundown (Figure 4.2). The magnitude of NA-evoked currents 
after opioid application compared with those evoked before were similar for all agonists 
(Figure 4.6). This findings suggests that the desensitization observed in Compound 1-
evoked currents is not due to heterologous desensitization. 
 
 
Figure 4.6 – Noradrenaline-evoked GIRK currents in opioid-treated LC neurones 
The magnitude of noradrenaline (NA, 100M) evoked GIRK currents was assessed 
before and after application of described opioids, at receptor saturating concentrations, 
in the presence of prazosin (1M) and cocaine (3M). Data collected from experiments 
of the type presented in Figure 4.2. Data are presented as mean  SEM, where n = 4 – 
8. No significant difference was observed between the magnitudes of post-opioid NA-































































4.2.2 Apparent Compound 1-induced MOPr desensitization is not due to peptide 
degradation or indirect GIRK inhibition 
One potential explanation for the decline in Compound 1-evoked currents could be that 
the peptide is readily degraded. A mechanism such as observed with Met-enkephalin, 
whereby the peptide is readily degraded by native peptidases when incubated with brain 
slices (Williams et al., 1987a; Konkoy et al., 1995), is unlikely in this case due to constant 
superfusion of Compound 1-containing aCSF. However, it is possible that Compound 1 
undergoes a slow degradation within the aCSF solution before it is perfused on to the 
brain slice. Alternatively, the free concentration of Compound 1 within the solution could 
be gradually reduced through binding to the glass in which this solution is stored prior to 
perfusion, despite regular siliconization of glassware. 
To test this hypothesis, Compound 1 (30M) was applied for 10 min and the decline in 
evoked current was observed. Then, a freshly prepared solution of Compound 1 (30M) 
was applied (Figure 4.7A). The application of freshly prepared Compound 1 did not 
increase the magnitude of the evoked-GIRK current (Figure 4.7B), demonstrating that 
the decline in Compound 1-evoked GIRK currents was not due to peptide degradation 
or loss within the system. 
Another potential explanation of the rapid decline in Compound 1-evoked GIRK currents 
is that Compound 1 blocks GIRK channels with a slower kinetics of action to its activation 
of GIRK channels through MOPr. This hypothesis is informed by similar findings with 
methadone, which was identified as a GIRK blocker in LC neurons as well as being a 
MOPr agonist (Rodriguez-Martin et al., 2008).  
To investigate this, the ability of Compound 1 (30M) to inhibit GIRK currents evoked by 
a submaximal concentration of NA (3M) was assessed in the presence of naloxone 
(10M) to block MOPr-dependent actions of Compound 1 (Figure 4.8A). Compound 1 
had no effect on NA-evoked GIRK currents (Figure 4.8B), demonstrating that it does not 
indirectly inhibit GIRK channels. This finding suggests that the decline in Compound 1-




Figure 4.7 – Decay in Compound 1 currents is not a product of peptide degradation 
(A) A representative trace showing decline of Compound 1 (30M)-evoked GIRK current 
in a rat LC neuron. Decline of the evoked current was unaffected when the superfused 
Compound 1 which had been applied for 10 minutes was replaced with freshly prepared 
(‘fresh’) Compound 1 (30M). Compound 1-evoked currents were completely reversed 
with naloxone (NLX, 10M). Scale bars are representative of 20pA and 5 min. (B) Pooled 
average data from experiments of the type presented in A. The Compound 1-evoked 
current, expressed as a percentage of the peak response was unaffected by application 










































Figure 4.8 – Decay in Compound 1 currents is not a product of indirect GIRK 
inhibition 
(A) A representative trace of a GIRK currents evoked by a submaximal concentration 
(3M) of noradrenaline (NA) in a rat LC neuron. The NA-evoked current was assessed 
in the presence of naloxone (NLX, 10M), prazosin (1M) and cocaine (3M). With MOPr 
blocked by NLX, the application of Compound 1 (30M) had no effect on the magnitude 
of NA-evoked GIRK currents. Phentolamine (PA, 10M) completely reversed NA-evoked 
currents. Scale bars are representative of 20pA and 5 min. (B) Pooled average data from 
experiments of the type presented in A. Application of Compound 1 (30M) had no effect 
on the amplitude of NA-evoked currents, normalised to amplitude of the plateau NA-












































4.2.3 PZM21 is a low efficacy partial MOPr agonist in LC neurons 
The finding that the intrinsic efficacy of PZM21 for MOPr-GIRK activation was 
significantly lower than that of morphine in LC neurons was at odds with previous findings 
at the time of investigation. Initial characterisation of PZM21 by Manglik et al. (2016) 
described PZM21 as having an equivalent efficacy for G protein activation to morphine 
in heterologous cell-based assays. This is particularly important considering that efficacy 
is an important and potentially confounding factor in the assessment of relative bias 
(Kelly, 2013) (Chapter 3.3.2).  
In order to illustrate whether the intrinsic efficacy of PZM21 for activation of MOPr-GIRK 
currents was notably different to that of morphine, we assessed the ability of a receptor 
saturating concentration of PZM21 (30M) to inhibit the GIRK current evoked by 
morphine at a maximal concentration (10M) (Figure 4.9). In this case, we would 
hypothesise that upon its application, PZM21 would displace morphine from MOPr and 
exert its own functional effect. If PZM21 were to have a lower intrinsic efficacy for MOPr-
dependent GIRK activity than morphine, it would functionally act as an antagonist (Figure 
3.5A). If PZM21 and morphine truly had equivalent intrinsic efficacies, it would have no 
effect on morphine-evoked GIRK currents.  
The application of PZM21 markedly attenuated the magnitude of the morphine-evoked 
GIRK current, to around 65% of its original amplitude (Figure 4.9). The degree of 
inhibition observed here was proportionally similar to the relationship of the peak GIRK 
currents evoked by PZM21 (30M) to that of morphine (30M) (around 60%) (Figure 
4.3). This finding further illustrates that PZM21 does in fact have a lower intrinsic efficacy 
than morphine for G protein activation downstream of MOPr, in agreement with data from 





Figure 4.9 – PZM21 partially antagonises morphine-evoked GIRK currents 
A representative trace of a GIRK current evoked by an approximately maximal 
concentration of morphine (10M) in a rat LC neuron. Application of a receptor saturating 
concentration of PZM21 (30M) caused a robust reduction in the amplitude of morphine-
evoked GIRK current. Scale bars are representative of 20pA and 5 min. Data presented 






4.2.4 Compound 1 induces small but measurable antinociception in mice 
The rapid and efficacious analgesic effects of opioids, such as morphine, have cemented 
them as mainstays of significant pain management. Opioids produce their analgesic 
effects through activation of MOPr (Matthes et al., 1996). The molecular mechanisms of 
MOPr-mediated analgesia are G protein-dependent, with opioid-induced analgesia 
dependent on the expression of GIRK channels (Marker et al., 2004) and enhanced in 
mice lacking arrestin-3 (Bohn et al., 1999) or expressing knock-in phosphorylation-
deficient MOPr mutants (Kliewer et al., 2019).  
The analgesic properties of pharmacological agents are often studied through 
assessment of their ability to increase an animals response threshold to an acute 
nociceptive stimulus (Le Bars et al., 2001). The warm water tail withdrawal assay (or 
‘Tail-Flick’ test) is a simple, well-established animal model of nociception to thermal 
stimuli (Janssen et al., 1963). In this paradigm, the immersion of an animal’s (often 
mouse or rat) tail into warm water (around 50C) provokes a rapid movement of the tail 
away from the stimulus. The latency of an animal to evoke a response (tail flick) upon 
exposure to the stimuli is monitored as a measure of nociception.  
It is well-defined that opioids increase the response latency in this paradigm (Janssen et 
al., 1963), acting as antinociceptive agents. Given the agonist activity of Compound 1 at 
MOPr, we sought to characterise its antinociceptive properties in mice using a warm 
water tail withdrawal assay.  
Additionally, characterising the antinociceptive effects of Compound 1 would further 
enable us to study potential long-term tolerance induced by Compound 1 upon chronic 
administration. Repeated injection of opioids to naïve animals results in a rapid reduction 
in the function of these drugs (i.e., tolerance), which can be assessed through 
antinociceptive assays such as warm water tail-withdrawal (Bohn et al., 2000; Hull et al., 
2010; Melief et al., 2010). The rapid development of tolerance to opioid drugs severely 
limits their clinical utility, especially for chronic pain states. Given that opioid-induced 
receptor desensitization is suggested to play an important role in the development of 
opioid tolerance (Bohn et al., 2000; Bailey et al., 2009a; Kliewer et al., 2019), we hoped 
to study Compound 1-induced tolerance to further our understanding of the long-term 
functional consequences of biased agonism at MOPr in whole-animals.  
Nociceptive function in male CD1 mice (8 weeks) old was tested using a warm water tail-
immersion test using a water bath maintained at 52.5C. The control latency times of 
withdrawal were assessed 30 minutes and 15 minutes prior to injection in order to gain 
a baseline value for tail flick latency in each mouse (Figure 4.10A).  
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Upon injection, morphine (10 mg/kg, i.p.) produced a rapid and substantial increase in 
tail flick latency in the mice (Figure 4.10A). At 15 minutes post-injection, seven of the 
twelve mice administered morphine exhibited tail flick latency values which reached the 
set 15 second cut-off time. Both doses of Compound 1 (50 mg/kg and 100 mg/kg, i.p.) 
also appeared to increase the observed tail flick latency of the mice in the tail withdrawal 
assay (Figure 4.10A). In contrast to morphine, none of the six mice which received 50 
mg/kg Compound 1 and only one of the six mice administered 100 mg/kg Compound 1 
exhibited tail flick latency which reached the set 15 second cut-off time over the 60 
minute-post injection observation time.  
Raw tail latency time values (Figure 4.10A) were converted to % of maximum possible 
effect values (% MPE, Figure 4.10B), a metric of antinociception incorporating both the 
baseline response values and the set 15 second cut-off time (Harris et al., 1964). The % 
MPE data similarly demonstrates that both morphine (10mg/kg) and Compound 1 (50 
mg/kg & 100 mg/kg) produce an increase in tail flick latency in mice (Figure 4.10B). While 
there was no significant difference (Two-way ANOVA with Bonferroni’s comparison) 
between the peak antinociceptive effects induced by Compound 1 at both doses (50 
mg/kg and 100 mg/kg) and those induced by morphine (10 mg/kg), it appears the peak 
responses induced by Compound 1 were substantially lower (Figure 4.10B). 
The area under the curve (AUC) for the time-% MPE curves (Figure 4.10B) were taken 
in the case of each drug, in order to characterise their collective antinociceptive effect 
over the 60 minutes post-treatment (Meymandi et al., 2006). A Kruskal-Wallis test, used 
given the non-parametric nature of the AUC values due to the cut-off applied to response 
times, revealed a significant difference between the AUC values for time-effect curves 
for between treatment groups (Figure 4.10C). The AUC values for morphine (10 mg/kg) 
and both examined doses of Compound 1 (50 mg/kg and 100 mg/kg) were significantly 
higher than that of saline (following further Dunn’s multiple comparisons test), 
demonstrating that the examined doses of morphine and Compound 1 all produced 
antinociception in mice (Figure 4.10C). While no significant differences were observed 
between the AUC values for morphine and Compound 1 induced antinociception, it is 
clear that Compound 1 was not as efficacious as morphine at 50 mg/kg, and its efficacy 




Figure 4.10 – Antinociception induced by Compound 1 and morphine in CD1 mice 
(A) Administration of morphine (10mg/kg, i.p.) and Compound 1 (50mg/kg and 
100mg/kg, i.p.) increased the latency of tail flick responses (in seconds) of CD1 mice in 
a warm water tail withdrawal test of nociception. (B) Antinociceptive effects of Compound 
1 and morphine displayed as a percentage of the maximum possible effect (% MPE), 
normalising to baseline nociceptive responses (0%) and the 15s cut off time (100%). (C) 



























































































Averaged area under the curve (AUC) data for Compound 1- and morphine-induced 
antinociception calculated from data presented in B. * P < 0.05, significantly different 
from saline AUC value. Kruskal-Wallis test with post-hoc Dunn’s multiple comparisons 
test. n = 6 for Compound 1 50mg/kg and 100mg/kg groups, n = 12 for morphine 50mg/kg 
and saline groups. This work was performed with assistance from Dr Rob Hill (University 




Given the DOPr agonist properties previously demonstrated for Compound 1 (Figure 
3.6), we sought to determine whether the observed antinociceptive properties of 
Compound 1 were MOPr-dependent through studying its effect in MOPr knockout (KO) 
mutant mice. 
Similarly, to above, the nociception of both MOPr KO mice and wildtype C57/BLJ 
(background strain) (male and female, 25-30 g) was tested using a warm water tail-
immersion test using a water bath maintained at 52.5C. All animals received Compound 
1 (50 mg/kg, i.p.). The lack of saline (negative) or morphine (positive) control groups 
arises from a limited number of MOPr KO animals available for this study.  
Compound 1 did not produce an increase in tail flick latency in MOPr KO mice, when 
represented in raw values (Figure 4.11A) or as % MPE (Figure 4.11B). In contrast, 
Compound 1 produced a small increase in tail flick latency overall in C57/BLJ wildtype 
mice (Figure 4.11B). Compound 1-induced antinociception was significantly higher in 
C57/BLJ wild type mice than in MOPr KO mice at 45 mins and 60 mins post-treatment 
(Two-way ANOVA with Bonferroni’s comparison). Two of the eight C57/BLJ wildtype 
mice examined exhibited the maximal possible effect for antinociception after 
administration with Compound 1 at one or more timepoints, where this was not observed 
in any of the MOPr KO mice. These findings demonstrate that the small antinociceptive 
effect induced by Compound 1 in mice is MOPr dependent. However, due to substantial 
error values in this study, there was no significant difference observed between the AUC 
values for MOPr KO and C57/BLJ wildtype mice (Figure 4.11C) calculated from the 
%MPE curves (Figure 4.11B) (Mann-Whitney Test, p = 0.10). 
The lower magnitude of Compound 1 (50 mg/kg)-induced antinociception in the C57/BLJ 
mice (Figure 4.11B) compared to in the CD-1 mice (Figure 4.10B) likely results from the 
a lower opioid sensitivity of C57/BLJ mice in nociception assays, as previously reported 
(Pick et al., 1991). However, it is not possible to attribute this in the absence of a 




Figure 4.11 – Compound 1-induced antinociception in C57/BL6 MOPr KO and WT 
mice 
(A) Administration of Compound 1 (50mg/kg i.p.) caused a small increase in the latency 
of tail flick responses (in seconds) of C57/BL6 WT mice, but not MOPr KO mice (male 
and female 25-30g) in a warm water tail withdrawal test of nociception. (B) The effects 
of Compound 1 displayed as a percentage of the maximum possible effect (% MPE), 
normalising to baseline nociceptive responses (0%) and the 15s cut off time (100%). (C) 


































































calculated from data presented in B. ns P > 0.05, no significant difference was observed 
between the AUC values observed in C57/BL6 WT and MOPr KO mice, assessed 





4.3.1 The intrinsic efficacy of Compound 1 and PZM21 in LC neurones 
Agonist intrinsic efficacy is an important and potentially confounding factor in the 
assessment of biased agonism at GPCRs (Kelly, 2013; Gillis et al., 2020c). The accurate 
assessment of agonist efficacy in heterologous systems is often distorted by receptor 
overexpression, ceiling for assay effects and high levels of amplification in particular G 
protein assays (Chapter 3.3.3). As such, G protein efficacy for partial agonists relative to 
full agonists is often exaggerated when assessed in heterologous systems. This 
becomes problematic considering the differential amplification between assays of G 
protein activity which often contain substantial signal amplification and the near linear 
process of arrestin recruitment. This can lead to partial agonists being classified as full 
agonists for G protein activity but weak partial agonists for arrestin recruitment due to 
simple system bias rather than actual biased agonism. For example, the prototypical 
partial agonist morphine has often been classified as a full agonist for G protein signalling 
in highly amplified cAMP-based assays (Zaki et al., 2000; Hothersall et al., 2017; Schmid 
et al., 2017; Pedersen et al., 2020), which has led to misleading conclusions about it 
being a G protein-biased agonist (Kelly, 2013). The characterization of agonist intrinsic 
efficacy in isolated tissue preparations can provide valuable, undistorted estimates of 
agonist efficacy. While this approach could be naïvely perceived as antiquated in the age 
of the recombinant system, the physiological levels of receptor expression in these 
preparations provide valuable, undistorted data which is less liable to misinterpretation.  
The magnitude of peak GIRK currents induced by test opioids at receptor saturating 
concentrations in rat locus coeruleus neurons in this chapter provided an estimate of 
agonist intrinsic efficacy in the absence of full concentration response curves (Figure 
4.3). The magnitude of GIRK currents evoked by Compound 1 were statistically similar 
to those evoked by morphine (Figure 4.3), supporting data from our G protein BRET 
assay (Figure 3.1, Table 3.1) which suggests that Compound 1 and morphine have 
equivalent G protein efficacy. 
The lower magnitude of PZM21-evoked GIRK currents compared to those evoked by 
morphine was similarly in agreement with efficacy data from our G protein BRET assay 
(Figure 3.1, Table 3.1). Additionally, the fact that PZM21 partially antagonised morphine-
evoked currents in LC neurons (Figure 4.9) clearly illustrates that it has a lower efficacy 
than morphine at MOPr. While this finding disagrees with some data within the original 
description of PZM21 (Manglik et al., 2016), it is in full agreement with more recent data 
from other groups (Hill et al., 2018b; Yudin et al., 2019; Gillis et al., 2020a). It is likely 
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that the reportedly improved adverse effect profiles of PZM21 (but see (Hill et al., 2018b)) 
are in fact attributed to its low intrinsic efficacy rather than any apparent bias (Gillis et al., 
2020a). 
4.3.2 PZM21 induced minimal rapid MOPr desensitization 
As a lower efficacy agonist than morphine, it is unsurprising that PZM21 visually appears 
to induce less rapid receptor desensitization in LC neurons (McPherson et al., 2010) 
(Figure 4.4). Although, statistically the extent of MOPr desensitization induced by PZM21 
was not significantly different to that of morphine (Figure 4.5). Given that the fitted value 
of the half-life for the decline in PZM21-evoked currents was markedly slower than that 
of morphine (8.6 and 5.3 min respectively), it is possible that the time-scale used for 
investigations of PZM21-evoked currents was too short to observe the full extent of its 
desensitization. This is supported by the similarity of the plateau values (% peak 
response  SEM) for fitted curves of PZM21 (73  22) and morphine (67  11) induced 
desensitization (Figure 4.4), which suggest the extent of desensitization evoked by 
PZM21 and morphine would be fairly similar if observed over a longer timeframe. Future 
experiments could examine this by tracking PZM21- and morphine-induced 
desensitization for longer time-periods post-peak opioid response (e.g. 30 min), however 
we believed this was outside of the focus of our current experiments.  
Together, our data is in line with observations that tolerance to the antinociceptive effects 
of PZM21 develop in a similar rapid manner to that of morphine in vivo (Hill et al., 2018b). 
Our findings regarding PZM21-induced desensitization and other observations of PZM21 
tolerance  do question recent suggestions that low efficacy MOPr agonists are potentially 
being less liable to the development of tolerance (Gillis et al., 2020a). 
4.3.3 Compound 1 induced substantial MOPr desensitization 
Compound 1-evoked currents underwent more rapid desensitization than those evoked 
by morphine. Previously the ability of agonists to induce GRK/arrestin mediated-
phosphorylation and internalization has been strongly correlated with agonist G protein 
efficacy, with the important exception of the arrestin-biased agonist endomorphin-2 
(McPherson et al., 2010). Under this association it would have been expected that 
Compound 1, when disregarding its biased agonism, would produce at most similar 
levels of MOPr desensitization to morphine considering they have equivalent G protein 
efficacy (Figure 3.1, Table 3.1, Figure 4.3).  
Considering the propensity of arrestin-biased MOPr agonists to comparatively induce 
more receptor desensitization than the balanced agonist morphine, one would 
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hypothesise that the converse would be true for the G protein biased agonist Compound 
1. For instance, the arrestin-biased agonist endomorphin-2 has an equivalent G protein 
efficacy to morphine but a relatively higher efficacy for Ser375 phosphorylation, arrestin 
recruitment and receptor internalization (McPherson et al., 2010; Rivero et al., 2012). 
Accordingly, endomorphin-2 induces substantially more rapid receptor desensitization in 
LC neurons (Rivero et al., 2012). Given Compound 1 had a lower efficacy for arrestin-3 
recruitment than morphine (Figure 3.1, Table 3.1), we anticipated that it would produce 
less receptor desensitization in LC neurones. The fact that we found the opposite raises 
questions around the potential mechanisms of Compound 1-induced receptor 
desensitization. 
I confirmed that apparent Compound 1-induced receptor desensitization was not due to 
the presence of potentially confounding effects, such as heterologous desensitization 
(Figure 4.6), peptide degradation (Figure 4.7) or indirect GIRK inhibition by Compound 
1 (Figure 4.8). As such, the mechanism of Compound 1-induced MOPr desensitization 
could present a potentially novel mechanism responsible for the regulation of the long-
term functional effects of G protein-biased agonists in the absence of GRK/arrestin 
modulation.  
Aside from the canonical GRK/arrestin dependent mechanisms of MOPr desensitization, 
there have been a number of other kinase mediators e.g. PKC implicated in regulation 
of MOPr (Piñeyro et al., 2007; Kelly et al., 2008; Koch et al., 2008; Raehal et al., 2011b; 
Williams et al., 2013) (Chapter 1.2.5). In some cases, the involvement of these kinases 
is agonist-dependent (Kelly et al., 2008). It is possible that Compound 1 may induce 
MOPr desensitization through non-GRK/arrestin mechanisms previously implicated in 
MOPr regulation (further discussed in Chapter 5.1).  
In the following chapter I will be investigating the potential mechanisms of Compound 1-
induced MOPr desensitization in LC neurones, examining the role of kinases which have 
previously been implicated in MOPr regulation (GRK, PKC and JNK), through the use of 
known pharmacological inhibitors of these kinases. 
4.3.4 Compound 1 induced antinociception 
Compound 1 was found to induce antinociception typical of opioids in a warm-water tail 
withdrawal assay in CD1 mice (Figure 4.10). The antinociceptive effects of Compound 1 
were found to be mediated through MOPr, with an apparent absence of effect in MOPr 
KO mice (Figure 4.11). However, the antinociception induced by Compound 1 did not 
reach the levels achieved by morphine (10mg/kg) (Figure 4.11). Increasing the dose of 
 
 116 
Compound 1 to 100mg/kg did not increase the antinociception elicited, suggesting a 
ceiling to its effect. 
The finding that the peak antinociceptive effect induced by Compound 1 was 
substantially lower than morphine would not have been predicted based on results from 
our previous receptor pharmacology studies. Previous findings demonstrating that 
Compound 1 and morphine have equivalent intrinsic efficacy for G protein signalling in 
both our BRET assays (Table 3.1) and in rat LC neurons (Figure 4.3) suggest that the 
lower antinociceptive effect of Compound 1 is not due to its basic receptor pharmacology. 
Additionally, agonists of lower efficacy than morphine (such as pethidine, oxycodone and 
hydrocodone), often produce similar levels of analgesia to morphine in antinociceptive 
assays, in part due to a ceiling in reportable responses due to the time limits on 
nociceptive stimulus exposure applied for ethical reasons (Madia et al., 2009; Hull et al., 
2010). Therefore, we suggest that the lower relative magnitude of antinociception 
produced by Compound 1 is not due to lower intrinsic efficacy. 
The efficacy of drugs in whole-animal environments is influenced by factors beyond 
receptor pharmacology. For instance, the metabolic stability of Compound 1 is 
completely unknown. While this peptide has been cyclised in the hope of improving its 
metabolic stability (Li et al., 2016), degradation by peptidases upon systemic 
administration could feasibly explain limitations in its in vivo effects.  
Additionally, the levels of Compound 1 reaching the site of action upon systemic 
administration is unknown. In order to exert its effects at spinal/CNS sites of action, this 
large cyclic peptide would have to cross the blood-brain barrier (BBB), which is 
dependent on the physiochemical properties of Compound 1, but also factors such as 
saturable bidirectional transport mechanisms across the BBB (Kastin et al., 1999). 
Although the extent of Compound 1 blood brain barrier (BBB) permeability and its 
pharmacokinetic properties are unknown, as a high molecular weight peptide, it is 
unlikely that it has high BBB permeability and as such the brain levels of Compound 1 
could be limited One could entertain a possible mechanism whereby Compound 1 is 
transported across the BBB into the CNS through a saturable transport mechanism. If 
this was the case, it could explain the ceiling to the effect of Compound 1 (Figure 4.10).  
Regardless, without real examination of the pharmacokinetic properties of Compound 1, 
including brain levels upon administration, it is not possible to conclude what the 
relatively low analgesic effect of this drug is due to. Potential issues surrounding BBB 
permeability of Compound 1 could be circumvented by examining its effects when 
administered intracerebroventricularly (i.c.v.) (Cook et al., 2009), however this is an 
intricate and potentially problematic procedure in mice. Without the necessary 
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experience, it was decided that this experiment was outside of the scope of this current 
study but could feasibly be addressed in future experiments. 
In the absence of further pharmacokinetic data for Compound 1, we next focussed our 
research efforts on elucidating the mechanism of MOPr desensitization observed for 
Compound 1 in rat LC neurones rather than investigating potential in vivo tolerance to 




Chapter 5: Investigating the potential mechanisms of 
Compound 1-induced MOPr desensitization 
5.1 Introduction 
Work within the previous chapters of this thesis has characterised Compound 1 as a 
novel G protein-biased agonist. Compound 1 was demonstrated to induce substantial 
MOPr desensitization in rat LC neurones, opposing our original hypothesis that G 
protein-biased agonists would induce less receptor desensitization in this system.  
The canonical mechanism of MOPr desensitization is initiated by GRK-dependent 
phosphorylation of MOPr C-terminal serine and threonine residues, with subsequent 
recruitment of arrestin-3 and related cellular machinery driving receptor internalization 
(Williams et al., 2013). Specifically, in LC neurones, expression of GRK2 has been 
demonstrated to be integral to MOPr desensitization induced by DAMGO (Bailey et al., 
2009b). Additionally, the importance of C-terminal serine and threonine residue targets 
of GRK to Met-Enkephalin-induced MOPr desensitization has been demonstrated in both 
mouse and rat LC neurones, with loss of MOPr desensitization with the expression of 
phosphorylation-site deficient MOPrs (Arttamangkul et al., 2019a; Kliewer et al., 2019). 
Given its low coupling to arrestin pathways (Figure 3.1D), we hypothesised that the 
MOPr desensitization induced by Compound 1 could be occurring through a non-
GRK/arrestin based mechanism. Agonist-selective mechanisms of receptor 
desensitization and regulation have been widely discussed at MOPr, particularly in 
reference to that induced by morphine (Piñeyro et al., 2007; Kelly et al., 2008; Koch et 
al., 2008; Raehal et al., 2011b; Williams et al., 2013) (Chapter 1.2.5). It is possible that 
kinases previously implicated in agonist-selective mechanisms of MOPr desensitization 
could regulate Compound 1-induced desensitization. 
One such mediator is PKC, which has been demonstrated to mediate the rapid receptor 
desensitization induced by morphine in LC neurones (Bailey et al., 2004; Bailey et al., 
2009a; Bailey et al., 2009b) as well as the development of tolerance to morphine in vivo 
(Bohn et al., 2002; Hull et al., 2010). The relative contribution of PKC and/or GRK in 
opioid-induced MOPr desensitization has been associated with agonist intrinsic efficacy 
(Kelly et al., 2008). As such, high efficacy agonists at MOPr such as DAMGO and Met-
Enkephalin would desensitize predominately through GRK pathways (Bailey et al., 
2009b; Lowe et al., 2015) while lower efficacy agonists such as morphine would 
desensitize predominately through PKC (Bailey et al., 2004; Bailey et al., 2009a; Bailey 
et al., 2009b), with a smaller GRK component present (Lowe et al., 2015) (Chapter 1.2.5, 
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Figure 1.5). Given that Compound 1 is a partial MOPr agonist similar to morphine, it 
could be hypothesised that Compound 1-induced desensitization is mediated 
predominately by PKC rather than GRK.  
In addition to PKC, there are a number of other kinases which have been implicated in 
MOPr regulation (Chapter 1.2.5) (Williams et al., 2013). One such kinase is c-Jun-N-
terminal kinase 2 (JNK2). JNK2 has been implicated as a mediator of analgesic tolerance 
to morphine in mice (Melief et al., 2010). Additionally, JNK2 has been shown to regulate 
cellular tolerance to morphine in dorsal root ganglion neurons (Mittal et al., 2012). 
Recently, JNK has been demonstrated to play a role (alongside GRK and PKC) in MOPr 
downregulation in rat LC neurones, observed upon chronic morphine treatment (Leff et 
al., 2020). While it is possible that Compound 1-induced desensitization is JNK-
mediated, the role of JNK appears to be linked to arrestin signalling (Mittal et al., 2012). 
The work within this chapter sought to characterise the potential mechanisms involved 
in acute Compound 1-induced MOPr desensitization. By investigating potentially novel 
mechanisms of agonist-induced MOPr desensitization, we sought to further illustrate the 
long-term functional consequences of G protein-biased agonists at MOPr. In order to 
achieve this, we examined Compound 1-evoked GIRK currents in rat LC neurones in the 
presence of a number of pharmacological inhibitors of kinases previously implicated in 
the regulation of agonist-induced MOPr desensitization. 
In this chapter, I demonstrate that Compound 1-induced desensitization in LC neurons 
is a GRK-dependent process, independent of PKC and JNK. This finding was somewhat 
unexpected given the low arrestin recruitment induced by Compound 1 in recombinant 
systems (Figure 3.1D). Following this, we again turned to recombinant systems to refine 
our understanding of the potentially GRK-dependent, arrestin-independent mechanism 
of Compound 1-induced MOPr desensitization through assays of arrestin recruitment 
(BRET), MOPr internalization (ELISA) and MOPr phosphorylation (phosphospecific 
immunoblotting). These assays provided data in line with Compound 1 being a G protein-
biased agonist in recombinant systems, with Compound 1 inducing low recruitment of 
arrestins 2 and 3, minimal MOPr internalization, and nominal phosphorylation of serine 
and threonine residues known to be involved in GRK/arrestin-mediated MOPr 





5.2.1 Investigating the mechanisms of Compound 1-induced MOPr 
desensitization in rat LC neurones 
As described previously in Chapter 4, Compound 1 (30M)-evoked GIRK currents were 
studied in single LC neurones from brain slices obtained from 4-week-old Wistar rats 
through whole-cell voltage-clamped electrophysiological recordings (Chapter 2.4). In 
order to study the potential role of select kinases in Compound 1-induced 
desensitization, we perfused brain slices with known inhibitors for 20 minutes prior to, 
and during, the application of Compound 1 and recording of evoked GIRK currents.  
Kinase inhibitors were perfused for 20 min from the point of washing off the noradrenaline 
from the first control response (Figure 4.2). As such, the currents evoked in kinase 
inhibitor experiments would be observed at a later time point with respect to patching 
and application of noradrenaline, relative to the experiments done in Chapter 4 (Figure 
4.2). Additionally, the potential effect of the vehicle for kinase inhibitors (0.1% v/v DMSO) 
on Compound 1-induced desensitization could confound any comparisons made 
between experiments presented in Chapter 4 (Figure 4.2) and these kinase inhibitor 
experiments.  
As such, the extent of Compound 1-induced desensitization in the presence of select 
kinase inhibitors studied in this chapter was compared to that observed after 20 minutes 
perfusion of DMSO (0.1% v/v). As anticipated, the perfusion of DMSO had significant no 
effect on the magnitude of Compound-1 induced desensitization at 8 min post-peak 
opioid response (P = 0.31, two-tailed unpaired t-test) (Figure 5.1). However, the rate of 
desensitization appeared to be slightly slowed in the DMSO conditions compared to in 
previous Compound 1-evoked currents (Figure 5.1). The half-life for the decay of 
Compound 1-evoked currents (min) was slightly increased from 4.2 to 5.1 in experiments 
with perfusion of DMSO for 20 min. Accordingly, the time for observation of Compound 
1 currents post-peak response in all kinase inhibitor experiments was extended from 8 
min to 10 min, in an attempt to capture double the half-life of evoked currents as 
previously discussed (Bailey et al., 2003). The specific reasoning behind this small 
slowing of Compound 1-induced desensitization is unclear, however it is likely related to 
the time at which Compound 1-evoked currents were examined relative to patching the 




Figure 5.1 – The effect of DMSO on desensitization of Compound 1-evoked GIRK 
currents 
Representative traces of Compound 1 (30M)-evoked potassium currents in rat LC 
neurones after no preincubation of additional agents (A) or after 20 min preincubation of 
DMSO (0.1% v/v; B). Compound 1-evoked GIRK currents were reversed by naloxone 
(NLX; A 1M, B 10M). Scale bars are representative of 20pA and 300s. (C) Pooled time 
courses from experiments of the type presented in A & B showing the desensitization of 
Compound 1-evoked currents post-peak response in the presence or absence of DMSO 
preincubation. Data for Compound 1-evoked currents presented here is reproduced from 
Chapter 4 (Figure 4.4). Data are presented as mean  SEM, where n = 10 – 13.  







































5.2.2 Compound 1-induced MOPr desensitization in rat LC neurones is not 
dependent on PKC 
PKC has been demonstrated to play a significant role in morphine-induced MOPr 
desensitization in both HEK 293 cells (Johnson et al., 2006) and in LC neurones (Bailey 
et al., 2004; Bailey et al., 2009b). The relative contribution of PKC to agonist-induced 
MOPr desensitization was postulated to be dependent on agonist efficacy (Kelly et al., 
2008). This hypothesis was formed from observations of differential patterns of MOPr 
desensitization induced by DAMGO and morphine. In LC neurones, the full agonist 
DAMGO induces marked rapid receptor desensitization, through a GRK-dependent, but 
PKC-independent mechanism (Bailey et al., 2009b; Lowe et al., 2015). The partial 
agonist morphine induces minimal GRK-dependent receptor desensitization in LC 
neurones (Bailey et al., 2009b; Lowe et al., 2015), however morphine-induced 
desensitization is selectively enhanced when PKC activity was activated by phorbol-12-
myristate-13-acetate (PMA) or through activation of M3 muscarinic receptors in LC 
neurones (Bailey et al., 2004).  
Oxycodone, which has a similar efficacy for G protein activation as morphine 
(McPherson et al., 2010), also produces minimal GRK-dependent desensitization in LC 
neurones (Arttamangkul et al., 2008). While the role of PKC in potential oxycodone-
induced MOPr desensitization in LC neurones has not been examined, PKC does play 
a significant role in the development of tolerance to oxycodone (Hill et al., 2018a), as 
with the case of morphine, supporting efficacy as a determining factor in the relative 
contributions of GRK and PKC to agonist-induced MOPr desensitization. 
Given that Compound 1 appears to have a similar efficacy to morphine (Figure 3.1, Table 
3.1), we hypothesised that the observed Compound 1-induced desensitization in LC 
neurones could be regulated by PKC. I sought to test this hypothesis by first examining 
the effect of PKC inhibition on Compound 1-induced desensitization using GF109203X 
(Bailey et al., 2004), then investigating the effect of PKC activation on Compound 1-
induced desensitization using PMA.  
Brain slices were preincubated with GF109203X (1M) for 20 min prior to, and during, 
the application of Compound 1 (Figure 5.2A). Inhibition of PKC through GF109203X had 
no effect on the desensitization of Compound 1-evoked GIRK currents compared to 
DMSO control (Figure 5.2). No visible differences were observed in the rate of 
Compound 1 desensitization (Figure 5.2B) and no significant differences were seen in 
the overall extent of desensitization (Figure 5.2C) between slices preincubated with 




Figure 5.2 – Inhibition of PKC has no effect on Compound 1-induced 
desensitization 
(A) A representative trace of a Compound 1 (30M) evoked potassium currents in rat LC 
neurones after 20 min preincubation of GF109203X (1M). Compound 1-evoked GIRK 
currents were reversed by naloxone (NLX; 10M). Scale bars are representative of 20pA 
and 300s. (B) Pooled time-courses showing the desensitization of Compound 1-evoked 
currents post-peak response in the presence of GF109203X (1M) or control. (C) Pooled 
data for percentage of desensitization induced by Compound 1 10 min post-peak 
response following preincubation of GF109203X (1M) or control. Control represents 20 
min preincubation with DMSO (0.1% v/v, Figure 5.1C). Data are presented as mean  





































































These findings with GF109203X suggest that PKC is not responsible for the acute rapid 
receptor desensitization observed in rat LC neurones in response to Compound 1. 
However, LC neurones in the slice preparation are considered to be relatively dormant, 
with basal PKC activity considerably lower than in the same neurones in an intact system 
(in vivo). This is probably due to activity of Gq-coupled GPCRs, as well as calcium 
permeable ionotropic receptors from ongoing synaptic activity (Bailey et al., 2009a). As 
such, exogenous activation of PKC in LC slices is used experimentally to attempt to 
mimic physiological levels of PKC activity in brain slices. As such, given that the 
endogenous PKC activity in brain slices must be raised in order to observe its role in 
MOPr desensitization, it is perhaps unsurprising that Compound 1-induced 
desensitization in basal conditions was unaffected by PKC inhibition. Similar findings 
have been demonstrated for GF109203X on MOPr desensitization in the case of 
morphine and Met-Enkephalin, where desensitization induced by these agonists do 
show PKC-dependence when PKC is exogenously stimulated (Bailey et al., 2004). 
In order to study whether Compound 1-induced MOPr desensitization could be 
enhanced by activation of PKC, brain slices were preincubated with PMA (1M) for 20 
min prior to, and during, recording of Compound 1-evoked currents in rat LC neurones 
(Figure 5.3A). PMA had no significant effect on the overall desensitization of Compound 
1-evoked GIRK currents (Figure 5.3B & 5.3C).  
The increased apparent ‘noise’ levels in traces of the Compound 1-evoked GIRK current 
in Figure 5.3A was typical of all experiments with PMA. This ‘noise’ occurs through direct 
action of PMA to increase the frequency of spontaneous excitatory and inhibitory 
postsynaptic currents, which has been previously reported in rat LC neurones (Bailey et 
al., 2004) and other central nervous system synapses (Malenka et al., 1986). The 
occurrence of this induced ‘noise’ serves as a type of positive control confirming that 





Figure 5.3 – Activation of PKC has no impact on Compound 1-induced 
desensitization 
(A) A representative trace of a Compound 1 (30M)-evoked potassium current in rat LC 
neurones after 20 min preincubation of PMA (1M). Compound 1-evoked GIRK currents 
were reversed by naloxone (NLX; 10M). Scale bars are representative of 20pA and 
300s. (B) Pooled time-courses showing the desensitization of Compound 1-evoked 
currents post-peak response in the presence of PMA (1M) or control. (C) Pooled data 
for percentage of desensitization induced by Compound 1 ten min post-peak response 
following preincubation of PMA (1M) or control. Control represents 20 min 
preincubation with DMSO (0.1% v/v, Figure 5.1C). Data are presented as mean  SEM, 




































































In order to exclude the possibility that inactivity of the GF109203X and PMA used in this 
study was responsible for the lack of PKC effect observed in Compound 1 induced 
desensitization, we sought to reproduce previous findings for PMA and GF109203X on 
morphine-induced MOPr desensitization. The ability of PMA (1 M) to increase MOPr 
desensitization induced by morphine (30 M) was assessed in rat LC neurones as 
previously described for Compound 1 (Figure 5.3). Preincubation of LC neurones with 
PMA significantly increased the magnitude of observed MOPr desensitization to 
morphine (Figure 5.4B, D & E). The impact of PMA on morphine desensitization was 
compared to control conditions where brain slices were preincubated with 0.1% DMSO 
for 20 minutes (Figure 5.4A), to mitigate the potential effect of the 20 min incubation 
period on the extent of opioid-induced desensitization (as outlined in Figure 5.1). This 
finding was in agreement with previous findings with morphine and PMA (Bailey et al., 
2004), confirming the activity of PMA in our hands. In order to confirm the activity of 
GF109203X as a PKC inhibitor in our experiments, we investigated its effect on the PMA-
mediated increase in morphine-induced MOPr desensitization by co-incubating 
GF109203X (1 M) and PMA (1 M) for 20 min prior to perfusion of morphine (30 M) 
(Figure 5.4C). At concentrations used in previous experiments with Compound 1 (Figure 
5.2), GF109203X effectively inhibited the PMA-mediated increase in morphine-induced 
MOPr desensitization, with desensitization in the combined presence of GF109203X and 
PMA being statistically similar to baseline levels (Figure 5.4D & E), confirming its activity 
as a PKC inhibitor in our experiments. 
Together our findings for PMA and GF109203X intriguingly suggest that PKC is not 




Figure 5.4 –The role of PKC in morphine-induced MOPr desensitization in rat LC 
neurones 
Representative traces of morphine (30 M)-evoked GIRK currents in rat LC neurones 
after 20 min preincubation of DMSO (0.1% v/v) (A), PMA (1 M) and (B) GF109203X 
(1M) and PMA (1M) (C). (A-C) Morphine-evoked currents were reversed by naloxone 
(NLX; 10 M). Scale bars: 20pA and 300s. (D) Pooled time-courses from data shown in 
A-C showing the desensitization of morphine-evoked currents in the presence of DMSO 
control, PMA (1 M) or GF109203X (1 M) and PMA (1 M). (E) Pooled data for 

















































































following preincubation of DMSO control, PMA (1 M) or GF109203X (1 M) and PMA 
(1 M). n = 5. * P < 0.05, ns P > 0.05, one-way ANOVA with post-hoc Tukey tests. 
 
5.2.3 Compound 1-induced MOPr desensitization in rat LC neurones is GRK-
dependent 
The canonical mechanism of receptor regulation at MOPr occurs through GRK- and 
arrestin-dependent mechanisms (Williams et al., 2013) (Chapter 1.2.5). Historically, the 
study of the role of GRK in MOPr desensitization in live neurones has been limited by 
the lack of selective tools. Additionally, genetic mouse models of GRK2 KO are 
embryonically lethal, limiting the utilisation of genetic approaches to study GRK function 
in MOPr desensitization.  
The recent development of membrane permeable and selective small molecule inhibitors 
of GRK has greatly facilitated investigations into the role of GRKs in receptor 
desensitization (Thal et al., 2011). A comprehensive study in LC neurones showed that 
one such GRK inhibitor, Compound 101, significantly inhibited rapid MOPr 
desensitization induced by a range of MOPr agonists including the high efficacy agonists 
DAMGO and Met-Enkephalin, as well the partial agonist morphine and the arrestin-
biased agonist endomorphin-2 (Lowe et al., 2015). The effect of Compound 101 on acute 
MOPr desensitization induced by Met-Enkephalin in rat LC neurones was 
indistinguishable from the effect of expressing a mutant MOPr deficient in sites of GRK-
dependent phosphorylation (Leff et al., 2020), confirming that the effect of Compound 
101 on MOPr desensitization in LC neurones is dependent on inhibition of GRK-
mediated phosphorylation. In HEK 293 cells Compound 101 has been shown to inhibit 
DAMGO-induced MOPr internalization (Lowe et al., 2015), arrestin-3 recruitment (Miess 
et al., 2018) and phosphorylation of MOPr C-terminal serine and threonine residues 
(Gillis et al., 2020a). Compound 101 therefore provides a well-characterised tool to study 
the potential role of GRK in the MOPr desensitization induced by Compound 1 in rat LC 
neurones. 
We first wanted to affirm the ability of Compound 101 to inhibit DAMGO-induced MOPr 
desensitization in rat LC neurones in our hands. As previously demonstrated (Lowe et 
al., 2015), preincubation of brain slices with Compound 101 (30M) for 20 min prior to, 
and during, DAMGO application significantly attenuated DAMGO-induced MOPr 
desensitization in rat LC neurones (Figure 5.5). This confirms its ability to effectively 




Figure 5.5 – The GRK inhibitor Compound 101 inhibits DAMGO-induced 
desensitization 
(A) A representative trace of a DAMGO (10M)-evoked potassium current in rat LC 
neurones after 20 min preincubation of Compound 101 (30M). DAMGO-evoked GIRK 
currents were reversed by naloxone (NLX; 10M). Scale bars are representative of 50pA 
and 300s. (B) Pooled time-courses showing the desensitization of DAMGO-evoked 
currents post-peak response in the presence of Compound 101 (30M) or control. (C) 
Pooled data for percentage of desensitization induced by DAMGO 10 min post-peak 
response following preincubation with Compound 101 (30M) or control. Control 
represents DAMGO desensitization alone (Figure 4.4). Data are presented as mean  
SEM, where n = 3 – 8. * P < 0.05, two-tailed, unpaired t test. 
 
In order to assess the potential role of GRK in Compound 1-induced MOPr 
desensitization, we preincubated brain slices with Compound 101 (30M) for 20 min prior 
to, and during, Compound 1 application (Figure 5.6A). Compound 101 preincubation 
significantly inhibited the desensitization of Compound 1-evoked GIRK currents in rat LC 
neurones (Figure 5.6B & Figure 5.6C). This finding was against our initial hypothesis that 
Compound 1-induced desensitization would occur through a GRK-independent 
mechanism, considering its low efficacy for arrestin-3 recruitment and G protein bias 




































































Figure 5.6 – The GRK inhibitor Compound 101 attenuates Compound 1-induced 
desensitization 
(A) A representative trace of a Compound 1 (30M)-evoked potassium current in rat LC 
neurones after 20 min preincubation of Compound 101 (30M). Compound 1-evoked 
GIRK currents were reversed by naloxone (NLX; 10M). Scale bars are representative 
of 20pA and 300s. (B) Pooled time-courses showing the desensitization of Compound 
1-evoked currents post-peak response in the presence of Compound 101 (30M) or 
control. (C) Pooled data for percentage of desensitization induced by Compound 1 10 
min post-peak response following preincubation of Compound 101 (30M) or control. 
Control represents Compound 1 desensitization after 20 min preincubation with DMSO 
(0.1% v/v, Figure 5.1C). Data are presented as mean  SEM, where n = 5 – 13. * P < 
0.05, two-tailed, unpaired t test. 
 
Although Compound 101 is an effective GRK inhibitor, a previous screen has highlighted 
that this drug can to some extent inhibit a number of other ACG family kinases (Lowe et 
al., 2015). These off-target kinases include protein kinase C-related protein kinase 
(PRK2), serum and glucocorticoid-regulated kinase (SGK1) and Rho-associated protein 
kinase 2 (ROCK2). To test whether the effects of Compound 101 on Compound 1-
induced desensitization were in fact mediated by off-target inhibition of these kinases 
rather than GRK, slices were preincubated with a combination of GSK650394 (10M) 






































































GSK650394 and Y-27632 together had no effect on Compound 1-induced 
desensitization (Figure 5.7B & Figure 5.7C). This finding supports the hypothesis that 
the effects of Compound 101 on Compound 1-induced MOPr desensitization are GRK-
dependent.  
 
Figure 5.7 – Inhibitors of off-target kinases inhibited by Compound 101 have no 
effect on Compound 1-induced desensitization 
(A) A representative trace of a Compound 1 (30M)-evoked potassium current in rat LC 
neurones after 20 min preincubation of GSK650394 (10M) and Y-27632 (50M). 
Compound 1-evoked GIRK currents were reversed by naloxone (NLX; 10M). Scale 
bars are representative of 20pA and 300s. (B) Pooled time-courses showing the 
desensitization of Compound 1-evoked currents post-peak response in the combined 
presence of GSK650394 (10M) and Y-27632 (50M), or control. (C) Pooled data for 
percentage of desensitization induced by Compound 1 ten min post-peak response 
following preincubation of GSK650394 (10M) and Y-27632 (50M), or control. Control 
represents Compound 1 desensitization after 20 min preincubation with DMSO (0.1% 
v/v, Figure 5.1C). Data are presented as mean  SEM, where n = 5 – 13. ns P > 0.05, 
two-tailed, unpaired t test. 
  











































































In order to confirm the role of GRK in Compound 1-induced MOPr desensitization, we 
sought to ulitise 14as; a novel, structurally distinct, paroxetine-derived GRK inhibitor 
(Waldschmidt et al., 2017).  
With the effects of 14as on MOPr desensitization uncharacterised in neurones, we first 
characterised its ability to inhibit desensitization of DAMGO-evoked GIRK currents in rat 
LC neurones after 20 min preincubation (Figure 5.8A). 14as (30M) inhibited DAMGO-
induced desensitization in a preliminary experiment (n = 1), to a similar extent as 
Compound 101 (30M) (Figure 5.8B & Figure 5.8C). Similarly, a preliminary experiment 
(n = 1) suggested that 14as (30M) also inhibited desensitization of Compound 1-evoked 
GIRK currents in rat LC neurones to the same extent as Compound 101 after 20 min 
preincubation (Figure 5.9). The % desensitization values for Compound 1 (15.4) and 
DAMGO (23.9) induced desensitization in the presence of 14as, lie outside the 95% 
confidence intervals for control Compound 1 (26.4 – 34.7) and DAMGO (42.2 – 55.3) 
values. This suggests, in the absence of proper statistical analysis, that in these cases 
14as inhibits agonist-induced desensitization in a similar manner to Compound 101. 
These preliminary data with a structurally distinct GRK inhibitor supports findings with 
Compound 101, demonstrating a central role for GRK in MOPr desensitization induced 
by Compound 1. Unfortunately, due to limited amounts of compound available at the 





Figure 5.8 – The GRK inhibitor 14as inhibits DAMGO-induced MOPr 
desensitization 
(A) A representative trace of a DAMGO (10M)-evoked potassium current in rat LC 
neurones after 20 min preincubation of 14as (30M). DAMGO-evoked GIRK currents 
were reversed by naloxone (NLX; 10M). Scale bars are representative of 50pA and 
300s. (B) Pooled time-courses showing the desensitization of DAMGO-evoked currents 
post-peak response in the presence of 14as (30M), Compound 101 (30M, Figure 5.5) 
or control. (C) Pooled data for percentage of desensitization induced by DAMGO 10 min 
post-peak response following preincubation of 14as (30M), Compound 101 (30M, 
Figure 5.5) or control. Control represents DAMGO desensitization alone (Figure 4.4). 








































































Figure 5.9 – 14as inhibits Compound 1-induced MOPr desensitization 
(A) A representative trace of a Compound 1 (30M)-evoked potassium current in rat LC 
neurones after 20 min preincubation of 14as (30M). Compound 1-evoked GIRK 
currents were reversed by naloxone (NLX; 10M). Scale bars are representative of 20pA 
and 300s. (B) Pooled time-courses showing the desensitization of Compound 1-evoked 
current post-peak response in the presence of 14as (30M), Compound 101 (30M, 
Figure 5.6) or control. (C) Pooled data for percentage of desensitization induced by 
Compound 1 ten min post-peak response following preincubation of 14as (30M), 
Compound 101 (30M, Figure 5.6) or control. Control represents Compound 1 
desensitization after 20 min preincubation with DMSO (0.1% v/v, Figure 5.1C). Data are 













































































5.2.4 Compound 1-induced MOPr desensitization in rat LC neurones is 
independent of JNK 
Some reports have suggested that JNK regulates the development of tolerance to the 
effects of morphine in vivo (Melief et al., 2010; Kuhar et al., 2015; Marcus et al., 2015), 
suggesting a potential role for JNK in agonist-induced MOPr desensitization. Given the 
potentially novel mechanism involved in Compound 1-induced desensitization, we 
sought to investigate a possible role of JNK in MOPr desensitization in rat LC neurones 
using the inhibitor SP600125 (Han et al., 2001).  
To investigate the potential role of JNK, brain slices were preincubated with SP600125 
(30M) for 20 min prior to, and during, application of either DAMGO or Compound 1 
(Figure 5.10A & Figure 5.11A). SP600125 had no effect on the extent of rapid MOPr 
desensitization elicited by DAMGO (Figure 5.10) or Compound 1 (Figure 5.11) in rat LC 
neurones, therefore suggesting that JNK does not play a role in the acute rapid MOPr 
desensitization induced by these agonists. 
Recent work in rat LC neurones, published after the period of our investigation, has 
demonstrated that JNK inhibitors are ineffective in inhibiting acute MOPr desensitization 
induced by Met-Enkephalin (Leff et al., 2020), in agreement with our findings for DAMGO 
and Compound 1. However, JNK was shown to play a partial role, alongside GRK and 
PKC, in MOPr desensitization observed in response to chronic morphine treatment (Leff 
et al., 2020). While we cannot exclude the possibility that JNK signalling is involved in 
cellular tolerance to Compound 1 and DAMGO over chronic exposure, our current 






Figure 5.10 – Inhibition of JNK has no impact on acute DAMGO-induced 
desensitization 
(A) A representative trace of a DAMGO (10M)-evoked potassium current in rat LC 
neurones after 20 min preincubation of SP600125 (30M). DAMGO-evoked GIRK 
currents were reversed by naloxone (NLX; 10M). Scale bars are representative of 50pA 
and 300s. (B) Pooled time-courses showing the desensitization of DAMGO-evoked 
currents post-peak response in the presence of SP600125 (30M) or control. (C) Pooled 
data for percentage of desensitization induced by DAMGO 10 min post-peak response 
following preincubation of SP600125 (30M) or control. Control represents DAMGO 
desensitization alone (Figure 4.4). Data are presented as mean  SEM or mean alone, 





































































Figure 5.11 – JNK inhibition has no effect on Compound 1-induced desensitization 
(A) A representative trace of a Compound 1 (30M)-evoked potassium current in rat LC 
neurones after 20 min preincubation of SP600125 (30M). Compound 1-evoked GIRK 
currents were reversed by naloxone (NLX; 10M). Scale bars are representative of 20pA 
and 300s. (B) Pooled time-courses showing the desensitization of Compound 1-evoked 
currents post-peak response in the presence of SP600125 (30M) or control. (C) Pooled 
data for percentage of desensitization induced by Compound 1 ten min post-peak 
response following preincubation of SP600125 (30M) or control. Control represents 
Compound 1 desensitization after 20 min preincubation with DMSO (0.1% v/v, Figure 
5.1C). Data are presented as mean  SEM, where n = 5 – 13. ns P > 0.05, two-tailed, 
unpaired t test. 
  




































































5.2.5 Controls for kinase inhibition work in rat LC neurones and summary of 
current findings  
In order to assure that the observed effects of our kinase inhibitors of opioid-induced 
desensitization were not dependent on alterations in agonist intrinsic activity, we 
compared the relative intrinsic activities of our opioid agonists in these different 
conditions. This was achieved by comparing the peak GIRK currents elicited by these 
opioids in the presence or absence of kinase inhibitors, as an estimate of intrinsic activity 
at receptor saturating concentrations (Section 4.2.1). As described previously, opioid-
evoked GIRK currents were normalised to the magnitude of noradrenaline-evoked GIRK 
currents within the same cell to reduce variability (Figure 4.2, Section 4.2.1). 
No significant difference was observed between the peak GIRK currents elicited by 
DAMGO in the presence of Compound 101 or control (Unpaired, two-tailed t-test, P = 
0.94; Figure 5.12). Similarly, no significant differences were observed in Compound 1 
peak GIRK currents after incubation with examined kinase modulators versus control 
conditions (One-way ANOVA, P = 0.85; Figure 5.13). Statistical analysis was not 
conducted on the possible effect of 14as on Compound 1 peak GIRK currents or 14as 
and SP600125 on DAMGO peak GIRK currents as the number of repeats for these 
conditions was not sufficient to conduct such analysis (Compound 1 in 14as, n = 1, Figure 
5.13; DAMGO in 14as, n = 1, DAMGO in SP600125, n = 2, Figure 5.12). However in 
these limited repeats, obtained values for peak opioid responses (% NA) for Compound 
1 in 14as (41.9), DAMGO in 14as (73.5) and DAMGO in SP600125 (102.4) lie outside 
of the 95% confidence intervals for control Compound 1 (51.2 – 76.8) and DAMGO 
(110.1 – 138.4) values. This highlights the need for additional data for the above 
experimental conditions. More generally, these findings demonstrate that the observed 
effects of kinases modulators, in particular the effect of Compound 101 on Compound 1, 





Figure 5.12 – Examined kinase inhibitors had no effect on the magnitude of 
DAMGO-evoked GIRK currents 
Pooled data from experiments of DAMGO-induced MOPr desensitization presented 
earlier in this chapter, examining the peak GIRK current evoked by DAMGO in control 
conditions (Figure 4.3) and after 20 min preincubation with Compound 101 (30M, Figure 
5.5), 14as (30M, Figure 5.8) or SP600125 (30M, Figure 5.10). Responses were 
normalised to the maximal 2-adrenoceptor-mediated currents evoked by noradrenaline 


































































Figure 5.13 – Examined kinase inhibitors had no effect on the magnitude of 
Compound 1-evoked GIRK currents 
Pooled data from experiments of Compound 1-induced MOPr desensitization presented 
earlier in this chapter examining the peak GIRK current evoked by Compound 1 after 20 
min preincubation with DMSO (0.1% v/v, Figure 5.1), Compound 101 (30M, Figure 5.6), 
GF109203X (1M, Figure 5.2), PMA (1M, Figure 5.3), GSK650394 & Y-27632 (10M 
and 50M respectively, Figure 5.7), SP600125 (30M, Figure 5.11) or 14as (30M, 
Figure 5.9). Responses were normalised to the maximal 2-adrenoceptor-mediated 
currents evoked by noradrenaline (100M) in the same cell. Data are presented as mean 


















































































The magnitude of noradrenaline (100M)-evoked currents was also assessed before 
and after application of Compound 1 and respective kinase modulators, as described 
previously (Figure 4.2, Figure 4.6). This was performed to examine potential 
heterologous desensitization induced by kinase modulators, as well as potential current 
rundown. 
For experiments of DAMGO-evoked currents, there was no significant difference 
between the magnitude of noradrenaline-evoked currents pre- and post- incubation with 
Compound 101 and DAMGO, and control (Unpaired, two-tailed t-test P = 0.08; Figure 
5.14). Similarly, in the case of experiments with Compound 1-evoked currents, no 
significant differences were observed between the magnitude of noradrenaline-evoked 
currents pre- and post- incubation when incubated with the described kinase inhibitors 
(One-way ANOVA, P = 0.09; Figure 5.15). Although the amplitude of NA-evoked currents 
post-Compound 1 appeared to be somewhat increased after incubation with Compound 
101, no statistical difference was observed between these values and the values of our 
controls (P = 0.16). Overall, these data demonstrate that the observed action of our 
kinase inhibitors is not through indirect modulation of heterologous desensitization. 
 
Figure 5.14 – Kinase inhibitors and DAMGO have no heterologous effect on 
noradrenaline-evoked GIRK currents 
Pooled data from experiments of DAMGO-induced MOPr desensitization presented 
earlier in this chapter examining the magnitude of noradrenaline (NA, 100M) evoked 
currents before and after DAMGO application (Control, Figure 4.4) and / or 20 min 
preincubation with Compound 101 (30M, Figure 5.5), 14as (30M, Figure 5.8), or 


































































Figure 5.15 – Kinase inhibitors and Compound 1 have no heterologous effect on 
noradrenaline-evoked GIRK currents 
Pooled data from experiments of Compound 1-induced MOPr desensitization presented 
earlier in this chapter examining the magnitude of noradrenaline (NA, 100M) evoked 
currents before and after application of Compound 1 and 20 min preincubation with 
DMSO (0.1% v/v, Figure 5.1), Compound 101 (30M, Figure 5.6), GF109203X (1M, 
Figure 5.2), PMA (1M, Figure 5.3), GSK650394 & Y-27632 (10M and 50M 
respectively, Figure 5.7), SP600125 (30M, Figure 5.11) or 14as (30M, Figure 5.9). 





















































































5.2.6 A summary of the mechanisms regulating Compound 1-induced MOPr 
desensitization in rat LC neurones 
A summary of our current work exploring the mechanism Compound 1-induced 
desensitization in rat LC neurones is presented in Figure 5.16. Our findings suggest that 
GRK appears to be the primary mediator of the observed MOPr desensitization induced 
by Compound 1, while PKC and JNK are not involved (Figure 5.16).  
The GRK-dependent nature of Compound 1-induced MOPr desensitization in LC 
neurones is particularly intriguing given the relatively low arrestin-3 recruitment induced 
by Compound 1 in HEK 293 cells (Figure 3.1D, Table 3.1), and its G protein-biased 
signalling profile at MOPr (Figure 3.2). As such, we aimed to address a number of 
outstanding questions around the induction of GRK/arrestin pathways by Compound 1 
in recombinant systems. Through addressing these outstanding questions, we hoped to 
build an understanding of the mechanistic basis of this potentially GRK-dependent, but 
arrestin-independent mechanism of MOPr desensitization induced by Compound 1. 
The selected unresolved questions are as follows (Figure 5.16):  
• Are differences in the levels of GRK expression causing a discrepancy in 
GRK/arrestin responses between assays in recombinant systems and in neurones? 
• Does Compound 1 favour the induction of arrestin-2 recruitment over arrestin-3? 
• Does Compound 1 induce MOPr internalization? 





Figure 5.16 – Summarising current findings around the mechanisms of Compound 
1-induced MOPr regulation  
A schematic summary of our current knowledge of the mechanism of Compound-1 
induced MOPr regulation based on findings in this thesis so far. Compound 1 has been 
demonstrated to induce minimal arrestin-3 recruitment (denoted by ‘’) in recombinant 
systems (denoted by ‘*’ due to difference in system of investigation) (Figure 3.1B), 
however its ability to recruit arrestin-2 is unknown (denoted by ‘?’). It was demonstrated 
that Compound 1 induces substantial MOPr desensitization in rat LC neurones (Figure 
4.5), which was dependent on GRK (Figure 5.6), but not PKC (Figure 5.2) or JNK (Figure 
5.11). The ability of Compound 1 to induce GRK-dependent phosphorylation of C-
terminal serine and threonine residues of MOPr is unknown. Additionally, while we have 
demonstrated that Compound 1 induces MOPr desensitization, the ability of Compound 




5.2.7 Investigating the dependence of agonist-induced arrestin-3 recruitment on 
GRK2 expression in recombinant cells 
One possible explanation for the lack of translation between the low arrestin recruitment 
of Compound 1 observed in recombinant HEK 293 cells and the marked desensitization 
Compound 1 induced in LC neurones could be that there are different levels of GRK 
expression within each system. To examine this, we repeated our MOPr arrestin-3 
recruitment BRET assay (Figure 3.1B and Figure 3.1D) in the presence of 
overexpressed GRK2, in an attempt to raise the endogenous GRK tone to levels which 
could be present in LC neurones.  
Under these conditions, the overall level of signalling (BRET ratio) for opioid-induced 
arrestin-3 recruitment was substantially amplified to around 4-fold the levels observed in 
cells with endogenous expression levels (Figure 3.1D, reproduced in Figure 5.17A, & 
Figure 5.17C). The observed amplification of arrestin-3 recruitment in these conditions 
is in line with previous findings (Zhang et al., 1998).  
While the overall level of agonist-induced arrestin-3 recruitment was amplified, there was 
no change in the rank order of intrinsic activity within our agonists for arrestin recruitment 
upon GRK2 overexpression (Figure 5.17). The rank order of intrinsic activity for arrestin-
3 recruitment was conserved between the two assays as DAMGO > Morphine > PZM21 
> Compound 1 (Figure 5.17D).  
In addition to the amplification of overall signal, GRK2 overexpression also promoted a 
substantial (~10 fold) increase in the potency of agonist-induced arrestin-3 recruitment 
for all agonists observed (Figure 5.17B). The respective pEC50 values were as follows: 
Arrestin 3, no GRK added: DAMGO, 6.0  0.1; Morphine, 5.9  0.2; PZM21, 6.5  0.2; 
Compound 1 6.5  0.4. Arrestin-3 + GRK2: DAMGO, 7.1  0.1; Morphine, 6.8  0.1; 
PZM21, 7.3  0.2; Compound 1, 7.7 0.2.  
The pattern of opioid-induced arrestin-3 recruitment was similar in cells additionally 
overexpressing a vector control (pcDNA3.1), in place of GRK2, compared with cells 
expressing only MOPr and arrestin-3 BRET reporters (Figure 5.17C & Figure 5.17A 
respectively). However, the lower R squared values for curves generated in the 
pcDNA3.1 cells compared with controls suggested that excessive expression of plasmid 
DNA had a detrimental effect on assay variability (R2 values Control, Figure 5.17A: 
DAMGO = 0.86, morphine = 0.66, PZM21 = 0.48, Compound 1 = 0.34. R2 values 
pcDNA3.1, Figure 5.17C: DAMGO = 0.79, morphine = 0.55, PZM21 = 0.24, Compound 
1 = 0.23). As such, comparisons have been made between cells expressing MOPr and 
arrestin-3 BRET reporters, and cells additionally expressing GRK2. 
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The heightened signal-to-noise ratio observed for arrestin-3 recruitment in the presence 
of overexpressed GRK2 has led some groups to ulitise these conditions to characterise 
signalling bias at opioid receptors (Manglik et al., 2016; Dekan et al., 2019; Gillis et al., 
2020a). As such, groups often compare agonist activity in G protein activation assays to 
arrestin recruitment assays in the presence of overexpressed GRK2. This act generally 
is deemed necessary to improve variable curve fitting for arrestin recruitment induced by 
weak partial agonists, however questions arise whether both systems utilised in these 
comparisons should be conducted in overexpressed GRK2.  
We reconducted assessments of biased agonism previously used in this thesis, this time 
assessing biased agonism between arrestin-3 recruitment in the presence of 
overexpressed GRK2 (Figure 5.17B) and previous G protein activation data (Figure 
3.1C) (Table 5.1). As suggested by the nature of Emax values for arrestin-3 recruitment 
in different GRK2 conditions (Figure 5.17D), the normalised  Emax values indicated 
Compound 1 displayed a similarly G protein-biased agonist compared to morphine for 
both arrestin-3 recruitment in an endogenous GRK environment and with the presence 
of overexpressed GRK2 (Table 5.1). The normalised  Emax value for PZM21 in the 
presence of overexpressed GRK2 tended towards displaying G protein-biased agonism 
when compared to previous analysis in the regular arrestin-3 recruitment assay (Table 
5.1). However, no significant difference was demonstrated between the normalised  
Emax value for PZM21 and that of morphine (P = 0.12). Analysis of biased signalling 
through the log(/KA) method again suggested that neither Compound 1 or PZM21 
display G protein biased signalling relative to morphine (Table 5.1). Interestingly, the 
log() method suggested that Compound 1 was significant bias for G protein activity 
when arrestin-3 activity was reassessed in overexpressed GRK2 (Table 5.1), in contrast 
to previous results (Figure 3.4B). This is likely due to the increased signal-to-noise ratio 
provided by the amplified arrestin-3 recruitment assay (Figure 5.17B). 
Together these data suggest that the G protein-biased profile of Compound 1 is 
unaffected by system levels of GRK2 expression. As such, this finding weakens the 
potential for the biased profile of Compound 1 to vary between HEK 293 cells and rat LC 
neurones, which could explain the substantial MOPr desensitization observed in LC 
neurones, due to differential GRK2 expression levels. However, in the absence of further 
experiments we are unable to exclude the possibility that higher expression of other GRK 





Figure 5.17 – The impact of GRK2 expression on opioid-induced arrestin-3 
recruitment in recombinant HEK 293 cells transiently expressing MOPr 
Opioid-induced arrestin-3 recruitment in HEK 293 cells transiently expressing 
recombinant MOPrs in the absence (A, Figure 3.1D) or presence of GRK2 
overexpression (B), or in the presence of additional pcDNA3.1 transfections (C). 
Arrestin-3 recruitment was assessed through BRET caused by agonist- and 
concentration-dependent association of arrestin-3-GFP10 with MOPr-RlucII. (D) Fitted 
EMax values for concentration-responses for arrestin-3 recruitment to MOPr in HEK 293 
cells in the absence (arrestin-3, A) or presence (+ GRK2, B) over overexpressed GRK2. 
Pooled EMax values were normalised to that of DAMGO. All data are presented as mean 
 SEM, where n = 5.    
Arrestin-3 Translocation 
(+ pcDNA3.1)























































































































































Table 5.1 – Revisiting quantification of biased agonism at MOPr in presence of 
overexpressed GRK2  
Calculated biased signalling metrics for PZM21 and Compound 1 relative to morphine. 
Relative MOPr agonist activity in the Gi G protein activation assay (Figure 3.1C) was 
compared to agonist activity in either the regular arrestin-3 recruitment assay (Figure 
3.1D, Figure 5.17A) (vs Arrestin-3, white rows) or in the arrestin-3 recruitment assay in 
the presence of overexpressed GRK2 (Figure 5.17B) (+ GRK2, yellow rows). Values for 
the “vs Arrestin-3” rows are graphically represented in Figure 3.2B, Figure 3.3B and 
Figure 3.4B. Values are presented as mean  SEM, where n=5. * p < 0.05, versus 





5.2.8 Investigating opioid-induced arrestin-2 recruitment in recombinant cells 
It is possible that in LC neurones Compound 1 induced-MOPr downregulation is 
mediated by arrestin-2, rather than arrestin-3, for which the coupling has been defined 
in HEK 293 cells (Figure 5.16). To explore this hypothesis, we examined arrestin-2 
recruitment in HEK 293 cells using BRET techniques similar to those described 
previously (Figure 3.1B).  
The levels of arrestin-2 recruitment to MOPr were considerably lower than that of 
arrestin-3 recruitment for all examined agonists (Figure 5.18A). The comparatively low 
coupling of arrestin-2 to MOPr demonstrated here is in line with previous findings at 
MOPr (Cheng et al., 1998; Thompson et al., 2015). This suggests that arrestin-2 has a 
lower coupling efficiency at MOPr than arrestin-3, however in this case we cannot 
exclude the potential that this effect is dependent on the relative efficiency of the 
interaction between specific arrestin BRET probes and the tagged MOPr (Thompson et 
al., 2015). While the full agonist DAMGO produced small but detectable levels of 
concentration-dependent arrestin-2 recruitment, no measurable responses could be 
obtained for the partial agonists morphine, PZM21 and Compound 1 (Figure 5.18B). This 
assay is subject to similar levels of noise as the arrestin-3 assay, for which the signal is 
substantially larger (Figure 5.18A), which results in the variability surrounding these 
small signals being particularly large (Figure 5.18B). Given these findings, it is therefore 
suggested that arrestin-2 recruitment is not responsible for Compound 1-induced 




Figure 5.18 – Assessing opioid-induced arrestin-2 recruitment in recombinant 
HEK 293 cells expressing MOPr 
(A) Concentration-response curves for opioid-induced recruitment of arrestin 2-GFP10 or 
arrestin 3-GFP10 in HEK 293 cells expressing MOPr-RlucII as assessed by the BRET 
technique (Figure 3.1B). Presented arrestin-3 recruitment data is replotted from Figure 
3.1D for comparison but was not run within the same experiment. (B) Data for opioid-
induced arrestin-2 recruitment plotted alone on enlarged axis to accommodate for 
substantially smaller signal levels. Data are presented as mean  SEM, where n = 5.  
  












































































5.2.9 Characterising opioid-induced MOPr internalization in recombinant cells 
While the low levels of arrestin recruitment induced by Compound 1 in HEK 293 cells 
(Figure 3.1D and Figure 5.18B) suggest that it would induce minimal internalization, the 
substantial MOPr desensitization produced by Compound 1 in rat LC neurones (Figure 
4.5) could suggest differently. To further characterise MOPr regulation upon activation 
by Compound 1, we investigated agonist-induced MOPr internalization in HEK 293 cells 
expressing HA-MOPr using the ELISA technique (Chapter 2.1.4). The loss of surface 
MOPr induced by receptor saturating agonist concentrations was assessed after 15, 30 
and 60 min of agonist incubation (Figure 5.19A). The area under the curve (AUC) values 
for agonist-induced loss of surface MOPr over time in the presence of different agonists 
were used for statistical analysis of agonist-induced effects (Figure 5.19B).  
DAMGO (10M) and, to a lesser degree, morphine (30M) produced significant 
reductions in surface MOPr levels over the 60 min incubation, PZM21 (30M) and 
Compound 1 (30M) did not induce significant loss of surface MOPr expression (Figure 
5.19). This indicates that Compound 1 does not induce MOPr internalization in HEK 293 
cells, in line with its low efficacy for arrestin recruitment in these systems (Figure 3.1D 
and Figure 5.18B). Our findings are in line with previous reports demonstrating a strong 
positive correlation between the efficacy of an agonist for arrestin recruitment and its 





Figure 5.19 – Characterising opioid-induced loss of surface MOPr in recombinant 
HEK 293 cells through ELISA. 
(A) Surface expression of rat HA-MOPrs transiently expressed in HEK 293 cells was 
determined through ELISA using an anti-HA antibody, after preincubation with DAMGO 
(10M), morphine, PZM21 or Compound 1 (30M) at the described time points of drug 
incubation. Surface expression was normalised to signal levels in blank HEK 293 cells 
(0%) and expression levels observed in untreated HA-MOPr HEK 293 cells (100%). (B) 
The area under the curve (AUC) values for agonist-induced loss of surface HA-MOPr 
over time, as presented in A. Data are presented as mean  SEM, where n = 5. * P < 
0.05, values were significantly different from 0 in one-sample t test. 
  
























































5.2.10 Defining the patterns of agonist-induced MOPr phosphorylation 
Findings within the above experiments have reiterated the low coupling of Compound 1-
activated MOPr to arrestin pathways, relative to the balanced agonist morphine. 
However, Compound 1 induced substantial MOPr desensitization in LC neurones 
(Figure 4.5), through an apparently GRK dependent mechanism (Figure 5.6). As such, 
we wished to explore the possibility of a GRK-dependent, but potentially arrestin-
independent mechanism of MOPr desensitization induced by Compound 1.  
The primary functional readout for GRK function at MOPr is the rapid agonist-induced 
phosphorylation of serine (Ser) and threonine (Thr) residues, primarily on the C-terminus 
of the receptor (Chapter 1.2.5). Ser375 is typically considered the primary target of GRK-
dependent, agonist-induced MOPr phosphorylation, with a number of additional C-
terminal serine and threonine residues also implicated (including Thr370, Thr376 and 
Thr379) (Doll et al., 2011; Mann et al., 2015; Miess et al., 2018). In order to gauge 
Compound 1-induced GRK activity, we studied the ability of Compound 1 to induce 
multisite C-terminal tail phosphorylation of MOPr compared to our reference agonists, 
through immunoblotting using phosphosite-specific antibodies. This work was kindly 
performed and analysed by Nina Kathleen Blum (University of Jena, Germany), who was 
supervised by Andrea Kliewer and Stefan Schulz (University of Jena, Germany). 
The full agonist DAMGO (10M) induced substantial phosphorylation at multiple C-
terminal serine and threonine sites on MOPr (Figure 5.20A). The partial agonist 
morphine (30M) induced significant phosphorylation at Ser375, with lower but still evident 
phosphorylation at other investigated residues (Figure 5.20A). This observed pattern of 
phosphorylation with DAMGO and morphine is typical of previous observations (Doll et 
al., 2011; Just et al., 2013; Miess et al., 2018; Gillis et al., 2020a). A low efficacy agonist, 
PZM21 (30M) induced minimal phosphorylation at the examined sites, with a low but 
noticeable levels of Ser375 phosphorylation (Figure 5.20A), similar to previous findings 
(Gillis et al., 2020a). Similarly, Compound 1 (1nM - 30M) induced minimal 
phosphorylation, with low levels of phosphorylation restricted to Ser375 solely at the 
highest examined concentrations (Figure 5.20A and Figure 5.20C). At receptor 
saturating concentrations, DAMGO and morphine produce significant Ser375 
phosphorylation compared to controls, whereas the low levels of Ser375 phosphorylation 
induced by PZM21 and Compound 1 were not significantly different from controls (Figure 
5.20C).  
Together, the pattern of Compound 1-induced MOPr phosphorylation is consistent with 
it being a G protein-biased agonist, showing minimal phosphorylation at key residues 
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implicated in GRK/arrestin mediated MOPr desensitization and trafficking. Based on 
findings from this experiment it is not evident that Compound 1 couples to GRKs in 
recombinant systems, however it is interesting to hypothesise that the GRK-dependent 
mechanism of Compound 1 evident in LC neurones could be mediated by factors other 






Figure 5.20 – Determining the patterns of opioid-induced MOPr phosphorylation 
in recombinant HEK 293 cells through phosphospecific immunoblotting. 
(A) HEK 293 cells stably expressing mouse HA-MOPr were preincubated with increasing 
concentrations of Compound 1 (1nM - 30M) or supramaximal concentrations of 
DAMGO (10M), morphine (30M) or PZM21 (30M) for 30 mins. Cells were lyzed and 
immunoblotted with phosphospecific antibodies labelling MOPr specifically 
phosphorylated at Thr370 (pT370), Ser375 (pS375), Thr376 (pT376) or Thr379 (pT379). To 
confirm equal loading of HA-MOPr, blots were subsequently stripped and immunoblotted 
with an anti-HA antibody (MOP). The blot presented here is representative of five 
individual experiments. The positions of molecular mass markers are indicated on the 
left in kDa. Pooled data from experiments as depicted in A is quantified in B and C. (B) 
Quantifying MOPr Ser375 phosphorylation induced by supramaximal concentrations of 
opioids, expressed as a factor of total receptor loaded. * P < 0.05, significantly different 
from vehicle control values (DMSO), one-way ANOVA with post-hoc Dunnett’s test. (C) 
Compound 1 (1nM - 30M) induces minimal MOPr Ser375 phosphorylation. DAMGO 
(10M)-induced MOPr Ser375 phosphorylation is also plotted for comparison of signal 
levels. For B & C, Data are expressed as mean  SEM where n = 5. This work was kindly 
performed and analysed by Nina Kathleen Blum (University of Jena, Germany), who was 





5.3.1 A summary of findings regarding the mechanisms of Compound 1-induced 
MOPr regulation in rat LC neurones and recombinant cells 
In this chapter, we aimed to characterise the regulatory mechanisms involved in the 
substantial MOPr desensitization induced by Compound 1 in rat LC neurones, outlined 
in Chapter 4. In light of previous work characterising Compound 1 as a G protein-biased 
agonist, we had hypothesised that Compound 1 would not couple strongly to GRK 
pathways in rat LC neurones. As such, it was postulated that observed Compound 1-
induced MOPr desensitization could be regulated by other mechanisms; such as PKC, 
especially considering previously demonstrated links to PKC involvement in 
desensitization induced by lower efficacy MOPr agonists. Surprisingly, in this chapter I 
demonstrated that the substantial MOPr desensitization induced by Compound 1 in rat 
LC neurones is apparently mediated by GRK, not by PKC (Figure 5.21A). 
Following these intriguing findings, we sought to address a number of unresolved 
questions around the involvement of GRK and arrestin pathways in Compound 1-
induced MOPr desensitization using recombinant systems (Figure 5.16). These 
experiments yielded data for Compound 1 in line with its previously described G protein-
biased profile; with it inducing significantly less arrestin-2 recruitment, MOPr 
internalization and Ser375 phosphorylation than morphine (Figure 5.21B).  
To summarise, in this chapter we characterised a GRK-dependent, potentially arrestin-
independent mechanism for Compound 1-induced MOPr desensitization in LC 
neurones. However, a number of questions remain around the possible disconnect 
between our findings for Compound 1-induced MOPr desensitization in LC neurones and 
in recombinant systems (Figure 5.21).  
The implications of findings from this chapter and previous will be more widely discussed 
as part of the final discussion of this thesis, alongside potential future experiments which 
could address outstanding questions (Chapter 6). In the following chapter-specific 
discussion, I will seek to address the more experimental-specific matters which have 





Figure 5.21 – A schematic summary of our findings on the mechanisms of 
Compound 1-induced MOPr regulation in rat LC neurones and in recombinant HEK 
293 cells 
(A) A schematic summary of our current knowledge of the mechanism of Compound-1 
induced MOPr regulation in rat LC neurones. Compound 1 induces substantial MOPr 
desensitization in rat LC neurones (Figure 4.5), which was dependent on GRK (Figure 
5.6), but not PKC (Figure 5.2) or JNK (Figure 5.11). The coupling of arrestin-2 and 
arrestin-3 to Compound 1 activated-MOPr is unknown in rat LC neurones. Similarly, the 
ability of Compound 1 to induced MOPr internalization in rat LC neurones is unknown. 
While GRK was demonstrated to regulate Compound 1-induced MOPr desensitization 
in rat LC neurones (Figure 5.6), it is unknown whether Compound 1 induces typical GRK-
dependent phosphorylation of serine and threonine residues in this system, or if 
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Compound 1 induces GRK recruitment to the receptor to regulate function in an alternate 
mechanism. (B) A schematic summary of our findings surrounding Compound-1 induced 
MOPr regulation in recombinant systems. We have demonstrated that Compound 1 
induces relatively low levels of arrestin-2-GFP10 and arrestin-3-GFP10 recruitment to 
human MOPr-RlucII constructs in recombinant HEK 293 cells (Figure 5.18 and Figure 
3.1B). Compound 1 induces relatively minimal internalization of rat HA-MOPr in 
recombinant HEK 293 cells (Figure 5.19). Additionally, we have shown that Compound 
1 induces relatively minimal phosphorylation of C-terminal serine and threonine residues 
on mouse HA-MOPrs in HEK 293 cells (Figure 5.20). It is unknown whether GRK is 
alternatively activated by Compound 1 in recombinant systems to potentially 
phosphorylate non-C-terminal serine and threonine residues or whether it is recruited to 
receptor. Additionally, we have not determined whether Compound 1 induces MOPr 
desensitization in recombinant systems to comparable levels to that observed in rat LC 
neurones (Figure 4.5). ‘?’ denotes the role of the outlined pathway is unknown. ‘’ 
denotes that the coupling of Compound 1 to this pathway was relatively lower than that 
observed for morphine. Ticks and crosses denote that the coupling of Compound 1 to 
such pathways was confirmed or denied respectively. 
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5.3.2 On positive controls for the study of the potential roles of JNK  
The power of our work characterising the role of JNK in opioid-induced MOPr 
desensitization in LC neurones is to an extent limited by lack of positive controls for the 
JNK inhibitor SP600125 (Figure 5.10 and Figure 5.11). In light of recent studies, 
published after these experiments were conducted, it is clear that JNK does not play a 
role in acute rapid MOPr desensitization in LC neurones (Leff et al., 2020). Therefore, 
no positive control of SP600125 activity could be performed in the paradigm of acute 
desensitization as we have assessed in this chapter. SP600125 activity could likely be 
confirmed through experiments examining cellular tolerance over chronic opioid 
exposure (Leff et al., 2020). While we are not able to provide a positive control for 
SP600125 activity in our experiments, our findings showing no effect of SP600125 on 
acute MOPr desensitization induced by DAMGO and Compound 1 are in line with those 
reported for acute MOPr desensitization induced by Met-Enkephalin (Leff et al., 2020). 
5.3.3 The potential role of off-target kinases inhibited by Compound 101 in 
Compound 1-induced desensitization 
In this chapter, we attempted to address the possibility that off-target kinases inhibited 
by Compound 101 could mediate Compound 1-induced MOPr desensitization. This was 
investigated through inhibition of select off-target kinases targeted by Compound 101 
using GSK650394 and Y-27632 (Figure 5.7). These well-characterised kinase inhibitors 
have been demonstrated to collectively inhibit PPK2, SGK1 and ROCK2, 3 non-GRK 
family kinases which were demonstrated to be inhibited by Compound 101 in a previous 
kinase screen (Lowe et al., 2015). The selection of these inhibitors and the 
concentrations at which they were used was guided by a previous experiment examining 
the potential role of these ‘off-target’ kinases in DAMGO-induced MOPr desensitization 
in rat LC neurones (Lowe et al., 2015). The power of this initial study, and therefore this 
study, is limited by the absence of a positive control for the activity of GSK650394 and 
Y-27632 in rat LC neurones at the examined concentrations. While the selection of these 
inhibitors and their concentrations was guided by previous effective concentrations of 
these inhibitors in vitro, we are unable to confirm their specific inhibitory activity in our 
experiments. 
Data from the kinase screen itself also brings the design of this experiment into question, 
with the activity of other kinases to some extent being inhibited by Compound 101, but 
which are not inhibited by GSK650394 and Y-27632 (Lowe et al., 2015). Most notable of 
these kinases is mitogen- and stress-activated kinase 1 (MSK1). Additionally, with the 
relatively low concentration for which Compound 101 was screened (1M) it is possible 
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that more kinases may be inhibited to a greater degree at the concentration examined in 
this and other studies (30M). However, the presence of an intact cell membrane in our 
studies may provide a barrier to Compound 101 activity, where in the aforementioned 
kinase screen, which was not run in intact cells, activity would not be limited in such a 
way. It could be possible to add additional inhibitors to the cocktail used to examine the 
role of off-target kinases inhibited by Compound 101 in MOPr desensitization, such as 
the MSK1 inhibitor SB-747651A (Naqvi et al., 2012). However, the effect of increasing 
DMSO concentrations in the perfusing aCSF as well as wide-scale kinase inhibition, on 
the longevity and health of LC neurones provides a limiting factor to further addition of 
inhibitors.  
A more practical means of confirming that the perceived effects of Compound 101 are 
not due to activity at non-GRK kinases could be through the study of structurally distinct 
GRK inhibitors. The availability of effective and selective GRK inhibitors has previously 
been limited. However, in recent years a number of selective GRK inhibitors have been 
described, with CCG224063 (Waldschmidt et al., 2016), 14as (Waldschmidt et al., 2017) 
and other indazole-paroxetine analogues (Bouley et al., 2017) all being based on a 
different chemical scaffold to Compound 101. It could be hypothesised that with different 
chemical scaffolds, these agents may differ from Compound 101 in their ability to interact 
with non-GRK targets. By demonstrating that 14as also inhibited DAMGO- and 
Compound 1-induced MOPr desensitization in rat LC neurones (Figure 5.8 and Figure 
5.9), we believe we have strengthened our contention that the effects of Compound 101 
are indeed dependent on inhibition of GRK. Unfortunately, our data for 14as is only 
preliminary (n = 1), with low availability of compound limiting the number of potential 
repeats.  
5.3.4 On the partial inhibition of MOPr desensitization by GRK inhibitors in LC 
neurones 
Compound 101 was able to partially inhibit MOPr desensitization induced by both 
Compound 1 and DAMGO in rat LC neurones (Figure 5.5C and Figure 5.6C). 
Additionally, the structurally distinct GRK inhibitor 14as similarly produced partial 
inhibition of the effect of DAMGO and Compound 1 in preliminary experiments (Figure 
5.8C and Figure 5.9C). The residual MOPr desensitization observed in the presence of 
Compound 101 is in line with previous observations in rat LC neurones (Lowe et al., 
2015; Leff et al., 2020). The effects of Compound 101 were not limited by concentration, 
with no additional inhibition of DAMGO-induced MOPr desensitization being observed in 
rat LC neurones when the Compound 101 concentration was increased to 100M (Lowe 
et al., 2015). 
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One possible reasoning behind this residual desensitization is that Compound 101 is 
only able to achieve partial inhibition of GRK action, given the amplification and strength 
of the response. Some data in HEK293 cells is in support of this hypothesis, with 
Compound 101 only partially inhibiting Ser375 phosphorylation (Gondin et al., 2019; 
Gillis et al., 2020a), arrestin-3 recruitment (Lowe et al., 2015; Miess et al., 2018), MOPr 
internalization (Lowe et al., 2015) and GRK2 recruitment to MOPr (Miess et al., 2018; 
Gondin et al., 2019) induced by DAMGO. However, the persistence of residual acute 
agonist-induced MOPr desensitization in both rat LC neurones overexpressing a GRK2 
dominant negative mutant (Bailey et al., 2009b) and those expressing a mutant MOPr 
deficient in GRK-dependent phosphorylation sites (Leff et al., 2020) suggests that an 
additional mechanism, not incomplete inhibition of GRK, may drive this residual 
desensitization. In previous studies, residual acute MOPr desensitization in rat LC 
neurones treated with Compound 101 was unaffected by supplementary inhibition of 
PKC, JNK or ERK1/2 (Lowe et al., 2015). This suggests that while a secondary kinase-
dependent mechanism is possible, kinases previously implicated in MOPr 
desensitization do not play a role.  
Sequestration of G subunits by a non-catalytic component (PH-domain) of GRKs could 
also be responsible for the residual component of MOPr desensitization (Raveh et al., 
2010). It is possible that this mechanism would not be attenuated by inhibition of GRK 
through pharmacological (Lowe et al., 2015) or genetic (Bailey et al., 2009b) approaches 
which target the active site of GRKs (Mundell et al., 1997; Thal et al., 2011). However, 
this mechanism has previously been shown to play little role in opioid receptor regulation 




Chapter 6: Discussion 
6.1 Research Summary and Introduction to Discussion 
The development of G protein-biased agonists at MOPr had been heralded by some as 
a holy grail, that is an opioid analgesic without associated adverse effects and in 
particular respiratory depression. A further advantage of G protein-biased agonists at 
MOPr might be that through low coupling to arrestin/GRK pathways, G protein-biased 
agonists may induce less receptor desensitization than balanced agonists, and therefore 
be less susceptible to the development of tolerance to their effects. If this hypothesis 
were true, then G protein-biased agonists at MOPr would be clinically beneficial, evading 
the common issue of tolerance development in the use of opioids for the treatment of 
chronic pain states. The research presented within this thesis broadly aimed to 
characterise the receptor desensitization and regulation induced by G protein-biased 
agonists at MOPr in order to further define their long-term functional effects and 
therapeutic potential.  
We first sought to characterise the signalling properties of potentially biased agonists at 
MOPr using BRET assays in heterologous systems (Chapter 3). Through these 
experiments, we have identified the cyclic endomorphin analogue Compound 1 (Try-c[D-
Lys-Phe-Try-Gly]) as a novel G protein-biased MOPr agonist, which possesses a greater 
degree of biased signalling than the previously described biased agonists at MOPr. The 
characterisation of Compound 1 as a G protein-biased MOPr agonist provides the field 
with a novel tool compound to further investigate the consequences of biased signalling 
at MOPr, as well as representing a potentially promising therapeutic lead. 
Subsequently, having defined Compound 1 as a G protein-biased agonist at MOPr, we 
aimed to characterise its ability to induce rapid MOPr desensitization in rat LC neurones 
using electrophysiological techniques (Chapter 4). It had been hypothesised that G 
protein-biased agonists, such as Compound 1, would induce less receptor 
desensitization than balanced agonists given their relatively low coupling to arrestin and 
GRK pathways, which are well recognised pathways of receptor regulation. However, 
Compound 1 induced rapid receptor desensitization to a greater degree than morphine, 
opposing our initial hypothesis. This finding suggests that the low arrestin-coupling of  G 
protein-biased agonists at GPCRs may not implicitly result in a lower propensity to 
undergo receptor desensitization and may have implications for their ability to induce 
tolerance  in vivo, and as such, their overall clinical utility. 
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In an attempt to translate and progress our findings of Compound 1-induced MOPr 
desensitization in brain slice electrophysiology, we aimed to define the ability of 
Compound 1 to induce antinociceptive tolerance in vivo in a warm-water tail withdrawal 
test of nociception in mice (Chapter 4). In these tests of nociception, Compound 1 
induced MOPr-dependent antinociception, however this effect was of a substantially 
lower magnitude than that of morphine. The reason for the low in vivo efficacy of 
Compound 1 was unclear but could feasibly be due to pharmacokinetic limitations given 
the unfavourable physicochemical properties of Compound 1 as a large cyclic peptide.  
Aside from the potential tolerance induced by Compound 1 in vivo, the mechanism 
through which Compound 1 induced rapid receptor desensitization was of particular 
interest. Agonist-selective, non-GRK mediated, mechanisms of MOPr desensitization 
are well described, with PKC in particular demonstrated to regulate MOPr desensitization 
in the case of some agonists. We aimed to investigate the potential roles of GRK and 
PKC in Compound 1-induced MOPr desensitization in LC neurones using 
pharmacological tools that target these kinases (Chapter 5). In fact, this work clearly 
demonstrated that Compound 1-induced desensitization was GRK-dependent but PKC-
independent. This was particularly surprising given the low arrestin coupling in 
recombinant cell systems. When considering findings in both of these systems, our 
findings highlight a potentially novel GRK-dependent, arrestin-independent mechanism 
of agonist-induced receptor desensitization at MOPr, providing new insight on the 
potential long-term functional effects of biased signalling at MOPr. 
Following our work in LC neurones, we sought to refine our understanding of the GRK-
dependent, potentially arrestin-independent nature of Compound 1-induced MOPr 
regulation through further experiments in recombinant cell systems. As such, we studied 
the ability of Compound 1 to induce arrestin-2 recruitment (as opposed to arrestin-3 
which we have already studied), MOPr internalization and MOPr phosphorylation 
(Chapter 5). Data from these assays was in line with Compound 1 being a G protein-
biased agonist, inducing no arrestin-2 recruitment, no MOPr internalization and minimal 
MOPr phosphorylation. These data confirm the G protein-biased profile of Compound 1 
in recombinant systems and suggests a potentially non-canonical mechanism of GRK-
dependent MOPr desensitization in the case of this novel drug.  
The following general discussion chapter builds on the preceding chapter-specific 
discussions in this thesis (Chapters 3.3, 4.3 & 5.3). The purpose of these previous 
chapter-specific discussions was to elaborate on isolated, data-specific issues arising 
within in a single chapter. Whereas, the purpose of this discussion is to more generally 
contextualise and examine the impact of findings of this thesis as a whole. Throughout 
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this chapter, I will be outlining research questions resulting from such discussion and 
suggesting potential future experiments to address such research questions as and 
when they arise. In sections 6.8 and 6.9, I will conclude by taking a broader look at the 
field of biased agonism, both considering the clinical utility of current and future biased 
agonists at MOPr (Chapter 6.8) and briefly re-examining the overall potential of biased 




6.2 PKC is not involved in Compound 1-induced 
desensitization in LC neurones 
Given the well-demonstrated role of PKC in the regulation of MOPr desensitization 
induced by low efficacy agonists in LC neurones (Bailey et al., 2004; Bailey et al., 2009b) 
(Chapter 1.2.5 and Chapter 5.2.2), we had hypothesised that MOPr desensitization 
induced by Compound 1, a low efficacy agonist, would be regulated by PKC. However, 
in Chapter 5, it was demonstrated that the magnitude of Compound 1-induced MOPr 
desensitization in rat LC neurones was unaffected by pharmacological inhibition (Figure 
5.2) or activation (Figure 5.3) of PKC but was instead dependent on GRK (Figure 5.6).  
This finding in the case of Compound 1 refutes the well-accepted hypothesis that, for all 
MOPr agonists, the relative contribution of GRK and PKC to agonist-induced MOPr 
desensitization is dependent on the intrinsic efficacy of the agonist examined (Johnson 
et al., 2006; Kelly et al., 2008). As such, low efficacy agonists such as morphine couple 
more weakly to GRK and desensitize primarily through PKC, whereas high efficacy 
agonists such as DAMGO desensitize through GRK with little or no PKC component 
(Figure 6.1). This hypothesis is well characterised in the case of the aforementioned 
agonists in both LC neurones and in recombinant systems (Johnson et al., 2006; Bailey 
et al., 2009b). Despite this, the direct mechanisms underlying agonist-induced regulation 
of MOPr by PKC are poorly understood (Chapter 1.2.5). The PKC hypothesis is 
additionally supported by thorough subsequent work demonstrating that the coupling of 
GRK-mediated regulatory pathways (Ser375 phosphorylation, internalization, arrestin 
recruitment, GRK2 recruitment) is closely correlated with agonist intrinsic efficacy, with 
all investigated low-efficacy agonists coupling weakly to these GRK-dependent 
pathways (McPherson et al., 2010; Gillis et al., 2020a). It is therefore speculated that in 
the relative absence of GRK coupling, PKC instead modulates MOPr regulation. 
Our finding that the mechanism of Compound 1-induced MOPr does not involve PKC 
could suggest that the involvement of PKC is a phenomenon specific to morphine rather 
than all low efficacy agonists. The involvement of PKC in MOPr-induced desensitization 
by other low efficacy agonists is indeed understudied. However, the finding that the 
development of tolerance to the effects of oxycodone, which has similar G protein 
efficacy to morphine (McPherson et al., 2010), is PKC dependent suggests that MOPr 
desensitization induced by this ligand could be regulated in a similar manner to morphine 
(Hill et al., 2018a). Additionally, PKC has been demonstrated to partially regulate MOPr 
desensitization induced by Met-Enkephalin in rat LC neurones (Bailey et al., 2004). As 
an agonist of intermediate intrinsic efficacy compared to DAMGO and morphine, findings 
for Met-Enkephalin are in support of the ‘wedge’ model (Figure 6.1) representation of 
 
 167 
PKC / GRK involvement in MOPr desensitization dependent on agonist efficacy (Kelly et 
al., 2008).  
In light of our findings for Compound 1, it is the author’s belief that further work is required 
to determine the validity of the previous hypothesis of the efficacy-dependent role of PKC 
in agonist-selective MOPr desensitization, for low efficacy agonists aside from morphine. 
One serendipitous outcome from the drive to develop potentially G protein-biased 
agonists at MOPr is that there is now a plethora of well-characterised, selective and 
potent partial agonists with lower intrinsic efficacy than morphine available for such 
study. These include, but are not limited to, TRV130, PZM21 and SR17018. These have 
advantages over previous tool low efficacy MOPr agonists buprenorphine and pethidine 
(meperidine), which could have other functional effects due to their promiscuous 
pharmacology (Latta et al., 2002; Falcon et al., 2016). We suggest that investigating the 
potential role of PKC in MOPr desensitization induced by PZM21 and TRV130 in rat LC 
neurones through pharmacological methods presented in this thesis (addition of PMA) 
would help determine whether morphine or Compound 1 is the outlier in the relationship 
of PKC to MOPr desensitization.  
Alternatively, while Compound 1 has equivalent G protein efficacy to morphine, it is also 
G protein-biased. Therefore, it is possible that it may stabilise a distinct activated 
conformation of the MOPr compared to morphine (Schneider et al., 2016; Dekan et al., 
2019). As such, this active state may have a lower coupling efficiency for PKC-mediated 
desensitization. Additionally, it could be speculated that in the absence of relatively 
ineffective regulation by PKC, even the low level of GRK activation induced by 
Compound 1 may be sufficient for the high level of MOPr desensitization it induces 
(Figure 4.5). Future work could study this hypothesis by examining the potential role of 
PKC in MOPr desensitization induced by bilorphin (Chapter 1.3.2) in LC neurones 
(Dekan et al., 2019), through pharmacological methods described in this thesis. Bilorphin 
has a similar pharmacological profile to Compound 1, being a G protein-biased MOPr 
agonist with equivalent efficacy for G protein signalling compared to morphine (Chapter 
3.3.2) (Dekan et al., 2019). If bilorphin-induced MOPr desensitization is found to not be 
regulated by PKC, but that induced by TRV130 and PZM21 is found to be regulated by 
PKC, we could attribute the lack of PKC regulation in Compound 1-induced MOPr to its 
biased profile.  
Together, the finding that Compound 1-induced desensitization is PKC-independent is 
in contention with our previous understanding of the PKC-dependence of MOPr 
regulation induced by lower efficacy agonists. Future work could investigate the role of 
PKC in desensitization induced by novel lower efficacy MOPr agonists (TRV130 and 




Figure 6.1 – A schematic depicting the relative contribution of PKC and GRK to 
MOPr desensitization, dependent on agonist efficacy 
An illustration of the current hypothesis around agonist-selective mechanisms of MOPr 
desensitization. MOPr desensitization induced by the partial agonist morphine is 
primarily mediated by PKC, with a smaller contribution by GRK. MOPr desensitization 
induced by the full agonist DAMGO is regulated solely by GRK with no contribution from 
PKC. Met-Enkephalin, an agonist of slightly lower efficacy than DAMGO, induces MOPr 
desensitization primarily through GRK, however PKC also has been demonstrated to 
play a partial role. Together this suggests the relative contribution of PKC to agonist-
induced MOPr desensitization is dependent on agonist efficacy. However, in contrary to 
this hypothesis, in this thesis I have demonstrated that Compound 1, a partial agonist 
with equivalent G protein efficacy to morphine, induces MOPr desensitization through a 
GRK-dependent, PKC-independent mechanism. The presentation of this diagram was 




6.3 Thoughts on our approach to characterise the mechanisms 
involved in Compound 1-induced desensitization in LC neurones 
In Chapter 5, we used pharmacological means of kinase inhibition to characterise the 
mechanisms underlying Compound 1-induced MOPr desensitization in rat LC neurones. 
While in this case this approach has proved relatively fruitful, more widely its utility is 
restricted by its low throughput, as well as practical drawbacks associated with the use 
of brain slices. Below I will summarise and discuss some alternative methods or 
approaches we could have adopted to assess MOPr desensitization, highlighting their 
potential advantages and their shortcomings in our situation. 
6.3.1 Non-selective kinase inhibition 
There has been a wide range of kinases which have been suggested to play a functional 
role in agonist-induced receptor desensitization at MOPr (Chapter 1.2.5) (Williams et al., 
2013). As such, some groups have opted to use non-selective kinase inhibitors such as 
the microbial alkaloid staurosporine (Rüegg et al., 1989; Karaman et al., 2008) to define 
the potential involvement of kinases in receptor processes (Arttamangkul et al., 2012). 
In the MOPr field, staurosporine has been often been utilised as a non-selective PKC 
inhibitor, as an alternate to (or in the absence of) selective inhibitors such as GF109203X 
as used in this study (Johnson et al., 2006; Arttamangkul et al., 2015). Alternatively, the 
use of non-selective kinase inhibitors could serve as a primary, triaging step to confirm 
the involvement of kinases in such processes before moving in on to more selective 
approaches (Pan et al., 1994; Sanders et al., 2002; Ponimaskin et al., 2005). However, 
staurosporine is not a potent inhibitor of GRKs (Karaman et al., 2008) and as such does 
not impact acute MOPr desensitization induced by DAMGO in recombinant systems 
(Johnson et al., 2006). We could therefore postulate that staurosporine would have had 
no effect on Compound 1-induced desensitization, revealing no role for PKC or other 
kinases in this desensitization, but a role for GRK would yet to be eluded in this case.  
6.3.2 Modulation of kinase activity through genetic approaches  
Genetic knockdown approaches could have been used to elucidate the role of kinases 
in MOPr regulation, as opposed to the pharmacological methods utilised in this study. 
One evident obstacle to this approach is the limited number of available knockout animal 
lines available for rats. In this study, opioid-evoked currents have been assessed in rat, 
rather than mouse, LC neurones, due to practical reasons surrounding the small 
magnitude of GIRK currents in mouse LC neurones (Bailey et al., 2009b). Additionally, 
GRK2 KO is embryonically lethal in mice, limiting the study of this principal kinase 
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through genetic means. In vivo viral-mediated gene-transfer has been utilised effectively 
as a method to overcome this problem in rat brain slices (Bailey et al., 2009b). In this 
case, viral transfection of rat LC neurones with dominant negative GRK mutants was 
used to demonstrate the role of GRK2, but not GRK6, in DAMGO-induced MOPr 
desensitization (Bailey et al., 2009b).  
Similarly, with the availability of a MOPr knockout rat (Envigo, USA), one group has 
demonstrated the use of virally-mediated gene transfer to effectively replace wild type 
MOPr for transfected mutant MOPr, deficient in GRK-dependent phosphorylation sites 
(Arttamangkul et al., 2019a). This elegant approach was used to characterise the role of 
specific C-terminal MOPr serine and threonine residues in agonist-induced acute 
desensitization and longer-term tolerance in rat LC neurones (Arttamangkul et al., 
2019a). The knock-in expression of phosphorylation-deficient MOPr has also been 
employed for studies of agonist-induced receptor desensitization in mouse LC neurones 
(Kliewer et al., 2019) and in AtT20 cells (Miess et al., 2018), as reviewed by Birdsong et 
al. (2020).  
Such genetic approaches to ablate GRK activity could provide important supporting 
information as to the GRK-dependent mechanism of Compound 1-induced 
desensitization described in rat LC neurones (Chapter 6.4). However, the utilization of 
this methodology is dependent on the accessibility of such tools, which are far less 
accessible as a starting point of investigation than the use of pharmacological tools.  
6.3.3 The viability of recombinant systems in the study of MOPr desensitization 
The use of cultured recombinant cells to study agonist-induced MOPr desensitization, in 
place of brain slices, could provide a substantial increase in throughput for such 
investigations. The relatively short lifespan and occasionally variable health of neurones 
in brain slice preparations often serves as a rate-limiting step in the generation of 
electrophysiological data. This is particularly evident in circumstances where 
experiments are relatively long in duration, as presented in Chapter 5 (~1 hr), and 
deteriorating cell health or seal quality can lead to lost recordings.  
In AtT20 cells, recombinantly expressing MOPr, are often adopted for 
electrophysiological studies within the opioid field (Birdsong et al., 2020), as these cells 
endogenously express functional GIRK channel subunits (Kozasa et al., 1996). While 
the use of cultured cells for electrophysiological studies provide some advantages 
regarding convenience, as well as greater opportunity for utilisation of genetic 
manipulation, the throughput of such assays is still very limited given its dependence on 
single cell recordings.  
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Many common recombinant assays of MOPr report signals associated with receptor 
regulation; such as receptor internalization, phosphorylation and arrestin recruitment. 
However, there is no common assay which can match the ability of electrophysiology to 
directly monitor the real-time desensitization of receptor function through the signal of 
agonist-induced GIRK currents. One possible high throughput approach to monitor 
MOPr-coupled GIRK channel function is through changes in membrane potential using 
fluorescent membrane potential-sensitive dyes (Knapman et al., 2013). This has been 
well-characterised for studying function and desensitization of GPCRs, including MOPr, 
in AtT20 cells (Knapman et al., 2013; Udoh et al., 2019). The strength of this assay 
format comes from its ability to provide real-time, continuous measure of receptor 
activation, similar to electrophysiological techniques. Given this assay is based on 
fluorescence responses, plate reader technologies such as Flexstation or FLIPR 
(Molecular Devices) can be utilised, allowing for experiments to be run in 96-well or 384-
well plates. As such, the sheer throughput of these assays compared to 
electrophysiological methods gives them an undeniable utility in the study of MOPr 
function and desensitization.  
However, the scientific value of the electrophysiological studies in brain slices is very 
important, as a measure of receptor function in an endogenous environment. While 
alternative methods using recombinant systems provide useful information on receptor 
function, in a more convenient format, they are inevitably tied to translatability issues 
arising from the study of receptors in heterologous expression systems (Chapter 3.3.3 




6.4 Relating observations of Compound 1-induced MOPr 
desensitization between studies in recombinant systems and LC 
neurones 
In Chapter 5, I demonstrated that the mechanism regulating Compound 1-induced MOPr 
desensitization in rat LC neurones was GRK-dependent. Subsequently, I aimed to follow 
up this surprising finding by further investigating MOPr regulation induced by Compound 
1 in recombinant systems (Chapter 5.2.7 through 5.2.10). These investigations produced 
data in line with Compound 1 being a G protein-biased agonist, with it producing minimal 
arrestin recruitment, MOPr internalization and Ser375 phosphorylation (Chapter 5.3.1). 
Accordingly, it appears as if our findings for the extent of, and potential mechanisms of, 
Compound 1-induced MOPr desensitization present disparate pictures between our two 
systems of investigation (Figure 5.21). As such, in assays performed in recombinant 
systems, Compound 1 reliably displays signalling in line with it being a G protein-biased 
agonist. However, in LC neurones, the extent and mechanism of MOPr desensitization 
it induces is more in line with expectations for an arrestin-biased agonist (Rivero et al., 
2012), rather than the G protein-biased agonist it is. 
6.4.1 Considering the influence of systems bias in the case of Compound 1 
It could be postulated that the contrasting profiles observed for Compound 1 in these two 
systems is simply an effect of systems bias (Smith et al., 2018), and potentially the bias 
profile of Compound 1 is altered in the environment in LC neurones. One factor which 
could drive systems bias was explored in Chapter 5, which was potentially differing levels 
of GRK2 expression (Chapter 5.2.7). Such system bias has been demonstrated to have 
functional relevance for the region-specific activity of D2 agonists, with increased relative 
cortical versus striatal activity attributed to elevated GRK2 and arrestin-3 expression in 
the former region (Urs et al., 2016). However, in our studies, GRK2 overexpression in 
HEK 293 cells did not disproportionally increase Compound 1-induced arrestin-3 
recruitment to MOPr (Figure 5.17). Based on this, we believe it is unlikely that potential 
differences in GRK tone between our systems effectively reverses the bias signalling 
profile of Compound 1.  
Additionally, systems bias may occur in the case of Compound 1 due to differential 
signalling efficacy dependent on the species variants of MOPr in which its function was 
tested. Such a phenomenon has been reported at KOPr, where the biased signalling 
profile of the agonist nalfurafine is considered to be substantially higher at the human 
form of the receptor than the rodent form (Schattauer et al., 2017). Due to limited 
availability of suitable constructs, the species from which MOPr constructs were derived 
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varied in the collective work of this thesis (Chapter 2.1). BRET assays of G protein 
activation (Figure 3.1B) and ELISA for agonist-induced MOPr internalization (Figure 
5.19) were performed using rat HA-MOPr, BRET assays of arrestin recruitment (Figure 
3.1D, Figure 3.5, Figure 5.17, Figure 5.18) were conducted using a human MOPr-Rluc 
construct, and immunoblotting assays of agonist-induced MOPr phosphorylation (Figure 
5.20) were conducted using mouse HA-MOPr. Evidently, when comparing the activity of 
Compound 1 in these assays to those conducted in LC neurones (rat MOPr), we must 
consider species of receptor as a factor. However, this seems unlikely given the high 
sequence homology of the human, rat and mouse MOPr (Pasternak et al., 2013). 
Regardless, theoretically if Compound 1 had equivalent efficacy to morphine at the rat 
MOPr (G protein BRET and LC), but had a lower efficacy than morphine at the human 
MOPr (arrestin-recruitment BRET), that could potentially be responsible for its reported 
G protein-biased profile as well as differences in the extent of its efficacy for receptor 
desensitization/regulation between recombinant systems and the LC. However, there 
are a number of lines of evidence against this hypothesis. Firstly, the ELISA which 
demonstrated Compound 1 did not induce MOPr internalization was run on a rat HA-
MOPr construct (Figure 5.19). Similarly, preliminary studies of opioid induced MOPr 
phosphorylation performed in house (prior to outsourcing this work to the Schulz lab 
group at the Friedrich-Schiller University, Jena, Germany) using the rat HA-MOPr 
demonstrated that Compound 1 produced no detectable Ser375 phosphorylation 
(Conibear & Kelly, unpublished findings), in line with findings in mouse (Figure 5.20).  
Together these lines of evidence oppose the hypothesis that apparent disparity in our 
findings for Compound 1-induced coupling to MOPr regulatory pathways is driven by 
species differences in our assays of MOPr activity. However, this highlights species 
differences as a common problem in the characterisation of ligands at GPCRs, which is 
often overlooked for convenience or when availability of constructs is limited. Further 
work could assure the G protein-biased signalling profile of Compound 1 is not species 
dependent by rerunning our arrestin-recruitment BRET assays using a MOPr-Rluc 
construct derived from the rat MOPr sequence.  
6.4.2 Potential methods to address remaining questions surrounding the 
mechanism of Compound 1-induced MOPr desensitization    
As illustrated in Figure 5.21, there are a number of additional questions which could be 
addressed in order to enhance our understanding of the mechanisms of Compound 1-




First, concerning experiments in LC neurones, it is unknown whether the mechanism of 
Compound 1-induced MOPr desensitization involves phosphorylation of MOPr C-
terminal serine and threonine residues or recruitment of arrestin proteins (Figure 5.21). 
While the coupling of Compound 1 to these pathways has been demonstrated to be weak 
compared to morphine in recombinant systems, I will below explore potential 
experimental approaches to address this question in LC neurones.  
Although appealing, the viability of potential studies of agonist-induced MOPr 
phosphorylation in LC neurones through immunoblotting experiments (Figure 5.20) is 
limited by a lack of suitable method for protein enrichment. This is due to the lack of a 
high quality MOPr antibody and the absence a tag (such as HA) at the natively expressed 
receptor. This could be overcome by virally overexpressing a tagged MOPr (HA or FLAG) 
in rat LC neurones or through genetic modification of the MOPr sequence to include such 
a tag. Therefore, under these circumstances one could feasibly assess Compound 1-
induced MOPr phosphorylation through immunoblotting experiments similar to those 
presented here in recombinant systems (Figure 5.19). 
An alternate, more functionally relevant, method of determining the potential role of 
phosphorylation of MOPr C-terminal serine and threonine residues in Compound 1-
induced MOPr desensitization is to study Compound 1 function at mutant MOPrs 
deficient in GRK-dependent phosphorylation sites (11S/T-A) (Just et al., 2013). The 
recent development of these MOPr mutants has provided excellent tools to study the 
role of GRKs in MOPr desensitization in recombinant systems (Miess et al., 2018) as 
well as the contribution of GRK and arrestin pathways in physiological responses to 
opioids in vivo in mutant mice (Kliewer et al., 2019). Additionally, brain slices from knock-
in phosphorylation-deficient MOPr mice have been utilised to demonstrate the 
importance of multisite-phosphorylation by GRKs in rapid desensitization of Met-
Enkephalin-evoked GIRK currents in LC neurones (Kliewer et al., 2019). Rather 
elegantly, these phosphosite-deficient MOPr mutants have also been utilised in LC brain 
slice electrophysiology experiments in rat, through viral-mediated gene transfer of 
mutant MOPrs into a commercially available MOPr-KO rat (Arttamangkul et al., 2019a) 
(Chapter 6.3.2). These experiments demonstrated similarly that acute desensitization of 
Met-Enkephalin-evoked GIRK currents as well as the cellular opioid tolerance in rat LC 
neurones is dependent on the expression of these C-terminal serine and threonine 
residues (Arttamangkul et al., 2019a). 
The investigation of Compound 1-induced MOPr desensitization in rat LC neurones 
expressing phosphosite-deficient MOPr mutants would represent a pivotal future 
experiment. If Compound 1-induced MOPr desensitization would be decreased upon 
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deletion of MOPr phosphorylation sites, it would inform us that GRK is acting in a typical 
manner to regulate the Compound 1-activated MOPr. Alternatively, if deletion of MOPr 
phosphorylation sites did not impact Compound 1-induced MOPr desensitization, it could 
inform us that GRK is acting in a non-canonical manner to mediate Compound 1-induced 
receptor desensitization (Chapter 6.5).  
It would be of significant interest to be able to observe the agonist-induced recruitment 
of arrestins to MOPr in LC neurones (Figure 5.20). In the case of Compound 1, 
understanding the degree of its arrestin recruitment in LC neurones relative to morphine 
would likely reveal whether its G protein-bias profile is retained across different systems 
(Chapter 6.4.1). It may be possible in the near future to achieve this through BRET or 
FRET techniques in brain slices derived from genetically modified mice (Sun et al., 2016; 
Rathod et al., 2018), however the introduction of mutated receptor and arrestin 
constructs defeats the purpose of examining this process in a native environment. As 
such, a suitable methodology for the determination of unlabelled arrestin recruitment to 
MOPr in a native environment is currently unavailable. 
Similarly, the study of native MOPr internalization in brain slices would be of particular 
interest in order to further characterise Compound 1-induced MOPr regulation in LC 
neurones. This may be possible through fluorescence microscopy with the expression of 
mutant GFP tagged-MOPr, either virally in MOPr-KO rats, or in a genetic knock-in mouse 
(Arttamangkul et al., 2006; Kieffer et al., 2009). However, this approach is again limited 
as it does not examine the endogenous receptor. Traceless affinity labelling of 
endogenous MOPr has recently been demonstrated in LC neurones in brain slices using 
a naltrexamine-acylimidazole fluorescent probe (Arttamangkul et al., 2019b). This probe 
is able to bind endogenous MOPr, covalently link a fluorescent dye to the receptor, and 
be liberated from the orthosteric site. There is great potential for use of this probe to 
explore internalization of endogenous MOPrs in native brain slices through two-photon 
fluorescence microscopy without the need for genetically encoded tags (Arttamangkul et 
al., 2019b). However, receptor internalization has been demonstrated not to be involved 
in rapid agonist-induced MOPr desensitization in LC neurones (Arttamangkul et al., 
2006), suggesting that mechanism of Compound 1-induced MOPr desensitization in LC 
neurones does not involve MOPr internalization anyway. 
Alternatively, the gap in our understanding regarding Compound 1-induced MOPr 
regulation could be approached using studies of recombinant systems. While Compound 
1-induced arrestin recruitment, MOPr internalization and MOPr phosphorylation have 
been characterised in these systems, it is not known whether Compound 1 induces 
MOPr desensitization in such systems as observed in LC neurones (Figure 5.21). AtT20 
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cells are commonly used in recombinant study of MOPr desensitization, due to their 
endogenous expression of  GIRK channels (Kozasa et al., 1996) (Chapter 6.3). Opioid-
induced activation of GIRKs through MOPr can be effectively assessed in AtT20 cells 
(or HEK 293 cells recombinantly expressing GIRKs) through either electrophysiological 
techniques (Yousuf et al., 2015; Dekan et al., 2019; Birdsong et al., 2020) or through the 
use of membrane-potential sensitive fluorescent dyes (Knapman et al., 2013; Gillis et al., 
2020a). Through these methods, acute agonist-induced MOPr desensitization can be 
assessed in a similar manner to that in LC neurones (Chapter 4). Indeed, these assays 
produce similar findings to those in LC neurones regarding opioid-induced MOPr 
desensitization (Yousuf et al., 2015). Future investigations of Compound 1-induced 
MOPr desensitization in recombinant cells through either electrophysiological or 
fluorescence-based methods could provide valuable information. Such experiments 
could outline whether the cellular context of LC neurones is responsible for the 
magnitude of Compound 1-induced MOPr desensitization observed, or whether this 
desensitization is conserved across systems (Chapter 6.4.1). Additionally, if Compound 
1-induced MOPr desensitization was present in recombinant systems, its dependence 
of GRK could be similarly be assessed through pharmacological or genetic means. It 
would also be possible to conduct such experiments in HEK 293 cells expressing GIRKs, 
the same cellular background as assays of arrestin-recruitment, GRK phosphorylation 




6.5 Potential non-canonical roles of GRK in Compound 1-
induced MOPr desensitization 
In spite of demonstrating that Compound 1-induced MOPr desensitization in LC 
neurones is GRK-dependent (Figure 5.6), we did not observe significant phosphorylation 
of typical GRK-substrate residues on the C-terminal tail of MOPr by Compound 1 (Figure 
5.20) (Just et al., 2013; Miess et al., 2018). It is possible therefore that GRK may be 
acting in a non-canonical manner to regulate MOPr desensitization induced by 
Compound 1 in LC neurones (Figure 5.21). Below I will discuss some potential non-
canonical mechanisms through which GRK could be acting in the case of Compound 1.  
6.5.1 GRK-dependent phosphorylation of non-C-terminal MOPr residues 
One possibility is that GRK regulates MOPr desensitization induced by Compound 1 
through phosphorylation of serine and threonine residues outside of the well documented 
residues examined in this study. The involvement of such  C-terminal MOPr residues in 
agonist-induced receptor desensitization is well characterised (Just et al., 2013; Miess 
et al., 2018), however the phosphorylation of other extra-C-terminal residues has been 
implicated in MOPr regulation (Williams et al., 2013). One such MOPr residue is Thr180 
in the second intracellular loop, which undergoes GRK3-dependent phosphorylation 
upon activation of MOPr by DAMGO in both oocytes and AtT20 cells (Celver et al., 2001; 
Celver et al., 2004). Phosphorylation of Thr180 was demonstrated to play a functional role 
in DAMGO-induced MOPr desensitization, but not MOPr internalization, in oocytes and 
AtT20 cells (Celver et al., 2004), however the function of this residue has not been 
demonstrated in neurones. This residue could potentially be important in the Compound 
101-sensitive mechanism of MOPr desensitization induced by Compound 1, and such 
agonist-induced phosphorylation will not have been recorded in our studies of MOPr 
phosphorylation (Figure 5.20). The phosphorylation of intracellular loop serine and 
threonine residues has similarly been demonstrated as a mechanism of receptor 
desensitization and internalization at other class A GPCRs (Pals-Rylaarsdam et al., 
1997; Clayton et al., 2014).  
The practicality of future investigations to determine the potential role of Thr180 
phosphorylation in Compound 1 induced-MOPr desensitization are limited by the lack of 
a phosphospecific antibody agonist this specific residue on MOPr. This means this 
interaction must be determined in a different way to the phosphospecific immunoblotting 
techniques used in Chapter 5 (Figure 5.20). Mutated MOPrs in recombinant systems 
could be used to characterise the function of Thr180 in Compound 1-induced 
desensitization, examining the effect of a T180A mutant on desensitization of 
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Compound-1 evoked GIRK currents in recombinant AtT20 cells or oocytes (Celver et al., 
2004). If Compound-1 induced desensitization is reduced at the T180A mutant MOPr, it 
would suggest that phosphorylation of this residue is important for Compound 1-induced 
MOPr regulation. However, difficulties could arise in translating this finding to neurones. 
Alternatively, phosphoproteomics of MOPr samples could give a wider, whole receptor 
view of the patterns of Compound 1-induced MOPr phosphorylation (Moulédous et al., 
2015). This has been demonstrated as a viable technique to determine the 
phosphorylation status of mouse brain MOPr (Moulédous et al., 2015), suggesting the 
possibility of examining rat brain MOPr phosphorylation induced by Compound 1. This 
information could be valuable in linking current phosphorylation data in recombinant 
systems to MOPr desensitization observed for Compound 1 in rat LC neurones. 
Additionally, the wide scope of this technique would be highly beneficial, allowing us to 
observed potential Compound 1-induced phosphorylation beyond archetypal residues.  
6.5.2 Exploring a potential non-phosphorylation-dependent mechanism of GRK 
in Compound 1-induced MOPr desensitization 
In light of observing no significant Compound 1-induced phosphorylation in recombinant 
systems, it could be speculated that the mechanism of GRK-mediated Compound 1-
induced MOPr desensitization in rat LC neurones is regulated by a non-phosphorylation 
dependent regulation through GRK. Such a phosphorylation-independent regulatory 
mechanism has been characterised for GRK2 at the metabotropic glutamate receptors 
mGluR1 and mGluR5, which are Class C GPCRs. In these cases, GRK2 has been 
shown to functionally inhibit G protein signalling through recruitment and binding to the 
second intracellular loop of the receptor (Dhami et al., 2005; Ribeiro et al., 2009). Future 
experiments could investigate this by studying potential recruitment of GRK2 to MOPr 
through established BRET methods in recombinant systems (Miess et al., 2018; Gillis et 
al., 2020a). If a phosphorylation-independent, steric hinderance-based mechanism 
underpins the Compound 101-sensitive, GRK-dependent MOPr desensitization induced 
by Compound 1, one could hypothesise that such experiments would show Compound 
1 inducing substantial GRK recruitment to MOPr. One could postulate based on the data 
from LC neurones that if this was the case, the standing of Compound 1 would be higher 
than morphine within the rank order for GRK-recruitment compared with its relative 
standing for arrestin recruitment and Ser375 phosphorylation.   
Another phosphorylation-independent mechanism of GRK action has also been 
demonstrated, with GRK able to induce heterologous desensitization of GPCR-linked 
GIRK currents through sequestration of G subunits in recombinant systems (Raveh et 
al., 2010). However, in rat LC neurones the extent of DAMGO-induced MOPr 
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desensitization that occurs through heterologous GRK-dependent G sequestration 
has been demonstrated to be minimal in mature cells (Llorente et al., 2012). Additionally, 
in the case of Compound 1, findings in Chapter 4 showing that Compound 1 did not 
induce marked heterologous desensitization of NA-evoked currents relative to other 
opioids (Figure 4.6). This finding suggests that this heterologous mechanism of GRK 




6.6 The potential structural determinants underlying the 
biased signalling of Compound 1 
In Chapter 3, I characterised the cyclic endomorphin analogue ‘Compound 1’ as a G 
protein-biased agonist at the MOPr (Figure 3.2). Compound 1 displayed a substantially 
higher degree of bias than previously purported biased agonists at MOPr (Conibear et 
al., 2019; Dekan et al., 2019). The factors underlying the distinctive pharmacology of 
Compound 1 warrant further study, in particular the structural determinants of its 
signalling profile. This question could be approached from two angles: Firstly, what 
factors around the structure of Compound 1 define its G protein-biased signalling profile? 
Secondly, what can the manner in which Compound 1 interacts with and stabilises MOPr 
tell us about the receptor conformations which give rise to biased receptor signalling at 
MOPr?   
In the initial stages of this project, we speculated that the cyclic nature of Compound 1 
may predispose it to being a G protein-biased agonist at MOPr (Li et al., 2016). Whether 
dependent on its cyclic nature or otherwise, we have conclusively characterised 
Compound 1 as a G protein-biased agonist at MOPr within this thesis (Figure 3.2, 
Chapter 3.3.2). This initial hypothesis was based on the similarity of the in vivo 
pharmacological profiles presented by previously reported cyclic endomorphin 
analogues, notably ZH853 and CYT-1010, to those of G protein-biased agonists (Zadina 
et al., 2016; Webster et al., 2020) (Chapter 1.3.2 and Chapter 3.1). While the signalling 
properties of these cyclic peptides has not been published, their pharmacological profiles 
are certainly akin to those previously associated with G protein-biased agonists at MOPr. 
With the cyclic Compound 1 outlined as a G protein-biased agonist in this thesis, and 
given that linear endomorpin-2 itself is an arrestin biased agonist at MOPr (Rivero et al., 
2012), it could be hypothesised that the cyclisation of the endomorphin series provides 
the chemical ‘switch’ to provide signalling bias for G protein over arrestin signalling at 
MOPr.  
It would be possible to test this hypothesis through the generation of linear analogues of 
Compound 1. In fact, both linear and head-to-tail cyclic analogues of Compound 1 have 
been generated by our collaborators (Li, unpublished data). Future experiments 
characterising the signalling profiles of these linear and head-to-tail cyclic Compound 1 
analogues relative to Compound 1 through BRET based methods demonstrated in this 
thesis (Figure 3.1) could evaluate the impact of cyclisation on agonist signalling. If the 
linear analogue of Compound 1 was found to lack the G protein-biased signalling profile 
of its parent molecule at MOPr, it could indicate the value of cyclisation as an approach 
to develop G protein-biased peptide agonists at MOPr. 
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It is conventionally thought that biased signalling stems from the ability of certain agonists 
to stabilise distinct GPCR conformations which favour coupling to different intracellular 
signalling mechanisms (Kenakin, 2011). Through modelling approaches such as 
molecular dynamics, it could be possible to determine the possible MOPr conformations 
stabilised by Compound 1, as a mechanism for further elucidating the structural 
mechanisms of biased signalling at MOPr at a receptor level. Such modelling processes 
have been employed at MOPr in attempts to further understand biased signalling, 
however many of these studies suffer in that the test agonists examined have 
subsequently been demonstrated to be low efficacy agonists, rather than G protein-
biased (Chapter 3.3.2). These include studies on TRV130 (Schneider et al., 2016; Cheng 
et al., 2018; Kapoor et al., 2020; Zhao et al., 2020) and PZM21 (Zhao et al., 2020). 
However, molecular dynamics studies contrasting the MOPr conformations stabilised by 
bilorphin and endomorphin-2 provide information on the distinct conformations 
underlying biased signalling in the case of a validated G protein-biased agonist (Dekan 
et al., 2019). This study interestingly highlighted that bilorphin, in contrast to the arrestin-
biased agonist endomorphin-2, interacted with TM1 and evaded interactions with the 
extracellular loops of MOPr (Dekan et al., 2019). TM1 has similarly been implicated in 
TRV130-induced MOPr signalling  and is part of the binding pocket for exendin-P5, a G 
protein-biased agonist at the GLP-1R (Liang et al., 2018).  
It would be of significant interest to determine whether Compound 1 as a G protein-
biased agonist also interacts with TM1 in a manner similar to bilorphin through future 
molecular dynamics experiments. If this interaction with TM1 is common to Compound 
1 and bilorphin, it could be considered a distinct stabilization induced by G protein-biased 
agonists at MOPr and could provide valuable information for the further structure-based 
design of future G protein-biased agonists. However, given that Compound 1 is a large 
cyclic peptide, such molecular dynamics modelling would not be trivial. Additionally, the 
functional worth of identifying distinct conformations with such modelling methods could 
be questioned, particularly considering that in silico multiple distinct conformations have 
been illustrated for MOPr agonists such as TRV130, PZM21 and methadone (Schneider 
et al., 2016; Cheng et al., 2018; Kapoor et al., 2020; Zhao et al., 2020), a finding likely 
unrelated to potential biased signalling. As such, individual agonists may induce subtle 
individual differences in MOPr conformations with little to no functional consequence, 
highlighting the need for determining the significance of such distinct interactions in 
functional assays.   
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6.7 Investigating Compound 1-induced tolerance 
In this thesis, I have demonstrated that Compound 1 induces substantial MOPr 
desensitization in rat LC neurones. Agonist-induced receptor desensitization is often 
studied as a cognate of agonist tolerance at GPCRs. Indeed, at MOPr, there is good 
experimental evidence that receptor desensitization is the inaugural process in the 
development of tolerance to opioids in vivo (Bohn et al., 2000; Bailey et al., 2009a; 
Kliewer et al., 2019). The direct study of the potential development of Compound 1-
induced tolerance would further the translatability of our findings regarding the long-term 
functional consequences of biased signalling at MOPr. Normally, this could simply be 
assessed through repeated dosing and paired assessment of opioid function through 
standard assays of nociception (Chapter 4.2.4). However, in Chapter 4 I demonstrated 
that the MOPr-dependent antinociceptive effect of Compound 1 when administered i.p. 
was limited, potentially due to pharmacokinetic concerns or low BBB permeability (Figure 
4.10 and Figure 4.11). Unfortunately, the limited effect of Compound 1 when 
administered i.p. hindered study of Compound 1-induced tolerance in such a system. 
Below I will discuss some other potential means to investigate Compound 1-induced 
tolerance and highlight issues which may be addressed through its study. 
Firstly, issues surrounding the potentially problematic BBB permeability could be 
circumvented through administering the drug intracerebroventricularly (Cook et al., 2009) 
or intrathecally (Dekan et al., 2019). If the antinociceptive effect of Compound 1 was 
comparable to morphine through these administration routes, it could highlight that the 
limited effect of Compound 1 when administered i.p. is due to BBB permeability, rather 
than a result of its receptor pharmacology (Chapter 4.3.4). Additionally, of course, this 
would also open up opportunities to conduct repeated dose experiments with Compound 
1 to study potential tolerance. However, it must be considered that the possible 
mechanisms and extent of agonist-induced tolerance may differ between administration 
routes. Furthermore, intracerebroventricular and intrathecal injection are intricate and 
potentially problematic procedures in mice which require adequate experience and 
training, which has prevented its immediate study.  
Given the potentially therapeutically interesting G protein-biased profile of Compound 1, 
an immediate thought from a medicinal chemistry perspective would be to develop 
analogues of Compound 1 which possess more favourable pharmacokinetic and BBB 
penetration properties. Such agonists could provide valuable tool compounds for the 
study of the long-term functional consequences of biased agonism at MOPr, as well as 
potentially interesting therapeutic leads. Such chemical modifications could include 
glycosylation, previously show to improve the membrane permeability and 
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pharmacokinetics of enkephalins and endorphins (Li et al., 2012). Future development 
and functional study of Compound 1 analogues would be of particular interest for this 
project. However, a cautionary parallel can be drawn from such a study to the recent 
story of the G protein-biased MOPr agonist bilorphin (Dekan et al., 2019). Here, Dekan 
et al. (2019) demonstrated that bilorphin lacked activity in nociceptive assays upon 
systemic administration, however it did have antinociceptive activity when administered 
intrathecally, hereby attributing this systemic inactivity to poor BBB permeability. 
Bilactorphin was developed in attempts to develop bilorphin analogues with more 
favourable BBB penetration characteristics, indeed showing potent antinociceptive 
properties after system administration. However, through modifications made to 
bilorphin, bilactorphin lost the G protein-biased signalling profile of its parent molecule, 
making it a balanced MOPr agonist. As such, caution arises that developed analogues 
of Compound 1 may not possess the same signalling profile as Compound 1, and that 
therefore such pharmacological profiles must be thoroughly examined before the utility 
of such analogues is concluded. 
An alternative approach to characterise the long-term functional effects of Compound 1 
on MOPr would be to study cellular tolerance in rat LC neurones as opposed to whole 
animals. Such approaches have either revolved around assessing opioid function after 
long periods (4-6 hours) of low opioid exposure in vitro (Bailey et al., 2009a) or after 
repeated or continuous opioid administration in animals from which slices are derived 
(Dang et al., 2004; Bailey et al., 2009a; Leff et al., 2020). The latter approach is evidently 
limited in the circumstances of Compound 1, due to uncertainties around its BBB 
permeability upon systemic administration as outlined above. Future work characterising 
cellular tolerance to Compound 1 through chronic in vitro exposure however would be of 
particular interest. Such studies could provide scope on the long-term functional effect 
of Compound 1 beyond the short time-scale (10-15 mins) of rapid receptor 
desensitization examined thus far. Additionally, such studies could also provide insight 
into important regulatory processes which occur over a longer time-frame (Williams et 
al., 2013), which have been little discussed in this thesis up to this point; namely receptor 
resensitization and recycling. Of course, while such in vitro chronic exposure 
experiments could give further insight into Compound 1-induced MOPr regulation, they 
would not provide the translational information desired from experiments of chronic 
treatment in whole animals or assessment of analgesic tolerance.  
Given the role of arrestin-3 in MOPr recycling, as well as internalization and 
desensitization (Chapter 1.1.4), one could hypothesise that Compound 1 activated 
MOPr, which couples weakly to arrestins (Figure 3.1), would likely undergo little 
recycling. This may imply that desensitization and tolerance to Compound 1 would be 
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protracted, as in the case of morphine, in the absence of receptor resensitization (Martini 
et al., 2007), under arguments set out under the “RAVE” (for “relative activation versus 
endocytosis”) hypothesis (Whistler et al., 1999). However, the recovery of MOPr function 
after receptor desensitization was unexpectedly accelerated in LC neurones of arrestin-
3 KO mice compared to their wildtype counterparts (Dang et al., 2011). This suggests 
that arrestin pathways actually impair recovery of MOPr function, with resensitization in 
LC neurones likely dependent on dephosphorylation (Dang et al., 2011; Doll et al., 2011). 
It would be of interest to characterise the recovery from Compound 1-induced MOPr 
desensitization to gain a more complete picture of long-term MOPr regulation by 
Compound 1 in future experiments. Common protocols used to study recovery of MOPr 
function in brain slices rely on agonist wash out. As such, the readily degraded Met-
Enkephalin (Williams et al., 1987a) is used as a test ligand, with repeated ‘pulses’ applied 
to track the recovery of MOPr function. (Arttamangkul et al., 2019a; Birdsong et al., 2020; 
Leff et al., 2020). As a consequence, unfortunately such experiments are not possible in 
the case of Compound 1, for which the time required for total washout is exceedingly 
long, similar to the majority of MOPr agonists which do not undergo assisted-degradation 




6.8 Assessing the therapeutic potential of current and future 
biased agonists at MOPr 
The development of G protein-biased agonists MOPr has dominated the field of opioid 
development over the last decade. Drug development campaigns from both industrial 
and academic groups have yielded a number of notable putatively G protein-biased 
agonists, including TRV130 (DeWire et al., 2013), PZM21 (Manglik et al., 2016) and 
SR17018 (Schmid et al., 2017). Similarly, opioids well established in our clinical arsenal, 
such as buprenorphine and morphine, have been retroactively categorised as G protein-
biased by some groups (Raehal et al., 2011a; Ehrlich et al., 2019). To date, TRV130 
(oliceridine, brand name Olinvyk) is the only new purportedly G protein-biased MOPr 
agonist to reach FDA approval for clinical use (Markham, 2020). It merits mention that 
the approval of TRV130 is quite remarkable given its previous refusal in 2018, with 
clinical trial data demonstrating little to no evidence of a favourable safety profile in 
comparison to morphine (Singla et al., 2019), and a widespread appreciation that it does 
not in fact possess a significant G protein-biased profile at all (Lambert et al., 2020).  
As previously discussed in this thesis (Chapter 3.3.2 and 4.3.1), the putatively G protein- 
biased profiles of the current crop of novel agonists at MOPr have come under scrutiny 
(Conibear et al., 2019). Thorough work from Gillis et al. (2020a) has recently highlighted 
that the profiles of aforementioned ‘G protein-biased’ agonists may in fact be due to low 
intrinsic efficacy rather than any indication of biased signalling. This work echoes 
previous demonstrations of the importance of efficacy in the assessment of functional 
selectivity, which argued against the incorrect categorisation of the partial morphine as 
a biased agonist (Kelly, 2013). As such, the work of Gillis et al. (2020a) casts doubt on 
the proposed ‘biased’ profiles of TRV130, PZM21, SR17018 and buprenorphine, 
ascribing their pharmacological profiles instead to their low efficacy. The crisis of mis-
accreditation within biased signalling, which is particularly evident in the case of MOPr, 
largely stems from limitations in the standard methods of bias calculations in the case of 
partial agonism, particularly in amplified systems (Chapter 3.3.3).    
Despite contradictory findings around the pharmacological profiles of the current panel 
of purportedly G protein-biased agonist at MOPr, the same body of work suggested that 
in fact the low intrinsic efficacy of aforementioned agonists drives an increase in their 
therapeutic window (Gillis et al., 2020a). This inverse correlation between intrinsic 
efficacy and therapeutic window could provide good evidence that newly developed low 
efficacy agonists such as TRV130, PZM21 and SR17018 could possess a more 
favourable clinical safety profile over agonists such as morphine regardless of purported 
bias. Indeed, the intrinsic efficacy at receptor level required for an opioid to evoke reliable 
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analgesia is thought to be relatively low, with opioids such as buprenorphine, which have 
very low efficacy in cell systems, consistently considered ‘strong opioids’ in a clinical 
setting (Schmidt-Hansen et al., 2015). One could therefore argue that previous drug 
development, blinkered by the natural inclination that stronger equals better, has 
developed drugs that possess efficacy far beyond what is required for effective 
analgesia, potentially making them more liable to induce adverse effects. Therefore, the 
demonstration of this inverse correlation between intrinsic efficacy and improved 
therapeutic window by Gillis et al. (2020a) has prompted a drive within drug discovery to 
develop low efficacy partial MOPr agonists as potentially safer analgesics. 
It could however be argued that the demonstration of this inverse correlation between 
intrinsic efficacy and therapeutic window by Gillis et al. (2020a) is heavily dependent on 
data from PZM21 and buprenorphine, which yields two contentious points: firstly, the 
favourable therapeutic window of PZM21 is heavily dependent on an apparent ceiling in 
the respiratory burden of PZM21 upon increasing doses. Furthermore, the extent of 
respiratory depression induced by PZM21 relative to morphine at 60 mg/kg and 100 
mg/kg is substantially lower than that observed by Hill et al. (2018b) at 40 mg/kg. 
Additionally, the PZM21 ED50 data in the Gillis et al. (2020a) study from which its 
therapeutic window is derived was fitted from responses to only two doses, limiting 
confidence in curve fitting. Secondly, results for buprenorphine clearly drive the 
correlation, with buprenorphine producing minimal respiratory depression up to 10 
mg/kg. However, low intrinsic efficacy at MOPr may not be the exclusive factor mediating 
this previously documented limited respiratory burden induced by buprenorphine (Dahan 
et al., 2006), with its pharmacokinetics and affinity at DOPr, KOPr and the nociceptin 
receptor all potentially confusing the interpretation of findings for this often perplexing 
drug (Gudin et al., 2020).  
Regardless, the inadvertent development of highly specific MOPr weak partial agonists 
in TRV130, PZM21 and SR17018, among others, provides an excellent toolset to truly 
investigate whether MOPr agonists of lower intrinsic efficacy could provide safer 
analgesics as hypothesised (Gillis et al., 2020c). While weak partial agonists of MOPr 
currently exist and have been historically widely used in clinical practise, including 
buprenorphine, pethidine, tramadol and levorphanol, their utility as tool compounds and 
to some extent therapeutics is limited by their interaction with receptors other than MOPr.  
One key question which influences the utility of lower efficacy MOPr in clinical practise 
is the potential development of tolerance to their analgesic effects. As hypothesised in 
the case of G protein-biased agonists, their lower relative coupling to arrestin and GRK 
regulatory pathways could make them less liable to induce receptor desensitization and 
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subsequent development of tolerance. Limited clinical evidence suggests, as expected 
for a weak partial agonist, that tolerance to the analgesic effects of buprenorphine 
develops more slowly than to the effects of fentanyl (Sittl et al., 2005). However, 
tolerance to the antinociceptive effects of buprenorphine is still evident in mouse models 
(Melief et al., 2010). Current knowledge around the ability of previously described G 
protein-biased agonists, or low efficacy agonists, is limited and variable. TRV130 was 
shown to induce less antinociceptive tolerance than morphine in mice after 3-4 days of 
repeated administration (Altarifi et al., 2017; Liang et al., 2019). Similarly, SR17018 has 
been reported to not produce analgesic tolerance after 6 days of oral dosing (Grim et al., 
2020). On the other hand, PZM21 produces robust antinociceptive tolerance in mice over 
4 days (Hill et al., 2018b). The variability of these findings may be in part due to 
differences in the efficacies of these specific agonists. Additionally, as outlined above, 
the varied experimental protocols and routes of administration could also account for the 
differences observed for these agonists. Nevertheless, further studies into the propensity 
of low efficacy opioids to induce MOPr desensitization and the subsequent development 
of tolerance to their effects will improve our understanding of their wider clinical utility.  
As discussed above, the current crop of putatively ‘G protein-biased agonists’ at MOPr 
have not delivered on the pharmacological properties initially promised, an observation 
skewed by contradictory findings on the reality of the apparent bias of these ligands. This 
begs the question as to whether truly G protein-biased agonists would indeed induce 
less respiratory depression and tolerance while maintaining the analgesic properties of 
balanced MOPr agonists, as was originally hypothesised based on historical arrestin-3 
knockout work by the Bohn group (Bohn et al., 1999; Raehal et al., 2005). Below I will 
be discussing recent findings which have caused a shift in the current thinking of biased 
signalling at MOPr. First, I will outline recent findings demonstrating the G protein 
signalling-dependent, arrestin-independent nature of opioid-induced respiratory 
depression. Subsequently I will be summarising recent work further examining the 
arrestin/GRK-dependent nature of tolerance to opioids, bringing in the findings around 
the G protein-biased agonist Compound 1. 
The hypothesis that opioid-induced respiratory depression is mediated by MOPr/arrestin 
interactions is central to the proposed clinical benefit of G protein-biased MOPr agonists. 
In contradiction to the original findings of morphine-induced respiratory depression in 
arrestin 3 knockout mice (Bohn et al., 1999; Raehal et al., 2005), there is now good 
evidence that MOPr activation inhibits activity in nuclei involved in respiratory control 
(preBötzinger and Kölliker-Fuse neurones (Varga et al., 2019)) through G protein-
dependent signalling (Gillis et al., 2020b). In the preBötzinger complex, morphine effects 
on respiratory rate have been shown to be mediated by GIRK channel activation 
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(Montandon et al., 2016). Additionally, a presynaptic mechanism of opioid-induced 
inhibition of preBötzinger neurons has been shown, through MOPr-dependent activation 
of voltage-gated calcium channels (Wei et al., 2019). Similarly, opioid-induced inhibition 
of Kölliker-Fuse neurones occurs through MOPr-dependent activation of GIRK, 
suppressing inspiratory drive (Levitt et al., 2015). These mechanistic studies refute the 
previous hypotheses of the arrestin-dependent nature of opioid induced respiratory 
depression based on previous arrestin-3 KO data. Additionally, reports demonstrating 
the worsening of morphine- and fentanyl-induced respiratory depression in mice 
expressing phosphorylation-site deficient MOPrs also refutes the previously held 
hypothesises of opioid-induced respiratory depression being arrestin-dependent 
(Kliewer et al., 2019). Finally, a report from a consortium of 3 independent laboratories 
showing that morphine- and fentanyl-induced respiratory depression persists in arrestin-
3 knockout mice, directly refuting the findings of Raehal et al. (2005), raises concerns 
around the validity and reproducibility of the findings on which the arrestin hypothesis 
was built (Kliewer et al., 2020). 
In light of this recent evidence, previous theories suggesting G protein-biased MOPr 
agonists will be safer analgesics with regard to their propensity to induce respiratory 
depression now appear to be mechanistically invalid. However, recent evidence has 
suggested that G protein-biased agonists could induce less receptor desensitization and 
tolerance than balanced agonists. In LC neurones from mice expressing 
phosphorylation-site deficient MOPrs, desensitization of Met-Enkephalin-evoked GIRK 
currents is significantly reduced (Kliewer et al., 2019). Additionally, tolerance to the 
antinociceptive effects of morphine and fentanyl is lost in mice expressing 
phosphorylation-site deficient MOPrs (Kliewer et al., 2019). While this evidence does 
suggest G protein-biased agonists may be clinically beneficial with regard to the 
induction of MOPr desensitization and subsequent tolerance, work within this thesis 
highlights that MOPr desensitization can occur in a agonist-specific manner, through 
multiple mechanisms (Kelly et al., 2008). The finding here that the G protein-biased 
MOPr agonist Compound 1 induces substantial receptor desensitization underscores 
that G protein-biased agonists at GPCRs could still induce receptor desensitization and 
tolerance through non-canonical, agonist-specific mechanisms. Further work is therefore 
required to fully understand the long-term functional consequences of G protein-biased 




6.9 The potential of harnessing biased signalling to aid the 
development of effective therapeutics at other GPCR targets 
The phenomenon of biased signalling has been applied to a multitude of GPCR targets 
in the anticipation that it will allow for the development of more refined, safer 
therapeutics. Biased agonism has been explored at GPCR targets including the M1 
muscarinic acetylcholine receptor (Bradley et al., 2020), neurotensin receptor 1 (Slosky 
et al., 2020), the ghrelin receptor (Mende et al., 2018) and the ATIIR (Violin et al., 2010) 
for the development of novel therapeutics for conditions ranging from dementia and 
addiction to obesity and heart failure. More specifically, there is great interest in the 
development of biased agonists at other opioid receptors. In the case of DOPr, G protein-
biased agonists are suggested to possess desired antihyperalgesic effects for the 
treatment of chronic pain states without producing the proconvulsant activity previously 
prohibiting the development of DOPr agonists (Dripps et al., 2018; Conibear et al., 2020). 
At KOPr, recently developed G protein-biased agonists have been reported to be 
effective antinociceptive and antipruritic agents, but do not induce dysphoria, psychosis 
and sedation which previously held back the development of KOPr agonists (Spetea et 
al., 2017; Mores et al., 2019).  
However, despite the persistent efforts of drug discovery groups targeting GPCRs across 
the GPCR-ome, the MOPr agonist TRV130 is the only ‘biased’ GPCR therapeutic to 
reach licenced approval for clinical use (Lambert et al., 2020). One could argue that the 
currently unfulfilled promise of biased agonism as a viable drug discovery strategy is 
hindered by methodological limitations as well as our limited comprehension of the 
subtleties of GPCR signalling (Michel et al., 2018). 
Methodologically, the development of biased agonists within drug discovery is limited by 
the non-trivial means of bias quantification. As previously discussed (Chapter 3.3.3) in 
relation to efficacy as a potentially confounding factor in calculations of bias signalling, 
great care must be taken when establishing GPCR signalling assays for calculation of 
bias. For example, the kinetic context of each assay must be given consideration which 
further complicates interpretation of such data (Lane et al., 2017). The unappreciated 
complexity of this process often leads to the misclassification of biased signalling in many 
settings. Practical considerations, such as the number of different GPCR signalling 
assays which must be run, also presents an obstacle for drug discovery to define or 
refine the biased signalling of their candidate ligands, where efficiency and high 
throughput are of paramount importance. Additionally, high profile clinical failures of 
bellwether biased agonists in clinical trials (Pang et al., 2017) along with the rising doubts 
about the supposed biased profile of developed agonists (Gillis et al., 2020a) has 
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currently increased concerns about the potential utilisation of biased signalling as a 
useful drug discovery tool.  
Perhaps the biggest obstacle for drug discovery based on biased agonism is the current 
lack of understanding concerning pathway-specific GPCR signalling and its functional 
implications (Michel et al., 2018). Even for a target as established as the MOPr, long 
considered the front-running target for biased agonism drug discovery, new evidence 
highlighting our previous misconceptions regarding the consequences of arrestin-
dependent signalling and its role in respiratory depression have shattered our hopes for 
this once promising approach (Gillis et al., 2020b; Kliewer et al., 2020). For biased 
agonism to be a viable approach in future drug development programmes, the specific 
physiological roles of GPCR signalling patterns (G proteins, arrestins, or other) which 
mediate the therapeutically beneficial and adverse effects of GPCR function must be 
conclusively defined. The recent development of more refined approaches and tools to 
study the functional roles of specific pathways in GPCR signalling could provide the 
proper target validation required for this process. These approaches include the 
development of knock-in mouse lines expressing phosphorylation-deficient ‘G protein-
biased’ GPCRs, for example MOPr and M1 muscarinic acetylcholine receptor, to probe 
the role of arrestin-dependent signalling (Kliewer et al., 2019; Bradley et al., 2020). The 
main benefit of this approach is that observations are not dependent on or limited by the 
quality of available supposedly biased agonists at the GPCR of interest. However, 
caution should be exercised as perceived toxicity from stimulation of G protein-biased 
GPCRs in this approach could result from overstimulation stemming from a lack of 
regulatory arrestin control, rather than from G protein signalling specifically (Bradley et 
al., 2020).  
Given the proposed requirement for such thorough signalling characterisation in the 
development of therapeutics harnessing biased signalling, one fears that its utilisation 
may be limited to cases where the GPCR of interest is an established therapeutic target. 
In turn this may limit the development of biased agonists to the second or third generation 
of therapeutics at a given target. The development of such refined agents at established 
therapeutic targets is important, and established targets bring a certain security from a 
drug discovery standpoint. However, one could argue that targeting lesser studied GPCR 
targets may yield more meaningful advances in the field of GPCR therapeutics and 
medicine generally, rather than attempting to teach an old dog new tricks.  
Current FDA approved GPCR-targeting drugs mediate their effects through 108 GPCR 
targets, which accounts for 27% of the potential pool of human non-olfactory GPCRs 
currently targeted by therapeutics (Hauser et al., 2017). Each established GPCR target 
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is currently targeted by an average of 10.3 distinct approved agents (Hauser et al., 2017), 
highlighting a near saturation of drug discovery within the current target space. That said, 
the mass de-orphanisation of GPCRs which has occurred over the past 2 decades 
following the so-called cloning age (Hill, 2006) has advanced our knowledge of GPCR 
biology, leading to an expanded arsenal of druggable GPCRs. In turn, the field is 
beginning to bear the fruits of this labour with the recent approval of novel therapeutics 
targeting lesser known GPCR targets. Two recent examples of this are the orexin 
receptors (orexin receptor 1, OX1 and orexin receptor 2, OX2) and the CGRP receptor. 
Dual orexin receptor antagonists, including suvorexant (Yang, 2014) and lemborexant 
(Scott, 2020), have been approved as first-in-class hypnotic drugs, with OX1 receptor 
antagonists being clinical explored for the treatment of addiction (James et al., 2017). 
Similarly building on new biology at previously unstudied GPCR targets, the recent 
development and approval of several CGRP receptor antagonists for migraine has 
revolutionised treatment for this condition (Edvinsson et al., 2018; Markham, 2018). 
These advances among many others (Hauser et al., 2017), strengthens the case for 
expanding our search for novel therapeutics beyond currently established targets. This 
is particularly pertinent when considering that 30% of the non-olfactory human GPCRs 
are orphan receptors (not definitively paired with endogenous ligands), highlighting a 
wealth of unexplored biology which is likely to yield valuable therapeutic targets (Hauser 
et al., 2020). 
Numerous lesser studied GPCRs are currently under investigation as novel therapeutic 
targets for the development of non-opioid analgesic drugs (Che, 2020). For instance, 
metabotropic glutamate receptors (mGluRs) are expressed throughout nociceptive 
pathways, regulating pain transmission (Latremoliere et al., 2009). Both the 
predominantly postsynaptic mGluR1 and 5 (Sevostianova et al., 2006) and presynaptic 
mGluR2 and 3 subtypes (Johnson et al., 2017) have been preclinically demonstrated as 
effective targets for the treatment of pain. Similarly to opioids, the use of cannabinoids 
for pain relief is deep-rooted into our history. The CB1 cannabinoid receptor is expressed 
in both ascending and descending pain pathways and is upregulated in chronic pain 
states (Lim et al., 2003). The development of G protein-biased agonists at CB1 such as 
PNR-4-20 could provide novel cannabinoid agonists with reduced propensity to produce 
typical cannabinoid psychoactive effects (Ford et al., 2017). The GPCR neurokinin 1 
receptor (NK-1R), the primary target of the pronociceptive peptide Substance P, 
presents another potential GPCR target which has been explored for the development 
of novel analgesics (Sanger, 2004). Interestingly NK-1R and MOPr are co-expressed in 
sensory neurones, and bifunctional peptides with both MOPr agonist and NK-1R 
antagonist activity show analgesic efficacy with favourable adverse effect profiles 
(Starnowska et al., 2017). Current orphan GPCRs may also present future therapeutic 
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targets for the treatment of pain (Nourbakhsh et al., 2018). For instance, GPR40 (now 
identified as free fatty acid receptor 1 (FFA1 receptor)) has been implicated as a 
regulator of descending pain control, with activation of GPR40 decreasing formalin-
induced pain behaviours in mice (Nakamoto et al., 2015).  
 
 193 
6.10 Final Conclusion 
The research presented within this thesis aimed to characterise the receptor 
desensitization and regulation induced by G protein-biased MOPr agonists, in order to 
further define their long-term functional effects and overall therapeutic potential. In this 
thesis I have characterised the cyclic endomorphin analogue Compound 1 as a novel G 
protein-biased agonist at MOPr. In spite of its G protein-biased signalling profile, 
Compound 1 induces substantial rapid receptor desensitization in LC neurons though a 
potentially novel GRK-dependent, arrestin-independent mechanism. More widely, our 
findings refute the assumption that G protein-biased agonists at MOPr, and at other 
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